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Acute  Respiratory  Distress  Syndrome  (ARDS)  is  a  life-­threatening  illness  which  can  
follow  major  surgery,  including  oesophagectomy.    This  thesis  aimed  to  confirm  the  
importance  of  ARDS  in  this  cohort  and  assess  the  effects  of  GSK2862277  
Methods  
Analysis   of   previous   oesophagectomy   trials  modelling   ARDS   sought   differences  
between  the  studies  and  identified  risk  factors.    The  immunomodulatory  effects  of  
oesophagectomy   and   critical   illness   and   novel   therapeutic   GSK2862277   on  
macrophage  and  neutrophil  function  were  investigated  using  in  vitro  assays.  
Results  
Previous  trials  showed  the  harm  to  patients  associated  with  ARDS,  but  falling  ARDS  
rates  more  recently.    Active  smoking  and  pre-­operative  dihydropyridine  use  were  
risk   factors   for  ARDS.     Oesophagectomy  and   critical   illness  modulate   neutrophil  
extracellular  trap  formation  but  not  phagocytosis.    GSK2862277  appears  to  cause  
an  off-­target  effect  increasing  neutrophil  extracellular  trap  formation.    GSK2862277  
increases  alveolar  macrophage  phagocytosis.  
Discussion  
Perioperative   ARDS   has   decreased   following   oesophagectomy   although   it   is  
harmful  to  patients  who  develop  it.    Oesophagectomy  is  no  longer  useful  as  a  model  
of  ARDS.     Major  surgery  and  critical   illness  effect  neutrophil   function,  which  may  
drive   complications   in   these   cohorts.      Macrophage   function   was   modulated   by  
GSK2862277,  suggesting  it  may  have  promise  in  future  for  preventing  or  treating  
ARDS  and  other  post-­operative  pulmonary  complications.     
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1.1  Surgery,  perioperative  risk  and  outcome  
Surgery  is  performed  with  the  aim  of  curing,  improving  or  palliating  disease.    The  
modern   era   of   surgery   has   only   been   possible   with   the   advent   of   anaesthesia,  
permitting  optimisation  of   the  surgical   field  and  making   invasive  procedures  both  
physiologically  and  psychologically  tolerable  for  the  patient.    Perioperative  mortality  
is  now  low,  especially  in  developed  nations  with  advanced  healthcare  [1],  but  some  
patients  and  procedures  are  associated  with  increased  risk  of  mortality  and  post-­
operative  morbidity  [2,  3].    Risk  of  death  attributable  specifically  to  anaesthesia  fell  
over  ten-­fold  from  before  the  1970s  to  the  1990s  [4].    For  very  high  risk  patients,  
surgery  remains  much  more  dangerous,  with  a  48-­fold  increase  in  risk  for  those  who  
are  American  Society  of  Anesthesiologists’  (ASA)  Score  IV-­V,  compared  to  I-­III  [1].    
The  proportion  of  high  risk  patients  has  increased  over  the  decades  [1],  due  to  the  
increased   frailty   and   medical   complexity   of   patients   requiring   surgery   [5].    
Perioperative   complications   adversely   affect   the   patient   and   increase  healthcare  
cost  [2,  6],  therefore  prevention,  rescue,  complication  limitation  and  mitigation  are  
all  important  strategies  to  develop  for  optimal  care  and  outcome  [7].  
1.2  Oesophagectomy  
One   such   high-­risk   surgical   intervention   is   oesophagectomy   [8,   9].    
Oesophagectomy   is  usually   performed   for   carcinoma  of   the   oesophagus  or   pre-­
neoplastic  lesions,  but  also  occasionally  for  severe  benign  diseases.    The  sources  
of  perioperative  risk  are  multifactorial.    Patients  affected  are  typically  middle-­aged  
or   older.      Squamous   cell   carcinoma   is   associated   with   alcohol   and   cigarette  
consumption   and   poor   oral   hygiene   and   therefore,   often   there   is   comorbid  
3  
  
ischaemic  heart  disease,  vascular  disease  and/or  COPD,  whilst  adenocarcinoma  is  
associated  with  obesity  and  gastro-­oesophageal  reflux  [10].      
Upper  gastrointestinal  surgery  was  associated  with  the  highest  risk  of  complications  
in   the   International   Surgical   Outcome   Study   (ISOS)   [2].      Multi-­cavity   surgery   is  
required   for   most   oesophagectomy   surgery,   frequently   necessitating   one-­lung  
ventilation,   associated   with   a   risk   of   respiratory   complications   [11].      The  
anastomosis   is   formed   at   the   extreme   end   of   the   supply   of   the   foregut   and   is  
therefore  vulnerable  to  ischaemia  (Figure  1)  [12].    Infections  in  the  mediastinum  can  
be  devastating   [13].     Post-­operatively,   it   is  challenging   to  manage  pain,  nutrition,  
thromboembolic  risk  and  rehabilitation  back  to  normal  activity.      
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Figure   1:   The   formation   of   the   gastric   conduit   and   its   blood   supply   following  
oesophagectomy.      Note   the   anastomosis   is   formed   at   the   extreme   end   of   the  
foregut,  therefore  at  the  point  furthest  from  the  origin  of  its  arterial  supply  from  the  





Efforts   have   been   made   to   reduce   risk   and   optimise   outcome.      Moving  
oesophagectomy   to   high   volume   centres   is   associated  with   lower  mortality   [14],  
although  best  surgical  technique  remains  to  be  resolved  [13].    Minimally  invasive  
techniques   (involving   laparoscopic   and   thoracosopic   or   even   robotic   techniques)  
are   increasingly   used  and  associated  with   lower   pain,   pulmonary   complications,  
length  of  stay  and  better  patient  quality  of  life  score  in  experienced  centres  [15].  
1.3  Post-­operative  pulmonary  complications  
Post-­operative  pulmonary  complications  (PPCs)  are  the  most  common  complication  
following  oesophagectomy  [16].    What  qualifies  as  a  PPC  varies  between  studies  
[17],   although   attempts   have   been   made   to   produce   international   consensus  
definitions  [18].    A  range  of  patient,  disease  and  surgical  factors  contribute  to  the  
high  risk  of  PPCs  in  the  oesophagectomy  cohort.  
Patients  are  harmed  by  PPCs.    There  is  increased  mortality  in  both  the  short-­  [19,  
20]  and   long-­term   [21,  22].     This  has  been  demonstrated   in  patients  undergoing  
oesophagectomy  [23].    Morbidity  is  also  increased,  for  example  increased  length  of  
stay  and  intensive  care  utilisation  [22,  24].      
1.3.1  Patient  related  factors  
Major  risk  factors  for  both  oesophageal  cancer  and  respiratory  disease  (in  general  
and  post-­operatively)  include  smoking  and  alcohol  consumption  [10,  17].    Chronic  
obstructive   pulmonary   disease   has   been   demonstrated   to   be   a   risk   factor   in   a  
thoracic  surgical  cohort  [22].    Both  smoking  and  alcohol  use  have  been  associated  
with  Acute  Respiratory  Distress  Syndrome  (discussed  further  below)  [25].  
1.3.2  Surgical  and  anaesthetic  factors  
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Surgery   for   oesophagectomy   involves   both   abdominal  and   thoracic   phases   [26].    
The  surgical  intervention  is  by  definition  pro-­inflammatory  [27],  and  even  minimally  
invasive  techniques  represent  a  significant  “hit”  to  the  patient  [13,  15,  28].      
1.3.2.1  Perioperative  ventilation  
General  anaesthesia,  especially  with  neuromuscular  blocking  drugs,  is  associated  
with  a  number  of  processes  that  adversely  affect  the  respiratory  system,  including  
loss   of   respiratory   drive,   altered   lung  mechanics,   atelectasis,   impairment   of   the  
mucociliary  escalator,  adverse  effects  of  hyperoxia  and  denitrogenation  and  post-­
operative   respiratory  dysfunction   [17,  29].     Traditional  anaesthetic   techniques   for  
perioperative  ventilation  included  using  a  large  tidal  volume  as  a  method  to  reduce  
atelectasis   [30,   31].      Some   anaesthetists   have   felt   relatively   short   periods   of  
ventilation,  even  without  a   lung  protective  strategy,  were   too  brief   to  cause  harm  
[31].    A  meta-­analysis  of  available  controlled  trial  data,  including  2127  patients  in  
total  [32],  showed  there  were  fewer  PPCs  in   the  lung  protective  group  and  those  
who  developed  a  PPC  had  longer  ICU  and  hospital  stays  and  higher  mortality.    ASA  
score,  surgical  type,  body  mass   index  and  gender  did  not  modify  effects.     Lower  
tidal  volume  in  those  with  PEEP  was  associated  with  fewer  PPCs,  but  had  no  effect  
on  length  of  stay  or  mortality.    A  recent  meta-­analysis  demonstrated  reduced  ARDS  
in   elective   surgical   patients   provided   with   lung   protective   ventilation   (low   tidal  
volume  and  high  PEEP),  although  no  difference  in  pneumonia  or  atelectasis  [33].  
There   are   benefits   to   protecting   the   lung  with   low   tidal   volume   ventilation   intra-­
operatively  even  in  circumstances  where  the  lung  is  healthy,  although  the  role  of  
PEEP   remains   to   be   better   elucidated   by   further   trials   [34,   35].      An   intriguing  
retrospective  study  has  suggested  that  there  may  be  benefit  of  volume-­controlled  
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over   pressure-­controlled   ventilation   [36]   but   this   has   been   criticised   [37]   and  
requires  assessment  in  prospective  trials.    In  patients  starting  surgery  with  healthy  
lungs,  much  of  the  damage  to  the  lung  is  due  to  the  harmful  effects  of  ventilation.  
1.3.2.2  Ventilator  Induced  Lung  Injury  (VILI)    
During   conventional   mechanical   ventilation,   intermittent   positive   pressure  
ventilation  exposes  regions  in  the  lung  with  differing  mechanics  to  excess  overload  
(volutrauma),  excess  pressure   (barotrauma)  and  periods  of   repeated   recruitment  
and  airway  closure  (atelectrauma)  which  can  primarily  cause  injury  to  the  alveolar  
epithelium  and  endothelium  or  exacerbate  the  inflammatory  process  in  an  already-­
vulnerable   lung   (the   multi-­hit   hypothesis)   [38].      The   worsening   of   ARDS   by  
inflammatory  processes   is   termed  biotrauma   [39].     More   recent  work  has  unified  
these  mechanisms.    Collapsed  areas  act  as  alveolar  stress  concentrators,  driving  
damage  in  adjacent  areas  of  lung  [40].  
Raised   capillary   pressure   has   been   shown   in   vitro   to   be   associated   with   pro-­
inflammatory  endothelial  signalling  [41].    Mechanical  overstretch  leads  to  mediator  
release,  then  disruption  of  intercellular  contacts,  causing  leak  and,  if  severe,  rupture  
of   plasma   cell   membranes   causing   necrosis   [39].      There   is   complex   interplay  
between  mechanical  stress,  immunological  and  coagulation  processes  driving    
1.3.2.3  One  Lung  Ventilation  
One   Lung   Ventilation   (OLV),   required   for   the   thoracic   phase   in   most   surgical  
techniques  for  oesophagectomy  [13]  is  injurious  to  the  lung.    Ventilating  one  lung  
subjects   the   ventilated   lung   to   volutrauma,   barotrauma   and   biotrauma   and  
potentially  atelectrauma  as  well  as  high  inspired  oxygen  tension.    The  deflated  lung  
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will   become  atelectatic   and   form  alveolar   stress   concentrators,   then   re-­recruited  
with   high   airway   pressures,   with   ischaemia-­reperfusion   and   biotrauma   [40,   42].    
Handling  may  cause  physical  trauma,  although  this  tends  to  be  less  injurious  than  
resection  [42].  
1.4  Strategies  to  prevent  PPCs.  
Recommendations   for   lung   protection   specifically   for   OLV   include   recruitment  
manoeuvres  before  OLV,  minimising   the  duration  of   lung   isolation,  application  of  
CPAP  to  the  deflated  lung  if  possible,  protective  tidal  volumes  in  the  ventilated  lung  
(4-­5mlkg-­1),   the   application   of   PEEP   and   permissive   hypercarbia.      With   the  
restoration  of  two-­lung  ventilation,  hyperoxia  should  be  avoided  [42].      
Post-­operative   ventilation   has   received   little   attention,   perhaps   because   of   the  
adoption  of  lung  protective  ventilation  for  most  patients  in  ICU.    Ventilation  practices  
following   cardiac   surgery   are   more   heterogeneous,   with   concerns   about   raised  
arterial  carbon  dioxide  levels  adversely  affecting  right  heart  function  [43].    However,  
one  study  in  patients  undergoing  cardiac  surgery  showed  increased  organ  failure,  
longer  duration  of  mechanical  ventilation  and  haemodynamic  instability  in  those  with  
“standard”  ventilation  (10-­12mlkg-­1),  compared  to  low  tidal  volume  as  less  than  10  
mlkg-­1  [44].  
1.5  The  Acute  Respiratory  Distress  Syndrome  
Amongst   the   most   severe   respiratory   complications   is   the   Acute   Respiratory  
Distress  Syndrome  (ARDS).    Post-­operative  ARDS  is  associated  with  a  mortality  of  
23.9%,  a  risk  exceeded  only  by  cardiac  arrest  [2].    The  current  clinical  definition  (the  
Berlin  Definition)  [45]  consists  of:  
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•   Acute  hypoxia  (arterial  oxygen  tension  to  inspired  oxygen  fraction  (P:F)  ratio  
of  less  than  40kPa).  
•   5cmH2O   or   more   of   positive   end-­expiratory   pressure   (PEEP)/continuous  
positive  airways  pressure.  
•   Bilateral  chest  x-­ray  infiltrates  (not  fully  explained  by  lung  collapse,  effusions  
or  nodules),  and  not  fully  explained  by  cardiac  failure  or  fluid  overload.  
•   Within  a  week  of  onset  or  worsening  of  respiratory  symptoms.  
Previously,  the  North  American  European  Consensus  Definition  (NAEC)  was  used  
[46].    Acute  Lung  Injury  (ALI)  defined  as:  
•   A  known  acute  cause.  
•   A  P:F  ratio  less  than  40kPa.  
•   Bilateral  chest  infiltrates.  
•   A  pulmonary  capillary  wedge  pressure  of  less  than  15mmHg.  
ARDS  was  defined  by  NAEC  as  a  more  severe  subset  of  ALI  with  a  P:F  ratio  of  less  
than  26.7kPa  [46].    For  the  purposes  of  this  thesis,  ARDS  is  used  as  an  overarching  
term  to  refer  to  both  ARDS  as  defined  by  the  Berlin  criteria  and  what  was  previously  
defined  as  ALI,  unless  otherwise  explicitly  stated.      
Some  studies  suggest  mortality  has  fallen  over  the  last  20  years  [47],  whilst  a  recent  
cohort   study   showed   mortality   remains   around   40%   [48].      Most   studies   of  
therapeutic   interventions   in  ARDS  have  been  performed   in  critical   care  patients,  
with  fewer  in  the  perioperative  setting.      
Ventilation   using   low   tidal   volumes   (6   rather   than   12mlkg-­1   based   on   ideal  
bodyweight)  was  associated  with  a  mortality  reduction  of  8.8%  in  established  ARDS  
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[49],  and  lung  protective  ventilation  has  been  shown  to  prevent  ARDS  in  ICU  [50].    
A   recent  meta-­analysis   demonstrated   reduced  need   for   post-­operative   ventilator  
support  with  intra-­operative  use  of  low-­tidal  ventilation,  although  mortality  or  length  
of  stay  was  not  affected  [51].      
Prone   ventilation   has  mortality   benefit   in   more  moderate   to   severe   ARDS   [52].    
Clearly,   this   is   of   limited   use   intraoperatively.      Extracorporeal   membrane  
oxygenation   is   increasingly   used   for   the   most   severe   ARDS,   however   its   use  
currently  is  limited  to  patients  with  a  very  high  predicted  mortality  and  is  restricted  
to  subspecialist  centres  [53].      
A  trial  of  muscle  relaxants  showed  a  reduction  in  adjusted  mortality  for  ARDS  at  day  
90,  with  fewer  ventilated  and  ICU  days,  although  overall  mortality  was  not  affected  
[54].    The  role  of  steroids  requires  further  clarification  [55],  but  steroids  are  now  no  
longer   used   routinely   [56].      The   lack   of   other   successful   therapies,   including  
negative  trials  for  intravenous  salbutamol  [57],  simvastatin  [58],  nitric  oxide  [59]  and  
exogenous  surfactant  [60]  suggests  that  preventing  ARDS  may  be  more  fruitful.      
The  risks  associated  with  ARDS  in  oesophagectomy  are  substantial.    A  landmark  
study  (using  NAEC  criteria)  demonstrated  an  incidence  of  ALI  of  23.8%  and  ARDS  
of  14.5%.    Mortality  in  those  with  ARDS  was  50%  compared  to  3.5%  in  those  without  
any  lung  injury  and  there  was  an  association  with  cardiorespiratory  instability  [8].  
Methylprednisolone  is  used  frequently  in  Japan  to  reduce  complications,  including  
ARDS,  following  oesophagectomy  [61]  but  this  is  yet  to  be  well  supported  by  robust  
clinical   trials.      A   meta-­analysis   of   the   use   of   pre-­operative   methylprednisolone  
demonstrated   a   reduction   in,   cardiovascular   complications,   respiratory  
complications,  hepatic  dysfunction,  sepsis,  anastomotic   leave,   length  of  stay  and  
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combined   organ   dysfunction,   but   not   mortality   or   renal   dysfunction   [61].      The  
neutrophil  elastase  inhibitor  sivelestat  is  licenced  in  Japan  and  South  Korea  for  use  
in  ARDS,  although   it   is  not   in  clinical  practice   in   the  Europe  or   the  USA  and  has  
been  evaluated  for  established  ARDS  and  lung  protection  during  oesophagectomy  
[62].    Use  of  intra-­operative  and  post-­operative  infusions  have  shown  reduced  risk  
of  ALI  and   reduced  duration  of  post-­operative  mechanical  ventilation  by  day   five  
(though  not  at  day  three)  [62].    Given  the  European  and  North  American  practice  of  
early  post-­operative  extubation  [12,  63],  its  applicability  to  current  practice  remains  
to  be  determined.  
1.6  Inflammatory  processes  in  the  lung  
Inflammation  is  a  key  component  of  the  development  of  and  complications  related  
to   ARDS.      Pathogen   and   damage   associated   molecular   patterns   (PAMPS   and  
DAMPs   respectively)   have  been   shown   to   initiate   pro-­inflammatory   cytokines   by  
alveolar  macrophages,  including  TNF  alpha  and  interleukins  (IL)  1-­beta,  8  and  10  
[64,   65].      Lung   epithelial   cells   and   fibroblasts   may   also   secrete   cytokines   [65].    
Epithelial  and  endothelial  barrier  failure  allows  protein-­rich  extracellular  fluid  to  flood  
the  alveoli.     Injury  to   type   two  alveolar  cells  reduces  alveolar   fluid  clearance  and  
surfactant  production   [65].    Subsequent   failure   for   the  epithelial   layer   to  heal  can  
lead  to  fibrosis,  with  increased  extracellular  matrix  formation  triggered  by  fibroblasts  
[65].    Neutrophil  recruitment  is  very  important  (discussed  below).  
VILI,   both   by   itself   and   in   ARDS,   is   associated   with   inflammation   [39].      Over-­
distension  of  the  lung  will  trigger  pro-­inflammatory  genes,  a  process  which  may  be  
seen  even  in  non-­injurious  ventilation  [66],  and  cytokines  release  may  occur,  even  
without  necrosis  [39].    During  surgery,  the  insult  of  the  controlled  tissue  injury  drives  
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inflammation,  driven  by  DAMPS.    DAMPs  are  a  variety  of  different  molecules  which  
trigger  immune  modulation  via  Pattern  Regulation  Receptors  (PPRs).    A  number  of  
these  share  homology  with  PAMPs,  which  arise  from  exogenous  pathogens.    As  a  
result,  there  is  a  molecular  convergence  in  the  immune  response  to  the  controlled  
damage  of  surgery  and  other   insults,  such  as  burns,  pancreatitis  and  sepsis   [67,  
68].  
Perioperative   vulnerability   of   the   lung   to   inflammation   arises   from   a   number   of  
sources.    The  risks  of  VILI  are  discussed  above.    Anaesthesia  causes  a  fall  in  the  
functional   residual   capacity,   altered   lung   mechanics,   increases   alveolar   stress  
concentrators   [40],   impairs  ciliary  clearance  and  airway  devices  overcome  upper  
airway   immunological   defence   mechanisms   [69].      Residual   anaesthesia,   high  
inspired  oxygen  fraction,  inadequate  humidification  of  gases,  opioids  and  pain  may  
lead  to  reduced  cough,  sputum  retention  and  atelectasis  [69].    Volatile  anaesthetic  
agents   are   thought   to   be   anti-­inflammatory   [70]   but   may   drive   complex  
immunomodulatory  effects  [71].  
1.7  Macrophages  
Macrophages  are  a  crucial  cell  in  the  innate  immune  system  [72].    They  are  active  
against  external  pathogens  and  key  immune  regulators  [72].    Macrophages  have  
been  broadly  sub-­typed  into  M1  (primarily  targeting  intracellular  pathogens)  and  M2,  
which  are  broadly  pro-­resolution  of  inflammation  [73].    M1  activity  includes  cytokine  
secretion,   reactive   oxygen   species   (ROS)   formation,   phagocytosis   and   the  
presentation  of  antigen  [72]  as  well  destroying  pathogens  and  host  tissue  [74].    M2  
function  appears   important   in   fungal  and  helminth   infections,  allergy  and   tumour  
pathogenesis   [74].      M2   macrophages   have   been   shown   to   be   crucial   in   the  
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resolution   of   lung   inflammation   and   the   recovery   of  ARDS,   including  by   clearing  
neutrophils  and  releasing  anti-­inflammatory  cytokines  [75].    The  M1/M2  phenotype  
probably  oversimplifies  a  much  more  complex  array  of  macrophage  activities  [73,  
76].  
1.8  Neutrophils  
Neutrophils   are   another   crucial   component   of   the   innate   immune   system,  
responsible  for  the  following  functions:  
•   Chemotaxis  towards  a  stimulus.  
•   Phagocytosis.  
•   Intracellular  killing.  
•   Release  of  inflammatory  mediators.  
In   addition,   more   recently   an   additional   function   has   been   recognised   –   the  
Neutrophil  Extracellular  Trap  [77].  
1.9  Phagocytosis  and  intracellular  killing  
The   mechanism   of   phagocytosis   remains   incompletely   understood,   but   its   vital  
importance  is  highlighted  by  its  conservation  amongst  diverse  eukaryotic  cells  [78].    
Neutrophils  may  target  pathogens  directly,  but  more  often  require  the  opsonisation  
of   the   targets  by   immunoglobulins  and/or  complement   [79].     Neutrophils  express  
groups  of  a  variety  of  phagocytosis-­triggering  receptors  to  initiate  phagocytosis  [80].    
Following  recognition,  where  ligand-­gated  binding  triggers  a  cascade  of  intracellular  
processes  which  cause  disassembly  and  reconstruction  of  the  actin  cytoskeleton  of  
the  cell,  which   in   turn  causes   the  membrane  bilayer   to  envelop   the  bacterium  or  
other  pathogen,  forming  a  phagosome  [78].    Up  to  1000  proteins  may  be  involved  
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[78].    Both  active  and  passive  function  of  the  zipper  mechanism  of  actin  reassembly  
makes   phagocytosis   a   reliable   immune   mechanism   at   the   cellular   level   [78].    
Incomplete   invagination   leads   to   partial   phagosome   formation,   indicating  
phagocytosis  is  not  a  binary  all-­or-­nothing  process  [78].    Once  the  phagosome  has  
formed,  it  then  fuses  with  intracytoplasmic  granules  which  attack  and  degrade  the  
micro-­organism.    Binding  of  ligands  to  neutrophil  cell  surface  receptors  upregulates  
reactive  oxygen  species  formation  which  provides  additional  mechanisms  to  kill  the  
target  [79].  
Killing  of  the  ingested  pathogen  is  driven  by  granule  formation  and  reactive  oxygen  
species   [79].     There  are  a   range  of  granules   (previously  classified  as  primary  or  
azurophil   (myeloperoxidase  positive)  and  secondary  (myeloperoxidase  negative))  
[79])  which  results  from  changes  in  the  proteins  synthesised  as  neutrophils  mature.    
These  proteins  include  receptors,  chemokines  and  other  cytokines  and  components  
of  the  apoptosis  pathway.    Neutrophils  express  low  levels  of  receptors  under  basal  
conditions,  but  these  are  up-­regulated  following  stimuli  [81].      
Granules  contain  myeloperoxidase,  which  generates  hypochlorus  acid,  and  multiple  
bactericidal  proteins,  as  well  as  bacterial  growth  inhibitors,  such  as  lactoferrin  which  
binds   iron   [79].      Lysozyme   damages   bacterial   cell   wall   integrity   by   degrading  
peptidoglycan.      NADPH-­oxidase   is   a   multi-­component   enzyme   that   generates  
superoxide  anions  which  are  highly  destructive  to  biological  tissues.    Interaction  with  
other  granule  components  can  form  other  toxic  species,  including  hypochlorus  acid,  
hydrogen   peroxide,   hydroxyl   radicals   and   single   ionised   oxygen   atoms.      The  




1.10  The  Neutrophil  Extracellular  Trap  
The  Neutrophil  Extracellular  Trap  (NET)  was  first  described  in  2004  [77]  and  may  
be  a  crucial  component  of  ARDS  pathogenesis  [82].    In  response  to  an  appropriate  
stimulus,   there   is   chromatin   de-­condensation,   disintegration   of   the   nuclear  
membrane,  followed  by  the  association  of  nuclear  and  cytoplasmic  structures,  which  
is  then  followed  by  cell  rupture  and  the  release  of  a  NET  [83].    Whether  this  process  
is  active  and  physiological  or  a  convenient  consequence  of  cellular  rupture  remains  
debated   [84].      NETosis   is   known   to   be   driven   by   bacterial,   fungal   and   parasitic  
pathogens   and   a   range   of   cytokines,   including   TNF   alpha   [85]   and   immune  
complexes  signalling  via  C5a  and  C5aR1  and  2  [86].      
NETosis   commences  with   reactive   oxygen   species   causing   the   disintegration   of  
neutrophil   granules,   with  myeloperoxidase   and   neutrophil   elastase   reaching   the  
nucleus.      Histone   modification   by   protein   arginine   deiminase   4   (PAD4)   causes  
chromatin  decompensation.    This  now  unwinding  DNA  associates  with  proteins  from  
the  granules  ahead  of  the  neutrophil  membrane  and  this  structure  now  forms  a  web  
in  the  intercellular  space  [87].  
NETs  can  kill  and/or  prevent  movement  of  bacteria   in  vivo,   including   limiting   the  
spread   of   bacteria   from   upper   to   lower   respiratory   tract   and   from   lung   to  
bloodstream.      NETs   have   also   been   shown   to   have   anti-­fungal   and   anti-­viral  
functions   [87].     NETosis   has  also   been   implicated   in   hypercoagulability.      Tissue  
factor   secretion   (vital   to   triggering   the   coagulation   cascade)  during  NETosis   has  
been  observed  and  neutrophil  elastase  has  also  been  shown  to  deactivate  tissue  
factor   inhibitors   and   promote   factor   Xa   activity   [85].      Markers   of   leukocyte   and  
platelet  function  have  been  associated  with  organ  failure  in  patients  with  sepsis  [88]  
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Patients   with   metabolic   failure   of   reactive   oxygen   species   generation,   who  
phenotypically  have  Chronic  Granulomatous  Disease,  are  unable  to  form  NETs,  but  
this  can  be  restored  in  vitro  in  the  presence  of  hydrogen  peroxide  [85].    Intriguingly,  
NET   formation   has   been   associated   with   both   myeloperoxidase   and   neutrophil  
elastase  [85,  89].    Neutrophil  elastase  is  necessary  for  nuclear  decompensation  and  
neutrophil  death  is  lower  in  the  presence  of  neutrophil  elastase  inhibitor.    Neutrophil  
elastase  is  necessary  for  NET  formation  and  mice  with  neutrophil  elastase  knockout  
did  not  form  NETs.    DNase  I  can  reduce  NET  formation  [90].      
1.11  Neutrophils,  macrophages  and  ARDS  
The  neutrophil  is  a  critical  cell  in  ARDS.    Both  infection-­triggered  and  sterile  ARDS  
models  have  shown  activation  and  mass-­migration  of  neutrophils  into  the  alveolar  
space,   driven   by   chemokines   from   epithelial   cells,   macrophages   and   other  
neutrophils  [85].    These  factors  can  promote  NETosis,  whilst  decreased  surfactant  
protein   levels   (SPA   and   SPB)   reduce   NET   clearance   [85],   alongside   surfactant  
deficiency  being  harmful  itself.    Although  peripheral  white  blood  cell  counts  are  lower  
in  ARDS  versus  at-­risk  patients,  bronchoalveloar  neutrophil  counts  are  increased  in  
ARDS  and  neutrophils  from  septic  patients  damage  in  vitro  endothelial  layers  [82].      
Alveolar   cell   injury   and   increased   alveolar-­capillary   permeability   arise   from   the  
various   direct  and   indirect  mechanisms  discussed  above.     Some  animal  models  
show   reduction   in  ARDS  with  neutrophil  depletion:   this   includes  LPS,  VILI,  acid-­
induced   and   transfusion-­associated,   whereas   oleic   acid   and   hyperoxia   induce  
ARDS  phenotypes  with  capillary-­alveolar  leak  even  with  neutrophils  depleted  [82].    
ARDS  has  been  described  in  neutropenic  patients,  suggesting  the  neutrophil  is  not  
essential  for  ARDS  [91].  
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In   a  murine   influenza   ARDS  model,  macrophage   depletion  was   associated  with  
clinical   illness  and  higher  viral   replication,  whereas  neutrophil  depletion  was  not.    
Macrophage   depletion   led   to   increased   neutrophil   numbers   and   worse   diffuse  
alveolar   damage   histologically.      Neutrophil-­depleted   rats   did   not   develop  
histopathological   evidence   of   ARDS,   although   they   did   have   bronchitis   and  
peribronchial  inflammation  by  day  five.    NET  formation  peaked  on  day  10,  and  was  
in  areas  of  heavily  damaged   lung  tissue,  worst   in  macrophage  depleted  animals.    
Myeloperoxidase  activity  was  higher  in  the  macrophage  depleted  group.  They  went  
on  to  show  wild-­type  mice  had  NETS  in  infected,  consolidated  areas  of  lung  and  
haemorrhagic  lesions,  when  challenged  with  lethal  doses  of  influenza  [92].    .  
The  instillation  of  histones  (a  key  component  of  formed  NETs)  instilled  into  the  lungs  
of   mice   produce   epithelial   damage,   alveolar   flooding   and   haemorrhage   and  
abnormal  thrombus  formation  in  the  lung’s  venules.    Neutrophil  depletion  reduced  
histone  levels  [93].    Humans  with  ARDS  showed  histones  were  present  in  ARDS  
bronchoalveolar  fluid  but  were  barely  detectable  in  controls  [93].    In  a  two-­hit  ARDS  
model,   lipopolysaccharide   (LPS)   combined  with   high-­volume   ventilation   induced  
NETosis,  but  NETosis  did  not  increase  with  LPS  alone  [90].    It  may  be  that  NETosis  
is   driven   by   secondary   insults   and   becomes   more   important   in   with   multiple  
pathologies.  
Preventing  neutrophil  degranulation  reduced  lung  injury  and  vascular  permeability  
in   a   Streptococcus   pyogenes   model   [82].      Neutrophil   elastase   damages   the  
endothelial  cytoskeleton,  targeting  actin,  E-­cadherin  and  VE-­cadherin,  contributing  
to   increased  alveolar-­capillary  permeability,   induces  apoptosis  and  releasing  pro-­
inflammatory   cytokines   [85].      Neutrophil   elastase   inhibition   has   been   shown   in  
animal  models   to   have  protective   effects   [82]   and   sivelestat   is   used   clinically   in  
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Japan   to   treat   ARDS   and   prevent   ARDS   following   oesophagectomy   (discussed  
above).    As  there  is  yet  to  be  an  agent  developed  which  selectively  inhibits  NETosis  
without   modulating   other   neutrophil   functions,   it   remains   to   be   conclusively  
determined  how   important  NETosis   itself   is   to  ARDS,  or  whether   it   represents  a  
marker  of  neutrophil  presence  [94].  
NETs  can  also  cause  microvascular  thrombosis  and  endothelial  dysfunction  as  well  
as   mediating   neutrophil-­platelet   interactions   [95].      Platelets   are   increasingly  
recognised   as   having   pro-­   and   anti-­inflammatory   effects,   and   disordered  
coagulation   is   an   important  pathogenic  mechanism   in  ARDS   [94].     NETosis   has  
been   linked   with   transfusion-­related   acute   lung   injury   (TRALI).      TRALI   is  
pathologically  distinct   from  ARDS,   in   that  donor  anti-­neutrophil  antibodies   (major  
histocompatibility   complex   class   one)   react   with   recipient   neutrophils   causing  
sequestration  in  the  pulmonary  vasculature.    The  importance  of  NETosis  in  TRALI  
has  been  confirmed  in  animal  models  and  supplementary  supporting  evidence  in  
humans  [96].      
In  surgery,  NETosis  has  been  shown  to  form  following  ischaemia-­reperfusion  from  
liver  resection,  with  larger  surgical  insult  being  associated  with  higher  NETosis  [97]  
and   NETosis   has   been   associated   with   primary   graft   dysfunction   following   lung  
transplant  [98].  
The  deposition  of   immune  complexes  has  also  been  associated  with  ARDS  [86].    
Furthermore,  inhibition  of  complement  C5a  or  its  receptors  (C5aR1  and  C5aR2)  can  
protect  against  the  development  of  ARDS  in  mouse  models  [86].  
1.12  TNF  alpha  
19  
  
The  Tumour  Necrosis  Factor  (TNF)  and  TNF  Receptor  (TNFR)  superfamily  is  highly  
conserved   in   nature   and   has   vital   functions   animals   as   diverse   as   mammals,  
zebrafish,  molluscs,  arthropods  and  corals  [99].    TNF  alpha  (initially  called  cachectin  
or   differentiation   inducing   factor)   plays   an   important   role   in   the   inflammatory  
response.    Initially  described  as  an  agent  that  allowed  macrophages  to  exert  control  
over  established  tumours  in  mice  [100],  it  has  an  array  of  roles  in  infection  and  the  
response  to  malignancy  [101].      
The  TNF  superfamily  has  19  ligands,  and  29  receptors  have  been  described  to  date  
[99].      TNF   alpha   is   a   type   two   transmembrane   glycoprotein   consisting   of   three  
monomer  units.    Production  largely  occurs  in  macrophages  and  T  lymphocytes,  but  
can  also  occur  in  other  immune  (B  lymphocytes,  natural  killer  cells,  neutrophils)  and  
non-­immune  cells  (endothelial  cells,  smooth  muscle,  cardiac  muscle,  fibroblasts  and  
osteoclasts)  [102].      
TNF   is   physiologically   available   in   soluble   and   membrane-­bound   forms.      This  
contributes   to   differential   effects   (see   below).      Transmembrane   TNF   has   a  
molecular   weight   of   75kDa,   higher   than   would   be   predicted   by   its   amino   acid  
sequence,  probably  from  glycosylation  and  phosphorylation  whilst  soluble  TNF  has  
a  molecular  weight  of  55kDa  [103].    Transmembrane  TNF  is  cleaved  by  TNF-­alpha-­
converting  enzyme  (TACE,  also  known  as  ADAM17)   to  a  soluble  17.6kDa  active  
unit,  although  other  proteases  can  have  the  same  effect  [101,  104,  105].    TACE  is  
a   member   of   the   adamalysin   family   of   zinc-­binding   metalloproteinases   and   is  
expressed  in  a  wide  range  of  tissues  [106].    In  TACE  gene  knockouts,  serum  TNF  
levels  fall,  whilst  membrane  bound  levels  are  higher  [106].      
1.13  Intracellular  signalling  from  TNFR1  and  TNFR2  
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Intracellular   signalling   from  TNFR1   and   TNFR2   is   complicated   and   not   yet   fully  
understood,  particularly  for  TNFR2  [107].    The  TNF  superfamily’s  receptor  signalling  
is   broadly   classified   into   two:   the   death   domain   receptors   (which   bear   a   death  
domain  that  can  trigger  apoptosis)  and  a  second  group  with  a  TRAF  (TNF  receptor  
adaptor  factor)  interaction  motif  (TIM)  domain,  which  are  able  to  bind  TRAF  proteins  
(although  they  may  also  be  able  to  signal  for  apoptosis  through  this  indirect  route)  
[108].  
TNFR1  assemble   as   trimers   prior   to   ligand  binding,  which   is   essential   for   signal  
transduction,  as  TNF  alpha  binding  changes  the  orientation  of  these  components  
[105,  109].    Signal  transduction  may  result  in  apoptosis,  necroptosis  or  cell  survival,  
depending  on  the  post-­receptor  modulation,  which  illustrates  the  complexity  of  TNF  
alpha’s  activity.    TNFR1  responds  to  both  soluble  TNF  and  membrane-­bound  TNF  
[108].      Upon   ligand-­binding,   two   receptor   signalling   complexes   form,   with   both  
spatial  and  temporal  separation.    Complex  one  activates  anti-­apoptotic  pathways,  
whilst  complex   two  (death-­inducing  signalling  complex  (DISC))   triggers  pro-­death  
processes  once  the  receptor  has  been  internalised  [108].  
Complex   one   consists   of   TNF   Receptor   Associated   protein   with   Death   Domain  
(TRADD)  interacting  with  TNFR1  via  its  death  domain,  alongside  a  number  of  other  
adaptor  proteins,  including  TRAF  2,  cellular  Inhibitor  of  Apoptosis  (cIAP)  1,  cIAP2  
and  Receptor  Interacting  Protein  (RIP)  1.    This  complex  in  turn  activates  Mitogen  
Activated  Protein  Kinase  MAP3K,  N-­terminal   jun  kinase  (JNK)  and  subsequently  
AP-­1,  whilst  it  may  also  acquire  LUBAC  (linear  ubiquitin  chain  assembly  complex),  
which  activates  I  kappa  B  kinase  (IKK)  and  so  upregulates  NF-­ΚB  [108].      
21  
  
TNFR1  complexes  may  also  be   internalised   [110],   deubiquitinated  and   form   the  
DISC   [108].      This   intracytosolic   vesicle   contains   TNFR1   associated   with   RIP1,  
TRADD,  FADD  and   caspase-­8.     Deletion   of   this   death   domain   inhibits   apoptotic  
signalling  [110].    If  NF-­KB  has  been  activated,  cFLIP  inhibits  complex  two  to  prevent  
caspase-­8  activation.    If  NF-­KB  is  inactive,  no  such  process  occurs  and  the  cell  will  
become   apoptotic.      If   caspase-­8   is   inhibited   or   deleted,   RIP1   and   3   can   be  
phosphorylated  and  trigger  necroptosis  [111],  although  this  cannot  occur  in  some  
cell  types  [108].      
NF-­ΚB  is  released  from  NF-­ΚB  inhibitor-­α,  via  IKK.    NF-­ΚB  moves  to  the  nucleus  
and  promotes  an  array  of  genes  [101]    NF-­ΚB  has  five  family  members  in  mammals,  
NF-­ΚB1.  NF-­ΚB2,  RelA,  RelB  and  c-­Rel  [112].    These  can  promote  a  range  of  gene  
modulations   which   are   responsible   for   the   manifestations   for   inflammation.      In  
ARDS,  NF-­ΚB  upregulation  is  a  crucial  component  of  ARDS  fibroproliferation  [113].  
Overall,  TNFR1  promotes  cell  survival   in  most  cell   types,  alongside   inflammation  
and  chemokine  synthesis,  whilst  promoting  death  of  infected  and  damaged  cells,  
and  orchestrating  both  organ  and  behavioural  responses  to  infection,  such  as  fever  
and  sleep  [107].      
TNFR2   responds   to   membrane-­bound   TNF,   whilst   soluble   TNF   is   a   much   less  
effective   ligand   [114].     When  membrane  bound  TNF  binds   to  TNFR2,   receptors  
trimerise  and  initiate  an  intracellular  signalling  cascade.    This  interacts  directly  with  
TRAF  2,  and  via  TRAF2,  TRAF1  and  3  and  cIAP  1  and  2  are  activated.    TRAF2  
activation  increases  NIK,  which  in  turn  decreases  IKBA,  activating  NFKB.    TRAF3,  
cIAP1  and  cIAP3  trigger  proteolytic  processing  of  p100,  which  also  leads  to  NFKB  
activation.     MAP3K  activation  also  upregulates  JNK   [108].      In  vitro  models  have  
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shown  both  TNFR1  and  2  signalling  is  needed  to  trigger  apoptosis  [115].    TNFR2  
lacks  a  death  domain,  so  direct  apoptosis  signalling  is  not  possible  [109].  
It  appears  TRAF2  is  subject  to  phosphorylation  initiated  by  TNFR2,  which  leads  to  
TRAF2’s   ubiquitination   and   proteasome-­dependent   degradation,   although   a  
number  of  other  possible  regulatory  pathways  have  been  described  [108].    TRAF2  
degradation  via  TNFR2  inhibits  anti-­apoptotic  signalling  in  some  situations  and  this  
implies   cooperative   signalling   for   apoptosis   between   TNFR1   and   TNFR2   [108].    
TNFR2  has  been  shown  to  protect  against  both  ischaemic  and  excitotoxic  effects  in  
the  central  nervous  system  [107].  
Although   it   has   the   capacity   to   trigger   apoptosis   indirectly,   it   is   thought   TNFR2  
primary  role  in  cell  signalling  is  to  trigger  cell  survival  and  differentiation  [101].    In  T-­
helper  cells,  TNFR2  is  important  for  T  regulator  cell  differentiation,  proliferation  and  
lineage  stability  [116].      
Both   TNFR1   and   2   are   cleaved   by   TACE   (like   TNF   alpha)   and   shed,   which  
decreases  cell  surface  expression  and  also  allows  the  free  receptor  to  bind  TNF,  
reducing  the  circulating  pool  [104].    TNFR2  levels  are  down-­regulated  via  reduced  
transcription  and  by  receptor  shedding.    The  resultant  TNFR2  is  able  to  bind  TNF  
but  signalling  function  is  lost  –  acting  in  two  ways  to  down-­regulate  TNF  by  reducing  
ligand  abundance  and  signal  transduction  apparatus  [103,  117].  
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Figure   2:   differential   signalling   pathways   for   TNFR1   and   TNFR2.      TNFR1   is  
stimulated  via  both  membrane-­bound  and  soluble  TNF,  whereas  TNFR2  responds  
to  membrane-­bound  TNF   only.      TRADD   allows   TNFR1   to   trigger   both   pro-­   and  
inflammatory  pathways,  providing  complex  regulatory  interplay  in  the  TNF  signalling  
cascade.  
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1.14  The  role  of  TNF  alpha  in  immunity  
TNF  and  TNFRs  are  important  for  the  effective  immune  response  but  also  many  of  
the  harmful  pathophysiological  processes  seen  in  sepsis  [102].    TNF  alpha’s  effects  
on   the   endothelium   promote   capillary   leakage   and   neutrophil   migration,   pro-­
coagulation  effects  and  anti-­viral  response  in  epithelial  cells  [118].    Both  capillary  
leakage  and   local  coagulation  are   important   in   the  pathogenesis  of  ARDS   [113].    
Macrophages  both  secrete  TNF  and  are  activated  by  it  [118].    Systemic  responses  
include   fever,   hepatic   modulation   of   acute   phase   reactants   and   haemopoietic  
regulation  [118].  
Mice   deficient   in   TNFR1   and/or   TNFR2   receptors   have   apparently   normal  
development  and  homeostasis   in  unstressed  conditions   [119].     Mice   lack  normal  
lymphoid  architecture  and  germinal  cell  formation  as  well  as  having  dysfunctional  
immune  response  and  tissue  repair  processes  [105].    TNFR1  knockout  mice  were  
susceptible  to  Listeria  monocytogenes  infection,  dying  at  what  would  be  sub-­lethal  
doses   in  wild-­type  mice.     This   indicates  TNF  alpha’s   importance   is   the  systemic  
immune  response,  although  liver  acute  phase  reactants  were  not  different  between  
knockout  and  wild-­type  mice,  indicating  preservation  of  multiple  immune  pathways.    
TNFR2   knockout   mice   were   comparable   to   wild-­type   controls   [119].      Both  
TNFR1/TNFR2   and   TNFR1-­alone   knockout   mice   were   protected   against   a  
combined   lethal   LPS-­D-­gal   (a   hepatotoxin   potentiated  by   LPS)   challenge,  whilst  
TNFR2  knockout  succumbed.    Resistant  mice  showed  no  symptoms  over  five  days.    
Sub-­lethal  dosing  showed   increased  susceptibility   in  TNFR2  knockouts   [119].     In  
contrast,   LPS   alone   was   less   lethal   in   TNFR1,   TNFR2   and   TNFR1/TNFR2  
knockouts  than  controls,  indicating  LPS  lethality  is  not  related  solely  to  TNF  alpha.    
This  indicates  although  TNFR1  is  critical  for  defence  against  pathogens,  its  function  
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is  complex  and  clearly  works  in  parallel  with  other  immune  pathways,  resulting  in  
overall  pro-­  or  anti-­inflammatory  effects  dependent  on  the  context  [119].  
TNF   increases   neutrophil   phagocytosis,   cytotoxicity,   endothelial   adhesion,  
degranulation  and  the  length  of  the  respiratory  burst  [120].    Roughly  similar  levels  
of  TNR1  and  2  have  been  reported  on  neutrophils,  whereas  TNFR2  predominates  
on  monocytes  [121].    Other  effects  include  regulation  of  organogenesis,  neuronal  
remyelination,   cardiac   remodelling,   cartilage   regeneration   and   inhibition   of  
tumorigenesis.    Pathogenic  functions  include  inflammation  induction,  necroptosis,  
inhibition   of   T-­regulatory   cells,   tissue   degeneration,   hypernocioception,  
tumourigeneisis  and  atherogenesis  [105].  
1.15  TNFR  signalling  in  vivo  
Transgenic  mice  bred  with  a  number  of  modifications  to  TNF  signalling  pathways  to  
elicit  the  relative  importance  of  TNF  signalling  by  different  cell  types.    Mice  bred  with  
uncleavable  membrane  bound  TNF  and  exposed  to  an  LPS  challenge  developed  
acute   restrictive   pulmonary   dysfunction,   unlike   completely   TNF   deficient   mice,  
which  did  not  respond.    BAL  neutrophil  and  macrophage  numbers  and  total  protein  
levels  (an  indicator  of  lung  permeability)  were  similar  between  mTNF  and  wild-­type  
mice   but   mTNF   mice   showed   reduced   lung   myeloperoxidase   activity.      Partial  
reductions   in   lung   inflammation   were   seen   in   mice   with   TNF   knockout   in   their  
macrophages   and   neutrophils   compared   to   wild-­type,   with   reduced   neutrophil  
recruitment  and  protein  leakage.    In  contrast,  mice  with  TNF  knockout  T  cells  had  
exacerbated   modelled   acute   respiratory   dysfunction,   with   significantly   higher  
neutrophil   numbers   [122].      This   illustrates   that,   even   in   a   comparatively   simple  
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situation   of   modelled   LPS-­induced   ARDS,   TNF   signalling   is   both   pro-­   and   anti-­
inflammatory,  depending  on  the  source  of  the  signal.  
There  is  an  interplay  between  ligand,  receptor  and  overall  activity;;  in  mice  deficient  
in  both  TNFR1  and  TNFR2,  TNF  levels  were  higher  following  an  LPS  challenge  than  
in  mice  lacking  either  receptor,  whilst  lowest  responses  were  seen  in  wild-­type  mice  
[119].    However,  hepatic  responses  in  terms  of  cytokine  secretion  were  similar  in  
both  receptor  knockout  mice  compared  to  wild-­type  controls,  again  demonstrating  
the  complexity  of  TNF  in  the  orchestration  of  the  immune  response  [119].  
TNFR  knockout  was  examined  in  mice  using  Micropolyspora  faeni  as  a  pneumonitis  
stimulus.      In  TNFR1  and  2  and  TNFR1   knockouts,   neutrophil   accumulation  was  
markedly   reduced,   whereas   lymphocyte   and   monocyte   levels   were   comparable  
across   strains.      In   comparison,  TNFR2   knockout  was  associated  with   increased  
neutrophil   influx   into   the   lung  [119].     However,  genotype  did  not  affect  neutrophil  
migration  in  response  to  intranasal  LPS  [119].    Increased  TNFR2  had  been  detected  
in  the  bronchoalveolar  lavage  fluid  of  patients  with  early  ARDS  (before  day  5  in  this  
study)  or  deemed  at  risk  of  ARDS,  although  not  in  the  late  ARDS  group  (after  day  
21)  [123].  
1.16  TNF  alpha  in  disease  states  and  as  a  pharmacological  target  
TNF   alpha   has   been   shown   to   upregulate   leucocyte   and   platelet   adhesion  
molecules,  upregulation  of  thrombogenic  and  fibrinolytic  pathways,  augment  other  
inflammatory  pathways  and  upregulation  of  vasodilators   including   inducible  nitric  
oxide.      Administration   of   TNF   in   animal   models   produces   patterns   of   organ  
dysfunction  similar  to  sepsis  [124].      
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An  array  of  different  inflammatory  mediators,  including  TNF  alpha,  play  a  role  in  the  
development  of  ARDS  [125].    TNF  alpha  causes  pulmonary  endothelial  apoptosis  
and  promotes  neutrophil  sequestration  from  the  circulation  to  the  pulmonary  tissue.    
It  increases  reactive  oxygen  species  generation,  which  increases  myosin  light  chain  
phosphorylation   and  decreases  epithelial   sodium  channel   expression,   promoting  
loss   of   the   epithelial   barrier   and   increased   alveolar   flooding   [125].      Increased  
vascular  permeability  may  also  be  observed  from  loss  of  barrier  function  of  epithelial  
cells  via  cytotoxic  effects  [115,  123].    Microtubular  disassembly  in  pulmonary  artery  
endothelium  has  been  demonstrated   [126,   127].     However,   TNF  alpha  has  also  
been   shown   to   promote   alveolar   fluid   clearance   via   increased   sodium   channel  
activation   in   the   alveolar   endothelial   cells,   driven   by   signalling   via   its   lectin-­like  
domain  [128,  129].    TNF  alpha  therefore  may  have  a  role  in  both  the  generation  and  
resolution  of  non-­cardiogenic  pulmonary  oedema  [129].  
There  has  been  a   therapeutic   revolution  with   the  development  of  antibodies   that  
bind   to   cytokines   to   modulate   disease,   including   in   rheumatology,   oncology,  
respiratory  medicine,  gastroenterology  and  haematology   [101].     TNF   inhibition   is  
effective  for  rheumatoid  and  other  arthritidies,  ankylosing  spondylitis,  psoriasis  and  
inflammatory  bowel  disease  [101].    TNF  appears  to  be  anti-­inflammatory  in  systemic  
lupus  erythematous,  whilst   improvements  have  been   shown   in  SLE  arthritis   and  
nephritis,  but  many  trials  have  been  abandoned  due  to  high  adverse  event  rates  
[130].    Multiple  sclerosis  is  made  worse  by  TNF  inhibition  [101].    Even  successful  
treatment   may   be   complicated   by   opportunistic   infection,   latent   tuberculosis  
reactivation,   lymphomas   and   autoimmune   disease   [101,   105].This   indicates   the  
complexity  of  TNF  in  disease  processes,  with  positive  effects  in  some  groups  and  
negative  in  others.    
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Agents   to   inhibit  TNF  were  based  on  binding   to  TNF  or  TNFR   to  prevent  signal  
transduction.    It  has  been  proposed  more  sophisticated  targeting  may  prevent  such  
complications,   including  natural  anti-­TNF   immunisation,   inhibiting  TNF  synthesis,  
blocking  multiple  cytokines  and  targeting  down-­stream  signalling  molecules  [131].    
Another  strategy  would  be  selective  TNFR  inhibition  or  stimulation  [132,  133].  
Animal  models  with  TNFR1  and  TNFR1/TNFR2  knockouts  using  a  polymicrobial  
intraperitoneal   sepsis   model   have   improved   survival   [134].      A   meta-­analysis   of  
clinical   trials  of  anti-­TNF  agents  sepsis   in  humans   in  showed  a  very  modest  net  
benefit,  but  this  has  not  translated  to  clinical  practice  and  uncertainty  remains  about  
timing  and  dosage  of   agents   [135].     Given   its   effects,   a   trial   requiring   in   excess  
10000  patients  would  be  needed  to  reliably  demonstrate  a  benefit  [136].  
Conventional  biologics  are  antibodies  require  parenteral  administration  because  of  
their  size  and  vulnerability  to  enteral  proteases.    However,  it  is  the  binding  domains  
which  are  of  crucial  importance.    A  Domain  Antibody  (DAB)  is  the  smallest  units  of  
an  immunoglobulin  that  will  bind,  which  may  be  generated  from  the  heavy  or  light  
chains  of  a  conventional  immunoglobulin  [137].    GlaxoSmithKline  have  developed  
an   anti-­TNFR1   DAB   GSK2862277,   which   consists   of   the   13kDa   fragment   of   a  
conventional  anti-­TNFR1  molecule’s  variable  region  and  bind  monovalently  with  the  
TNFR1   receptor   to   block   signalling,   avoid   receptor   stimulation   [137].      Selective  
TNFR1  blockade  has  been  proposed  as  a  possible  therapeutic  strategy  in  multiple  
sclerosis   [105,   107]   and   to   prevent   post-­operative   pulmonary   complications   and  
ARDS  [132].  
This  novel  agent  has  some  evidence  to  support  its  utility  for  ARDS.    In  mouse  VILI  
and  VILI/LPS  combined,  a  number  of  experiments  were  conducted  [132].    In  a  pure  
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VILI   model,   the   active   DAB   group   were   protected   from   deterioration   in   lung  
mechanics.     DAB  was  shown  to  reduce  neutrophil  counts   in   the   lung  and   lavage  
fluid  and  also  reduced  Intercellular  Adhesion  Marker-­1  (ICAM-­1).    BAL  protein  and  
TNF   levels  were   higher   in   the   untreated  group.     Alveolar   protein   deposition   and  
neutrophil  migration  were  attenuated  in  the  DAB  group.    Repeating  the  experiment  
with  the  VILI/LPS  model  showed  similar  results.    Monoclonal  anti-­TNF  did  not  show  
the  beneficial  effects  of  the  DAB.    The  benefits  of  the  DAB  over  monoclonal  anti-­
TNF  may   be   due   to   better   delivery   and/or   tissue   penetration   or   specific   TNFR1  
signalling  modulation  [132].    A  further  experiment,  using  inhaled  LPS  as  a  model  of  
mild  ARDS  in  healthy  human  volunteers,  showed  reduced  inflammatory  indices  and  
lower  BAL  neutrophil  counts  [133].  
As  DAB  was  administered  before  the  injurious  stimulus,  it  may  be  most  useful  as  a  
preventative  agent  or  early  in  ARDS.    This  may  differ  significantly  from  the  effects  
of  the  agent  in  established  ARDS,  and  indeed  may  alter  depending  on  the  stimulus  
(for  example,  pneumonia  or  non-­pulmonary  sepsis  may  very  well  be  different  from  
VILI).    Prevention  of  lung  injury,  using  pulmonary  vascular  permeability  index  (PVPI)  
and  extravascular  lung  water  index  (EVLWI)  as  biomarkers,  has  been  tested  in  a  
clinical   trial,  using  oesophagectomy  as  a  model  of  ARDS   (TFR116341  EudraCT  
Number:  2014-­000643-­33).  
1.17  Summary  
Post-­operative  respiratory  complications  and,   in  particular,  ARDS  are  serious  yet  
potentially   preventable   problems   that   follow   surgery.      Patients   undergoing  
oesophagectomy  are  at  particular  risk  of  post-­operative  pulmonary  complications  
and  ARDS.    Perioperative  strategies  to  prevent  ARDS  may  well  have  a  significant  
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role  to  play  in  the  reduction  in  harm  to  patients.    TNF  alpha  may  represent  a  useful  
therapeutic  target  and  there  are  existing  data  to  support  this.      
The  original  intention  of  this  thesis  was  to  analyse  the  clinical  and  biomarker  data  
from  the  TFR116341  trial,  its  translational  sub-­studies.    It  was  also  planned  to  study  
and   compare  with   prior   trials   utilising   oesophagectomy   as   a  model   of   ARDS   to  
assess   its   continuing   utility   as   a  model,   given   the   changes   occurring   in   clinical  
practice  in  this  cohort  [13].  
The  aims  of  this  thesis  were  to:  
1.   Confirm  the  importance  of  ARDS  in  the  context  of  oesophagectomy.  
2.   Investigate   the   differences   observed   between   trials   which   have   used  
oesophagectomy  as  a  model  of  ARDS  
3.   Seek  insights  into  the  evolving  challenges  of  recruiting  patients  undergoing  
oesophagectomy  to  trials  of  perioperative  pharmacological  interventions.  
4.   Investigate  perioperative  immune  modulation  in  oesophagectomy  relevant  to  
ARDS.  
5.   Investigate   the   effects   of   a   novel   agent   (GSK   2862277)   developed   as   a  
potential  ARDS  modulator  in  the  context  of:  
a.   Modulation  of  neutrophil  function  in  vitro.  
b.   Modulation  of  macrophage  function  in  vitro.  
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2.1  The  impact  of  the  acute  respiratory  distress  syndrome  on  outcome  after  
oesophagectomy  
Trial  participants  
Between   April   2008   and   June   2011,   362   adult   patients   undergoing   elective  
oesophagectomy   were   enrolled   into   the   BALTI-­Prevention   trial   at   12   academic  
hospitals  in  the  UK.  The  results  have  been  published  previously  [138].  The  North  
American-­European   Consensus   Criteria   were   used   to   define   ALI/ARDS:   (ALI  
PaO2:FIO2<40.0  kPa;;  ARDS  PaO2:FIO2<26.7  kPa)  at  the  time  and  for  the  design  
of  the  study  [46].  
Intervention  and  Data  collection  
Baseline   characteristics,   operative   information   and   postoperative   variables  were  
recorded   for   all   participants.   Anaesthetists   were   instructed   to   follow   a   low   tidal  
volume  and  fluid  conservative  strategy,  but  otherwise  management  was  left  to  the  
individual   clinician′s   discretion.   Patients   were   defined   as   having   ARDS   in   the  
presence  of  hypoxaemia  (PaO2:FIO2  ratio  less  than  40.0  kPa),  bilateral  infiltrates  
on  the  chest  x-­ray  and  absence  of  clinical  evidence  of  left  atrial  hypertension  and  
categorized  as  having  early  (day  0–3),  late  (day  4–28)  or  no  ARDS  according  to  the  
timing  of  the  first  episode  of  ARDS.  The  categorization  of  ARDS  was  made  a  priori  
into  ‘Early’  and  ‘Late’,  to  separate  ‘primary  ARDS’  associated  with  the  initial  insult  
of  surgery  and  anaesthesia   from  that  acquired  by   later  complications  (secondary  
ARDS),  such  as  anastomotic  leak.  
Study  outcomes  were  ventilator  free  days,  organ  failure  free  days,  28  and  90  day  
mortality  and  health-­related  quality  of   life  measured  by  Euroqol  Health  Outcome  
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Questionnaire  (EQ5D)  at  28  and  90  days.  Ventilator-­free  days  were  as  previously  
defined.22  Organ  failure–free  days  were  defined  in  a  similar  manner,  with  an  organ  
failure–free   day   being   a   day   without   evidence   of   non-­respiratory   organ   failure.  
Organ  failure  was  defined  by  a  Sequential  Organ  Failure  Assessment  score  of  four  
or  more.24  Postoperative  pneumonia  was  recorded  if  diagnosed  by  the  attending  
clinicians.  As  patients  had  undergone  recent  upper  gastrointestinal  surgery,  non-­
invasive   ventilation   was   not   used   as   a   standard   measure,   but   was   not   strictly  
prohibited.   Levels   of   care   were   determined   according   to   United   Kingdom  
Department  of  Health  definitions  [139].  
Statistical  analysis  
Linear  regression  of  secondary  outcomes  comparing  ARDS  status  was  undertaken  
with  and  without  adjustment  for  randomization.  Linear  regression  models  were  then  
fitted   for   the   secondary   outcomes   for   ARDS   status   with   an   interaction   term,   to  
examine  whether  treatment  difference  depended  on  observed  ARDS  status.  
Multivariate  logistic  regression  was  performed  to  establish  a  risk  model  for  ARDS,  
examining  all  recorded  potential  risk  factors.  A  forward  stepwise  regression  model  
was  produced  using  the  specified  baseline  variables  used  in  the  univariate  analysis,  
with  P  values  of  0.05  and  P  value  of  0.1  for  subsequent  removal  from  the  model.  
Multivariate  analysis  was  then  fitted  for  each  stage  of  ARDS,  to  examine  whether  
the  response  to  different  treatments  was  dependent  on  baseline  characteristics.  An  
unadjusted   model   was   fitted,   including   terms   for   treatment   allocation,   baseline  
moderation  and  terms  for   treatment  by  moderator   interaction.  An  adjusted  model  
was  also  produced,  containing  terms  for  treatment,  moderator  and  interaction  with  
terms  for  age  and  hospital.  
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Safety   outcomes   were   analysed   according   to   ARDS   status.   These   included  
respiratory,  cardiovascular,  surgical  and  other  complications  and  sepsis.  Adverse  
events  were  defined  as  atrial   fibrillation,  ventricular  bigeminy,  hypokalaemia  and  
sinus   tachycardia.   Serious   adverse   events   included   anastomotic   leak,   ARDS,  
arrhythmia,  pleural  effusion,  pneumonia,  chyle  leak,  respiratory  failure,  inoperable  
tumour,   pneumothorax,   sepsis,   surgical   complications   and   other.   Data   were  
analysed  using  STATA  Version  11,  (StataCorp  LP,  College  Station,  Texas,  USA).  
2.2  ARDS  following  oesophagectomy:  a  comparison  of  two  trials  
Details  of   the  methods  of   the  BALTI-­P   trial  and   the  associated   translational  sub-­
study  have  been  published  previously   [138].  Patients  were   randomised   to  either  
placebo  or   inhaled  salmeterol  preoperatively  and  postoperatively.  At   two  hospital  
sites  (Queen  Elizabeth  Hospital  Birmingham  and  Birmingham  Heartlands  Hospital,  
UK),   patients  were   recruited   to   the   translational   sub-­study.   The  VINDALOO   trial  
protocol   has   been   published   [140].   Patients   were   recruited   at   Queen   Elizabeth  
Hospital  Birmingham  and  Birmingham  Heartlands  Hospital,  UK,  and  randomised  to  
either  placebo  or  a  single  dose  of  300  000  IU  of  vitamin  D.  In  both  studies,  patients  
underwent  oesophagectomy  with  care  provided  as  deemed  clinically  appropriate  by  
the  attending  surgeons  and  anaesthetist  and  followed  for  their  hospital  stay.  
Databases  of  the  outcomes  from  the  two  trials  were  available  for  analysis.  Smoking  
status  was  self-­reported  in  both  trials.  We  collected  additional  data  retrospectively  
using  medical  notes,  intensive  care  unit  (ICU)  charts,  electronic  patient  databases  
and   clinical   letters,   which   provided   the   preoperative   drug   history,   data   for  
preoperative   risk   scoring   and   intraoperative   drugs   used.   The   administration   of  
regular  medications  on  the  morning  of  surgery  was  at  the  discretion  of  the  attending  
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anaesthetist.   In   the   BALTI-­P   sub-­study,   patients   were   excluded   if   they   did   not  
undergo   an   oesophagectomy   with   attempted   one   lung   ventilation   (OLV).   In  
VINDALOO,  only  patients  who  passed   the  primary  endpoint  of  oesophagectomy  
with  OLV  and  postoperative  PICCO   readings  were   included   (consistent  with   the  
VINDALOO  trial’s  analysis).  
Differences   in   the   baseline   characteristics   and   perioperative   care   between   trials  
were  assessed.  Outcomes  for  both  trials  were  determined  by  a  clinical  endpoints  
committee.  ARDS  was  defined  using  the  Berlin  criteria  [45]  for  the  VINDALOO  trial.  
The  BALTI-­P  trial  pre-­dates  the  Berlin  criteria,  which  could  not  be  applied,  as  applied  
positive  end-­expiratory  pressure  was  not  recorded.  Therefore,  we  defined  ARDS  in  
the  BALTI-­P  trial  participants  as  those  with  a  Pao2:Fio2  (P:F)  ratio  of  39.9  kPa  or  
below,  bilateral  chest  X-­ray  infiltrates,  absence  of  cardiogenic  dysfunction  sufficient  
to  explain  pulmonary  oedema  (based  on  the  opinion  of  the  attending  clinician)  and  
requiring  invasive  ventilation  (ventilation  with  positive  end-­expiratory  pressure  of  5  
cm  H2O  was  standard  care  in  the  ICUs  involved  and  non-­invasive  ventilation  was  
contraindicated  in  patients  following  upper  gastrointestinal  surgery  at  the  time  both  
trials  were  undertaken).  
Statistical  analysis.  
Continuous   variables   were   subject   to   normality   testing   using   the   Kolmogorov-­
Smirnov  test.  For  the  patients’  baseline  data  and  univariate  analysis  of  perioperative  
factors,  normally  distributed  continuous  variables  were  analysed  with  Student’s  t-­
test,  non-­normally  distributed  data  with  the  Kruskal-­Wallis  test  and  Mann-­Whitney  
U-­test  and  categorical  data  with  the  Χ2  or  Fisher’s  exact  test  as  appropriate.  Those  
factors   that  were   significant   (P<0.05)  were   then   subject   to  multivariate   analysis.  
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Multivariate   analysis   of   ARDS   status   was   undertaken   using   forward   conditional  
multivariable   binomial   logistic   regression   of   the   two   significant   factors   in   the  
univariate  analysis.  Analyses  of  baseline  and  univariate  data  were  undertaken  using  
GraphPad   Prism   V.6.07   for   Windows   (GraphPad   Software,   La   Jolla,   California,  
USA).   Multivariate   analyses   were   performed   using   SPSS   Statistics   V.22.0   for  
Windows  (Version  22.0,  IBM,  Armonk,  New  York).  
2.3  TFR116341  Trial  
The   TFR116341   trial   was   approved   by   the   West   Midlands   (Coventry   and  
Warwickshire)   Ethics   Committee   and   was   listed   in   the   European   Union   Clinical  
Trials   Register   (EudraCT   Number   2014-­000643-­33).      Patients   due   to   undergo  
oesophagectomy  for  cancer  were  randomised  to  receive  a  single  dose  of  novel  anti-­
TNFR1   agent   GSK2862277   or   placebo,   and   screened   systematically   for   ARDS  
post-­operatively.  
Patients   were   recruited   from   a   number   of   academic   hospitals   in   the   UK.      A  
translational  sub-­study  was  run  at  two  academic  centres  in  Birmingham.    Inclusion  
criteria  were  planned  surgical  transthoracic  oesophagectomy,  aged  18-­80,  capable  
of  giving  informed  consent,  without  substantial  derangements  of  liver  function  and  
normal   QT   interval.      Females   were   eligible   if   they   were   post-­menopausal,   had  
undergone  tubal  ligation  or  hysterectomy.  
Exclusion  criteria  were:    
•   a  positive  test  for  antibodies  binding  GSK2862277.  
•   pneumonia  within  14  days  of  dosing.  
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•   forced   expiratory   volume   in   one   second   under   50%   predicted   or   resting  
oxygen  saturation  of  less  than  92%  (in  those  subjects  where  these  tests  were  
performed).  
•   history  of  allergy  to  study  medication.  
•   having   received   or   due   another   investigational   product   within   30   days   of  
dosing,  corticosteroids  (10mgday-­1  or  more  of  prednisolone  or  equivalent),  
anti-­TNF  or  anti-­interleukin-­1  60  days  prior  to  dosing.  
•   history  of  severe  systemic  disease  the  investigator  felt  rendered  unsuitable.  
•   chronic  liver  disease.  
•   alcohol  intake  of  over  28  units  for  males  and  14  units  for  female.  
•   positive   serology   for   hepatitis   B   or   C,   human   immunodeficiency   virus  
infection.  
•   Mycobacterium   tuberculosis   infection   (demonstrated  by   positive   interferon  
gamma  release  assay  Quantiferon™  test).  
•   live  attenuated  vaccination  within  three  weeks  of  dosing  or  required  before  
day  28.  
Screening   for   antibodies   to   GSK2862277   was   performed   in   a   GSK   facility   in  
Philadelphia,   USA,   and   therefore   seven   days   from   recruitment   to   surgery   were  
required   to   allow   time   for   transportation,   US   Federal   customs   procedures   and  
testing.  
Patients   were   randomised   to   receive   either   drug   or   placebo   in   a   double-­blind  
manner,  via  an  eFlow  Rapid™  ultrasonic  nebuliser  (Pari,  Starnberg,  Germany),  one  
to   five   hours   prior   to   the   start   of   surgery.      Once   under   general   anaesthesia,   a  
PICCO™  cardiac  output  monitor  (Pulsion,  Feldkirchen,  Germany)  was  placed  with  
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a   femoral   intra-­arterial   catheter   and   readings   were   taken   before   surgery  
commenced.      At   the   end   of   surgery,   further   PICCO   readings  were   taken   and   a  
bronchoscopy  and  bronchoalveolar  lavage  (BAL)  was  performed  prior  to  extubation.      
The   primary   endpoint   of   the   study   was   the   change   in   pulmonary   vascular  
permeability   index   (PVPI)   [141]  on  completion  of  surgery.     Secondary  endpoints  
were  change   in  extravascular   lung  water   index  (EVLWI),  adverse  events,  clinical  
laboratory   safety   data,   ECG   readings,   vital   signs,   PaO2:FiO2   ratios,   BAL   fluid  
biomarker  ratios,  changes  in  ,  PaO2:FiO2  ratios,  PVPI,  EVWLI  and  sequential  organ  
failure  assessment  scores  on  days  two  to  four,  plasma  and  BAL  drug  concentrations  
and  derived  pharmacokinetic  data,  incidence  of  the  development  of  antibodies  to  
GSK2862277,  ARDS  incidence  to  day  28,  survival  to  day  28,  ventilator  free  days,  
ICU   and   hospital   length   of   stay,   organ   failure   free   days,   haemodynamic  
assessments,  oxygenation  index  and  plasma  biomarker  changes  over  time.  
It  was  estimated  having  40  patients   in  each  arm  would  provide  adequate  power,  
based  on  data  from  the  Beta  Agonists  in  Lung  Injury  –  Prevention  Trial  (BALTI-­P)  
[138].      Interim   safety   analyses   were   planned   at   10   and   40   patients   recruited.    
Recruitment   estimates   were   based   on   experience   from   the   BALTI-­P   [138]   and  
Vitamin   D   to   prevent   acute   lung   injury   following   oesophagectomy   (VINDALOO)  
[140]  studies.      
Statistical  analysis.  
Data  was  categorical  and  therefore  described  using  percentages.    Comparison  of  
the   number   of   patients   who   were   screened,   dosed,   withdrew   or   had   surgery  
cancelled/abandoned/changed,  was  made  using  a  chi-­squared  test.    Analysis  was  
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undertaken  using  GraphPad  Prism  V.6.07   for  Windows   (GraphPad  Software,  La  
Jolla,  California,  USA).  
2.4  Neutrophil  studies  
Whole  blood  was  available  from  the  following  sources:  
•   Healthy  young  controls:  volunteers  under  the  age  of  45  without  pre-­existing  
medical   conditions,   and   healthy   young   volunteers   (under   the   age   of   35)  
recruited   to   the  Mechanisms   for   the   susceptibility   to   bacterial   infection   in  
those  with  influenza  (REC  Ref  16/WM/0026).  
•   Healthy   elderly   controls:   patients   recruited   to   the   Mechanisms   for   the  
susceptibility   to   bacterial   infection   in   those   with   influenza   (REC   Ref  
16/WM/0026),  drawn  from  the  Healthy  Elders  cohort,  a  group  of  volunteers  
registered   with   the   Institute   of   Inflammation   and   Ageing,   University   of  
Birmingham,  who  donate  blood  and  participate  in  experimental  work  relating  
to  ageing  and  immunity.  
•   Pre-­operative  and  on  the  first  day  postoperatively  following  oesophagectomy  
from  the  TFR116341  trial  (EudraCT  Number  2014-­000643-­33).  
•   Patients  with  established  critical   illness  recruited  from  A  feasibility  study  of  
early   and   enhanced   rehabilitation   in   critical   care   and   potential   impact   on  
immuno-­endocrine  function  (trial  registry  number  ISRCTN90103222).  
2.4.1  Neutrophil  extraction  
Whole  blood  was  taken  and  mixed  with  dextran.    After  45  to  60  minutes,  the  plasma  
was  removed  and  overlaid  to  a  gradient  of  56%  and  80%  Percoll™  diluted  in  0.9%  
sodium  chloride  and  centrifuged  at  220g  for  20  minutes  with  minimal  acceleration  
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and   no   brake.      The   overlying   fluid   left   was   aspirated   and   discarded,   then   the  
granulocyte   layer   aspirated   into   phosphate   buffered   saline.      This   was   then  
centrifuged  at  400g  for  10  minutes,  then  the  neutrophils  re-­suspended  in  RPMI  with  
glutamine,  penicillin  and  streptomycin,  adjusted  to  give  a  final  count  of  1million  per  
ml.    100ul  samples  of  some  extractions  were  centrifuged  at  300rpm  for  5  minutes  
on  a  Cytospin  centrifuge  (Shandon,  Minnesota,  USA)  for  quality  control  checks.  
2.4.2  Neutrophil  extracellular  trap  chemiluminescence  assay  (figure  3)  
Neutrophils  were  extracted  from  whole  blood  taken  in  EDTA  containing  Vacutainer  
bottles  (BD,  Franklin  Lakes,  New  Jersey,  USA),  as  outlined  above.    Neutrophils  (3ml  
at  1  million  per  ml)  were  exposed   to  10ng/ml  soluble  TNF-­alpha   (for  priming)  or  
vehicle  control  for  15  minutes  at  37C  and  5%CO2,  before  being  centrifuged  at  400g  
for  10  minutes  at   room   temperature  and  being   re-­suspended  at  RPMI.     100ul  of  
neutrophils  at  1  million  per  ml  were  added  to  100ul  of  RPMI  as  vehicle  control  or  
PMA   (final   concentration   625ng/ml)   as   a   stimulant   with   or   without   DAB  
GSK2862277  or  dummy  DAB  at  10nM  final  concentration.    Each  condition  was  run  
in  quadruplicate.    They  were  incubated  for  three  hours  at  37C  and  5%  CO2.    Sytox  
Green  dye  (20ul  at  5uM  in  PBS)  was  added  to  each  well  with  200mIU  of  MNase.    
This  was  incubated  at  room  temperature  for  10  minutes  in  the  dark,  and  then  the  
contents   of   each  well  was  moved   to   a  micro-­Eppendorf   tube  and   centrifuged  at  
1500g  for  10  minutes.    160ul  of  supernatant  was  added  to  a  black  96-­well  plate  and  




For  experiments  with  DAB,  either  DAB,  Dummy  DAB  or  vehicle  control  were  applied  
during  the  15  minute  period  for  priming  (referred  to  as  “priming  phase”)  or  during  
the  three  hour  incubation  (referred  to  as  “incubation  phase”).     
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Figure   3:   flow   diagram   illustrating   Priming   and   Stimulation   phases   of   NETosis  
assay.  
  
     
43  
  
2.4.3  Phagocytosis  assay  
Neutrophils  were   extracted   from  whole   blood   taken   in   lithium-­heparin   containing  
Vacutainer  bottles  (BD,  Franklin  Lakes,  New  Jersey,  USA),  as  outlined  above.      
A  96  well  u-­bottomed  plate  was  prepared  by  instilling  wells  with  200ul  2%  BSA-­PBS  
then  removing  it.    100µL  of  neutrophils  prepared  at  1  million  per  ml  in  RPMI-­GPS  
were  added  to  all  wells,  except  for  the  0min  time  point,  which  were  placed  on  ice  in  
Eppendorfs.      Gram   positive   (Staphylococcus   aureus)   and   Gram   negative  
(Escherichia  coli)  pHrodo  bioparticles™  (Thermofisher,  Paisley,  United  Kingdom)  
were  added   to   the  appropriate  wells.     Samples  of  neutrophils   treated  with  CD16  
alone,   isotype  control  alone  and  untreated  were  also   run,   to   identify  background  
signal  and  as  controls  for  gating  the  assay  using  the  flow  cytometer.  
At  time  points  (60  minutes  and  30  minutes),  pHrodo  particles  were  added  to  wells.    
During  the  course  of  the  assay,  the  plate  was  incubated  at  37C  and  5%  CO2.    Once  
the   time   course   was   complete,   the   plate   was   placed   on   ice   to   stop   further  
phagocytosis,  and  the  Eppendorfs  kept  on  ice  added  to  the  plate.    It  was  centrifuged  
at  400g  for  5  minutes  at  4°C.    The  supernatant  was  removed  by  firm  tapping  and  
blotting  onto  paper.    100µL  of  2%BSA-­PBS  was  added  to  re-­suspend  the  cells.    1uL  
of   CD16   anti-­human   allophycocyanin-­conjugated   IgG1   antibody   (ThermoFisher,  
Paisley,  United  Kingdom)  was  added  to  the  CD16  control  and  the  timed  neutrophil  
wells.    An  isotype  control  (APC  IgG1,  ThermoFisher,  Paisley,  United  Kingdom)  was  
added  to  the  isotype  control  well.    These  antibodies  were  incubated  on  ice  for  20  
minutes.      Following   this,   a   further   99µL   of   2%   BSA-­PBS   was   added,   then  
centrifuged  at  400g  for  5  minutes  at  4°C.    The  supernatant  was  removed  by  firm  
tapping  and  blotting  onto  paper.    The  cells  were  re-­suspended  in  200µL  2%  BSA-­
44  
  
PBS  and  transferred  to  flow  cytometry  tubes.    The  samples  were  then  run  on  the  
Accuri  C6  flow  cytometer  (BD  Biosciences,  San  Jose,  California,  USA).    The  gating  
strategy  was  to  exclude  background  and  isotype  control  signals.    The  CD16  signal  
was  used  to  identify  neutrophils  from  the  background  of  pHrodo  particles,  then  the  
median   fluorescent   index   and   percentage   of   neutrophils   positive   for   signal   was  
obtained.    These  were  multiplied  to  provide  a  phagocytic  index.  
Phrodo   bioparticles   are   coloured   with   a   pH-­sensitive   dye.      When   they   are  
phagocytosed,  the  decrease  in  pH  in  the  phagosome  relative  the  media  causes  the  
dye  to  become  visible  when  exposed  to  FL2  laser  light  on  the  Accuri  C6.  
2.4.4  Neutrophil  receptor  analysis  
Whole  blood  was  taken  into  tubes  containing  lithium  heparin  as  an  anticoagulant.    
Following   a   protocol   from   R&D   Systems   (Minneapolis,   Minnesota,   USA)   100µL  
blood  was  placed  into  flow  cytometry  tubes,  to  which  0.5ml  0.5%  BSA  in  PBS  was  
added,  vortexed  and  centrifuged  at  500g  for  5  minutes  at  4°C,  twice.    Fluorochrome-­
labelled  antibodies  were  then  added  as  required  by  the  individual  experiments  and  
incubated  at   room   temperature   in   the   dark   for   30  minutes   (5µL  anti-­TNFR1,  PE  
conjugated   and   anti-­TNFR2,   FITC   conjugated,   R&D   Systems   Minneapolis,  
Minnesota,  USA  and  5µL  of  CD16  anti-­human  allophycocyanin-­conjugated   IgG1  
antibody   from   ThermoFisher,   Paisley,   United   Kingdom,   and   appropriate   isotype  
controls  from  the  same  manufacturer).    500µL  of  R&D  Flow  Cytometry  Buffer  (R&D  
Systems,   Minneapolis,   Minnesota,   USA)   was   then   added,   vortexed,   then  
centrifuged  at  300g  for  5  minutes  at  4°C,  the  supernatant  discarded  and  the  wash  
repeated.    1ml  BD  lysis  buffer  was  then  added  and  incubated  for  10  minutes  at  room  
temperature  in  the  dark.    This  was  then  centrifuged  at  300g  for  5  minutes  at  4°C,  
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then  washed  once  in  500µL  Flow  Cytometry  Buffer  and  centrifuged  at  300g  for  5  
minutes  at  4°C.    The  cells  were  then  re-­suspended  in  200ul  Flow  Cytometry  Buffer  
and  read  on  the  Accuri  C6  BD  Flow  Cytometer.  
Identification  of  neutrophils  was  as  follows.    The  forward  versus  side  scatter  was  
used  to  determine  populations  of  neutrophils  and  lymphocytes,  as  described  [142].    
Additionally,   the   CD16   marker   was   used   to   identify   neutrophils   from   within   the  
granulocyte   cluster.     Gates   for   TNFR1  and  TNFR2   labelled   antibodies  were   set  
against  blank  cells  and  isotype  controls.    An  FMO  control  run  against  the  blank  was  
performed.  
2.5  Cell-­free  DNA  
A  standard  curve  using  calf  thymus  DNA  (Sigma  Aldrich,  Gillingham,  UK)  serially  
diluted   in   Tris-­EDTA   was   formed,   of   200ul   ranging   from   0   to   250ngml-­1,  
corresponding  to  the  lower  and  upper  limits  of  detection.    100ul  of  plasma  samples  
in  EDTA  were  used,  combined  with  100ul  Tris-­EDTA.    20ul  of  sytox  green  at  20uM  
was  added  to  each  well  and  the  plate  incubated  for  10  minutes,  then  the  plate  was  
read  on  the  fluorometer.  
2.6  BALTI-­P  and  VINDALOO  cytokine  levels  
These   experiments   were   undertaken   by   the   original   trial   teams   and   the   data  
provided  by  Professor  D  Thickett  for  further  analysis.    Plasma  cytokine  levels  and  
S-­RAGE  biomarker  data  were  available   from   the  BALTI-­P   [138]  and  VINDALOO  
[143]   trials.      These   had   been   determined   using   Luminex   and   ELISA   kits   (R&D,  
Abingdon,  UK),   as   described   [138].      These  were   analysed   to   investigate   further  
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immunological  features  associated  with  oesophagectomy.    Equivalent  cytokine  data  
was  not  available  from  the  TFR116341  trial  due  to  slow  trial  recruitment.  
2.7  THP-­1  cell  work  
THP-­1   cells   are   a   human   monocytic   cell   line   which,   when   stimulated,   will  
differentiate   to  a  human  macrophage  model   [144].     THP-­1s   for   this  project  were  
provided   by   Dr   A   Scott,   Institution   of   Inflammation   and   Ageing,   University   of  
Birmingham.    THP-­1s  were  held  in  long-­term  culture  in  RPMI  10%  FCS  and  GPS.    
THP-­1s  were  recovered  from  suspension  by  centrifugation  at  500g  for  5  minutes  at  
4°C.    They  were  then  resuspended  in  a  known  volume  of  RPMI  10%  FCS  and  GPS  
and  their  concentration  determined  using  dilution  in  an  equal  volume  of  trypan  blue  
(Sigma   Aldrich,   Gillingham,   UK)   and   their   concentration   determined   using   a  
Haemocytometer.     They  were  constituted  at  500000  cells  per  ml   then  stimulated  
with  PMA  at  100ngml-­1.    These  were  plated  at  500ul  in  12  well  or  100ul  in  96  well  
(black  with  clear  bottom)  plates.    These  were  incubated  37°C  and  5%  CO2  for  24  
hours.    Media  were  changed  at  24  hours  and  the  THP-­1s  continued  in  culture  for  1-­
3  days.  
In   order   to   assess   the   effects   of   DAB,   those   cells   in   12-­well   plates   had  media  
removed,   then   250ul   added   with   vehicle   control,   DAB   or   Dummy   DAB   as  
appropriate  (concentrations  were  doubled  in  order  to  account  for  further  dilution  –  
see  below).    After  one  hour,  250ul  bronchoalveolar  fluid  (pooled  from  neutrophil-­rich  
BAL  available  from  the  VINDALOO  trial)  was  added  and  incubated  for  6  hours.    BAL  
contained  TNF  alpha  2.4pg/ml,   IL1  beta   12.9pg/ml,   IL1-­ra   35.7   pg/ml,   IL6   436.7  
pg/ml,   IL8   608.5   pg/ml,   IL10  0.11pg/ml,   IL17  0.68pg/ml,  TNFR1  231.8pg/ml   and  
TNFR2   375.8pg/ml.      This   addition   of   fluid   led   to   final   DAB   or   Dummy   DAB  
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concentrations  at  10  or  100nM.    Trials  were  also  run  with  1  or  10ng  of  sTNF.    After  
6  hours,  the  BAL  mix  was  removed  and  the  media  replaced  (with  DAB  and  Dummy  
DAB)   and   incubated   for   18-­24  hours.     After  24   hours,   this  media  was   removed,  
centrifuged  at  500g  for  5  minutes  and  the  supernatant   recovered  and  frozen  at  -­
80°C  until  further  analysed.  
2.7.1  Cell  viability  assay  
The  THP-­1  cells  treated  as  described  above  were  then  exposed  to  160ul  of  CellTiter  
96  Aqueous  One  Solution  (Promega  Corporation,  Madison,  Wisconsin,  USA).    The  
plate  was  incubated  for  2  hours  then  the  100ul  transferred  to  a  96  well  black  plate  
with  clear  bottoms,  then  read  on  a  plate  reader.    This  was  repeated  at  four  hours.  
2.7.2  DCFDA  assay  
In   order   to   assess   reactive   oxygen   species   formation,   a   kit   utilising   2’,7’–
dichlorofluorescin  diacetate  (DCFDA)  (Abcam,  Cambridge,  UK)  was  used.    The  96-­
well  plate  had  the  media  changed,  then  DAB  or  Dummy  DAB  added  into  50ul  media.    
After  one  hour,  50ul  of  pooled  BAL  was  added,  leaving  the  DAB  and  Dummy  DAB  
at  10nM.    This  was  incubated  for  6  hours,  then  the  media  replaced  and  DAB  and  
Dummy  DAB  was  added.     This  was   then   incubated   for  18-­24  hours.     The  media  
were  removed  and  100ul  of  buffer  was  added  to  each  well.    This  was  removed  and  
100ul  DCFDA  solution  was  added  and  incubated  for  4  hours  at  37°C  in  5%  CO2  in  
the  dark.    This  was  then  removed  at  a  further  100ul  buffer  added  and  the  plate  read.  
2.8  Alveolar  macrophage  recovery  
The  Midlands   Lung   Tissue   Collaborative   consents   patients   undergoing   thoracic  
surgery  at  Heartlands  Hospital,  Birmingham,  UK,  were  consented  to  provide  tissue  
48  
  
from  resections  which  was  not  required  for  histology  for  scientific  research.    These  
were  taken  for  macrophage  recovery.      
Samples  were  cut   from   tissue  after  surgical   resection,  placed   in  0.9%  NaCl  and  
stored  at  4°C  overnight,  prior  to  transport  to  the  laboratory.    The  lung  samples  was  
washed  with  0.9%  NaCl  under  pressure  through  a  16g  needle  until  the  tissue  was  
pale  and  the  fluid  running  clear.    The  0.9%  NaCl  used  for  transporting  was  added  
to  the  wash  and  centrifuged  at  500g  for  10  minutes  at  4°C.    The  supernatants  were  
combined  with  a  small  variable  volume  of  PBS  and  layered  over  Lymphoprep  (Axis-­
Shield,  Oslo,  Norway)  and  centrifuged  at  800g  for  30  minutes  at  4°C  with  minimum  
acceleration  and  no  break.     The  band  of  macrophages  was  recovered   into  PBS,  
centrifuged  at  500g  for  5  minutes  at  4°C  and  then  re-­suspended  in  RPMI  with  10%  
FCS  and  GPS.     10ul  of  suspended  cells  were  added   to  10ul  of   trypan  blue  and  
counted  on  a  haemocytometer,  to  determine  the  concentration  of  viable  cells.      
2.8.1  Alveolar  macrophage  phagocytosis  assay  for  E.  Coli  
Phagocytosis  particles  were  prepared  by  mixing  20μl  DMSO   to  15μg  Celltracker  
Deep  Red  (Thermofisher,  Paisley,  United  Kingdom).    125μl  stock  Escherichia  coli  
(Thermofisher,   Paisley,   United   Kingdom)   were   washed   in   10mls   fresh   lysogeny  
broth  (LB)  broth  and  centrifuged  at  2000g  for  5  mins  at  room  temperature.    It  was  
re-­suspended   in  4  ml   fresh  LB  and  add  20μl  Celltracker  Deep  Red  (with  an  end  
concentration  of  5μM  with  E  coli  at  50  million/ml).    This  was  then  incubated  in  the  
dark  at  37°C  and  5%  CO2  for  45minutes.    They  were  then  had  PBS  added  and  were  
then   centrifuged   at   2000g   for   5   mins   at   room   temperature.   This   was   then   re-­
suspended   in  2ml  PBS   (at  a   final  concentration  of  100  million/ml).     The  bacteria  
were  then  heat-­killed  at  65°C  for  2  hours  and  then  stored  until  use  at  4°C.  
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Recovered  alveolar  macrophages  were  plated  at  250  000  cells/well   in  a  12  well  
plate  in  500ul  of  RPMI  with  10%  FCS  and  GPS  and  incubated  for  24  hours  at  37°C  
and  5%  CO2  .    The  media  was  changed  at  24  hours  and  DAB  or  Dummy  DAB  added  
concentrations  under  test.    They  were  incubated  for  24  hours  at  37°C  and  5%  CO2.      
After   incubation,  cytochalasin  D  at  5μg/ml  was  added   to  negative  control  well   to  
inhibit  phagocytosis   followed  by   incubation   for  30  minutes  at  37°C  and  5%  CO2.    
Media   was   removed   then   E   coli   suspension   was   added   to   give   a  
macrophage:bacteria  1:50  ratio,  alongside  an  E  coli  only  control,  then  incubated  for  
four  hours  at  37°C  and  5%  CO2.     Media  were   then   removed  and  washed  gently  
three  times  with  PBS.    Warmed  trypsin  for  20  minutes  until  cells  detached.    An  equal  
volume  of  serum  containing  media  was  then  added.    Cells  were  transferred  to  flow  
cytometry  tubes,  then  centrifuged  at  500g  for  5  minutes  at  room  temperature,  then  
re-­suspended   in  R&D   flow   cytometry  buffer,   then  analysed  with   a  Fortessa   flow  
cytometer  (BD  Biosciences,  San  Jose,  California,  USA).  
2.8.2  Alveolar  macrophage  receptor  identification.      
Alveolar  macrophages  were  removed  from  suspension  in  RPMI  with  10%  FCS  and  
GPI.    Those  in  culture  had  their  media  removed  and  cells  were  liberated  from  the  
plate   using   non-­enzymatic   Cell   Dissociation  Solution   (Biological   Industries,   Beit-­
Haemek,  Israel).    Cells  were  added  to  round  bottomed  flow  cytometry  tubes  at  tube  
100ul  at  106/ml  and  washed  in  0.5%  BSA/PBS  and  centrifuged  at  500g  at  4°C  for  5  
minutes  twice.    Primary  antibodies  were  added  and  incubated  for  30  minutes.    The  
cells  were  then  washed  three  times  in  Flow  Cytometry  buffer  (R&D,  Minneapolis,  
Minnesota,  USA),  centrifuging  at  300g  for  5  minutes  at  4°C.    The  cells  were  then  re-­
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suspended   in   200ul   flow   cytometry   buffer   and   analysed   on   the   Accuri   C6   flow  
cytometer.  
2.9   Statistical   analysis   for   neutrophil,   macrophage   and   plasma   cytokine  
experiments  
Data   from   the   above   experiments   were   first   analysed   for   normality   using   the  
D’Agostino   and  Pearson  normality   test.      For   normally   distributed  data,   summary  
descriptive  data  of  mean  and  standard  deviation  were  reported.    Non-­normal  data  
were  reported  using  median  and  interquartile  range.      
If   data   were   normal,   multiple   groups   were   compared   with   ANOVA,   then,   if  
significant,  with   paired  or   unpaired   t-­tests   as   appropriate.     Non-­normal   unpaired  
data   were   analysed   using   the   Kruskal-­Wallis   test,   then,   if   significant,   individual  
groups  using   the  Mann-­Whitney  U-­test.     Non-­normal   paired  data  were   analysed  
using   first   Friedman’s   test,   then  Wilcoxon  Matched  Pairs   test.     Significance  was  
taken  as  p<0.05.    For  one  experiment,  an  outlier  was  excluded  using  Grubb’s  test,  
prior  to  analysis.      
Correlations   between   data   were   performed   using   Spearman’s   Rank   Correlation  
Coefficient,  as  data  in  all  analyses  were  non-­normal.      
Analyses  were  undertaken  using  GraphPad  Prism  V.6.07  for  Windows  (GraphPad  
Software,  La  Jolla,  California,  USA).  
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The   Acute   Respiratory   Distress   Syndrome   (ARDS)   frequently   complicates   the  
recovery  from  major  surgery.[145]    It  is  associated  with  high  mortality[146-­148]  and  
although  this  has   improved  with   time,[47]   it   remains  an   important  cause  of  death  
and   morbidity.   Management   of   patients   with   ARDS   consumes   substantial  
healthcare  resources.[149]    The  definitions  of  ARDS  were  recently  updated  in  2013,  
with  the  removal  of  the  term  acute  lung  injury  (ALI).[45]    For  the  purposes  of  this  
report,  the  term  ARDS  is  used  as  the  overarching  term  to  describe  the  cohort  of  ALI  
and  ARDS  patients.  
The  outcome  of  ARDS  varies  according  to  the  underlying  disease  process  which  is  
responsible   for   causing   it.      In   a  multicentre   prospective   observational   study,   an  
overall  hospital  mortality  of  41.1%  for  ARDS  was  found.    However,  mortality  was  
43.6%  in  patients  with  ARDS  caused  by  aspiration,  40.6%  by  pneumonia  but  21.4%  
by   severe   trauma.[146]      Major   thoracoabdominal   surgery,   especially   when  
combined   with   sepsis,   is   a   common   cause   of   ARDS   with   high   associated  
mortality.[145]      
Oesophagectomy   carries  a   high   risk   for  both  mortality  and  morbidity.      The  most  
common  complications  following  oesophagectomy  are  pulmonary.[12]    Tandon,  et  
al,  in  2001  reported  rates  of  ARDS  of  38.3%  and  the  mortality  of  patients  developing  
severe   ARDS   was   50%.[150]      A   French   study   from   2012   comparing   open  
oesophagectomy  to  hybrid  (laparoscopic  abdominal  and  open  thoracic  resection),  
reported  major  pulmonary  complications  in  43%  of  the  open  group  and  15%  in  the  
hybrid  group.    Out  of  280  cases,  21  cases  of  ARDS  were  reported  and  in  six  of  the  
12  post-­operative  deaths,  ARDS  was  diagnosed.    ARDS  was  less  common  in  the  
hybrid  group.[151]    A  large  Australian  study  reported  a  respiratory  complication  rate  
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of  27.4%  and  increased  length  of  hospital  stay  in  those  who  developed  pulmonary  
complications  [16].    
Despite  a  number  of  studies,  no  pharmacological  treatments  which  directly  target  
the   underlying   pathophysiological  mechanisms   implicated   in   the   development   of  
ARDS  have  been  identified.[56]    In  the  critical  care  setting,  trials  investigating  the  
role  of  intravenous  salbutamol,[57]  simvastatin,[58]  nitric  oxide[59]  and  exogenous  
surfactant[152]  in  treating  ARDS  have  all  failed  to  demonstrate  a  mortality  benefit.    
The  role  of  steroid  administration  remains  unclear.[55]  Reductions  in  mortality  have  
been   demonstrated   by   trials   of   lung   protective   ventilation   [49]   and   muscle  
relaxants.[54]      Prone   positioning   is   an   effective  measure   in   cohorts   with   severe  
ARDS.[153]      
Given   the   limited   treatments   available,   preventative   strategies   are   attractive   and  
could  have  substantial  benefits  if  implemented  in  high  risk  groups,  including  patients  
undergoing   oesophagectomy.[147]      Valid   clinical   models   are   imperative   for  
investigating  preventative  strategies.[154]    Patients  undergoing  one-­lung  ventilation  
(OLV),   such   as   occurs   in   patients   undergoing   oesophagectomy,   provide   a  
potentially  useful  model  for  investigating  ARDS.  
The  aim  of   this  study  was  to  undertake  a  secondary  analysis  of   the  multi-­centre  
Beta  Agonist  Lung  Injury  Prevention  trial  to  characterise  patients  developing  ARDS  
following  elective  oesophagectomy  and  identify  risk  factors  for  the  syndrome.    
  
3.2  Methods  





Of  the  362  patients  in  the  BALTI-­P  trial,  331  patients  were  included  in  the  analysis.    
Patients  who  did  not  undergo  surgery  (n=19,  5.2%)  and  who  withdrew  consent  (n=2,  
0.55%)  were  excluded,  as  were  patients  who  did  not  have  a  defined  ARDS  status  
(n=10,   2.8%).      Patient   age,   gender,   height   or   body   weight,   diagnosis  
(adenocarcinoma,   squamous   cell   carcinoma,   Barrett’s   or   other),   staging,  
chemotherapy  and  lung  function  were  all  similar  between  groups  (Table  1).      
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Table  1:  Clinical  characteristics  of  patients  undergoing  oesophagectomy  in  the  
BALTI-­P  trial  summarised  by  ARDS  status  (early  less  than  72  hours,  late  greater  
than  72  hours).  



































Missing   0   0   0   1  (0.4%)  
Diagnosis  














Other   malignant  
(eg  mixed)   0   0   0   4  (1.7%)  
Barrett’s  
Oesophagus   3  (5.1%)   2  (8.3%)   5  (6.0%)  
13  
(5.4%)  
Missing   0   0   0   6  
Pre-­operative  
chemotherapy  


















Mean  (SD)   4.1  (1.2)   4.3  (1.1)   4.2  (1.1)   3.9  (0.9)  
Missing   22   3   25   73  
Forced  
Expiratory  
Volume  in  One  
Second  (litres)  
Mean  (SD)   2.8  (0.9)   2.9  (0.7)   2.8  (0.8)   2.8  (0.7)  
Minimum   0.1-­4.5   1.1-­4   0.1-­4.5   1.1-­5.6  
Missing   22   4   26   75  
Staging  T  
1   3  (5.4%)   2  (8.7%)   5  (6.3%)   12  (5.0%)  














4   0   0   0   4  (1.7%)  
Missing   3   1   4   9  
Staging  N  
















     
Missing   4   1   5   11  
Tumour  
location  
Cervical   1  (1.7%)   1  (4.3%)   2  (2.4%)   3  (1.2%)  

















Missing   0   1   1   5  
Surgical  
approach  














Missing   0   0   0   2  
Open   stage;;   If  
open   surgical  
approach  







3  Stage   1  (2.9%)   3  (18.8%)   4  (7.8%)  
10  
(6.8%)  
Missing   8   5   13   38  
Thoracotomy;;  
If  open  surgical  
approach  














Missing   4   0   4   13  
N/A   0   0   0   1  (0.6%)  
ASA  grade  
I   1  (1.9%)   2  (8.7%)   3  (3.9%)   14  (5.9%)  












IV   0   0   0   2  (0.8%)  
Missing   5   1   6   11  
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In  total,  83  patients  (24.6%)  developed  ARDS  in  the  first  28  days  following  surgery,  
of  whom  59  (71.0%)  were  classified  as  early  and  24  (29.0%)  late.    Overall,  reduced  
ICU  and  hospital  length  of  stay  was  observed  for  those  patients  without  ARDS,  with  
a  longer  duration  for  those  with  late  versus  early  disease  (Table  2).    Specifically,  
there   were   fewer   organ   failure   free   days   in   the   early   and   late   ARDS   groups  
compared  to  those  who  did  not  develop  ARDS.      
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Statistics  (95%  CI)  
Early  or  late  ARDS  
versus  no  ARDS  






(6.2)   21  (6.8)  
26.8  
(3.2)  
Early  -­2.40  (-­3.60,  
-­1.19)  p<0.001  
Late  -­5.77  (-­7.55,  -­
3.99)  P<0.001  
Missing   0   0   2  
Any   ventilator  
support   on   day  
0-­28  
  




(29.1%)   RR  =  1.62  (1.23,  
2.15)  Missing   0   0   1  












Early  -­5.28  (-­6.81,  
-­3.76)  p<0.001  
Late  -­10.1  (-­12.4,  -­
7.89)  p<0.001  Missing   0   0   1  











Early  3.93  (2.09,  
5.77)  p<0.001  
Late  10.3  (7.63,  
13.1)  p<0.001  Missing   0   0   3  







(8.0)   7.3  (5.4)  
Early  4.82  (3.00,  
6.65)  p<0.001  
Late  12.9  (10.2,  
15.6)  p<0.001    
Duration   of   ITU  







(8.0)   7.3  (5.4)  
Early  4.78  (2.91,  
6.64)  p<0.001  
Late  12.9  (10.2,  
15.6)  p<0.001  Missing   2   0   2  
Duration   of  
level  0  or  1  care  
(days)  
Mean  





Late  2.40  (-­4.86,  
0.06)  p=0.06  Missing   0   0   1  
Duration   of  
level   2   care  
(days)  
Mean  
(SD)   5.0  (3.4)   8.0  (4.2)   4.0  (3.0)  
Early  0.98  (0.08,  
1.88)  p=0.033  
Late  4.06  (2.73,  
5.39)  p<0.001  Missing   0   0   1  
Duration   of  
level   3   care  
(days)  
Mean  
(SD)   5.3  (8.5)   9.5  (7.0)  
0.8  (2.2)  
  
Early  4.48  (3.21,  
5.74)  p<0.001  
Late  8.76  (6.90,  
10.6)  p<0.001  Missing   0   0   1  
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Early  -­0.08  (-­0.18,  
0.02)  p=0.119  
Late  0.24  (-­0.39,  -­
0.09)  p=0.002  
Missing   17   8   43  










Early  -­2.76  (-­8.60,  
3.08)  p=0.35  
Late  -­6.56  (-­15.70,  
2.57)  p=0.16  
Missing   18   9   42  








(0.3)   Early  -­0.02  (-­0.11,  0.06)  p=0.63  
Late  -­0.12  (-­0.26,  
0.01)  p=0.07  Missing   14   8   49  










Early  -­2.75  (-­8.81,  
3.30)  p=0.37  
Late  -­7.88  (-­17.42,  
1.65)  p=0.11  Missing   14   8   48  
Mortality*  







(99.2%)   HR  =  3.73  (0.74,  
18.7);;  
p-­value=0.086*  
Dead   at  
28  days  
3  
(5.1%)   0  
2  
(0.8%)    
Missing   0   0   3  






(99.2%)   HR  =  3.36  (0.83,  
13.6;;  
p-­value=0.072*    
Dead   at  
90  days   4  (6.8%)   1  (4.3%)   2  (0.8%)  
   Missing   0   1   1  
*Calculated  using  log-­rank  test  
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Patients  with   late  ARDS  had   fewer   ventilator-­free  days   (median  17,   interquartile  
range  (IQR)  11-­24),  compared  to  early  ARDS  (median  27,  IQR  18-­28)  and  no  ARDS  
(median  28,  IQR  27-­28).    The  duration  of  intensive  care  stay  was  shortest  in  those  
without  ARDS  (mean  7.3  days,  standard  deviation  (SD)  5.4),  longer  with  early  ARDS  
(mean  12.1  days,  SD  9.0)  and  longer  still  with  late  disease  (mean  20.2  days,  SD  
8.0).    There  were  no  observed  differences  in  mortality  at  28  or  90  days.    The  findings  
were  unchanged  in  the  sensitivity  analysis  which  adjusted  for  treatment  allocation  
to  salmeterol   (Supplementary  Table  S1).     Similarly,   there  were  no  differences   in  
quality  of  life  scores  at  28  or  90  days  (Supplementary  Table  S1).  
Table  3  shows  multivariate  analysis  grouped  according  to  lung  injury.    Early  ARDS  
was  associated  with  increased  age  (OR  1.06  (1.00  to  1.13),  p=0.05).  There  was  an  
increased  risk  of  ARDS  in  patients  with  mid-­oesophageal  tumours  (OR  7.48  (1.62-­
34.5),  p=0.01),  whilst  the  risk  was  reduced  with  gastro-­oesophageal  tumours  (OR  
0.21  (0.05-­0.85),  p=0.03).      
Analysis   was   undertaken   adjusting   for   treatment   allocation   (salmeterol   versus  
placebo),  but  this  made  little  difference  (Appendix  table  A2).     
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Table   3:  Multivariate   analyses  of   ARDS.  OR:  mean   estimated   odds   ratio   of   the  
interaction  term,  CI:  95%  confidence  interval  
   Early  ARDS   Late  ARDS   Total  ARDS  
   OR  (95%  CI)   p   n.  
OR  (95%  
CI)   p   n  
OR  (95%  
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0.77   325  
Late  ARDS  estimates  are  missing  due  to  insufficient  numbers  of  cases  in  these  groups  
for  these  to  be  calculated.  
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Of  those  patients  with  late  ARDS,  42%  were  also  diagnosed  with  pneumonia,  25%  
with   anastomotic   leak   and   13%   with   respiratory   failure,   whilst   other   surgical  
complications  occurred  in  12.5%.    In  those  with  early  ARDS,  10.2%  had  pneumonia  
and   surgical   complications   occurred   in   8.5%.      There   were   significantly   more  
surgical,  respiratory  and  “other”  complications  (p<0.0001  for  all),  but  no  significant  
difference  in  sepsis  between  the  groups.    For  surgical,  respiratory  and  other  non-­
cardiovascular  complications,  rates  were  higher  in  the  late  compared  to  the  early  
ARDS  groups  (figure  4).         
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Figure  4:  Safety  outcomes,  divided  by  early   (before  72  hours)  and   late   (after  72  
hours)   ARDS   in   BALTI-­P   participants.      Higher   complications   were   observed   in  
patients  with   ARDS,  with   higher   levels   late   versus   early   for   all   groups,   with   the  
exception  of  cardiovascular.      










































These   data   demonstrate   that   ARDS   was   common   following   oesophagectomy  
surgery,  with  an  incidence  of  almost  25%.  We  did  not  find  differences  in  mortality  
between  patients  with  early  and  late  ARDS  at  28  or  90  days,  nor  to  changes  in  their  
quality  of   life  scores.    This  may  be  due  to  insufficient  power,  especially  given  the  
study  was  not  designed  to  examine  this  outcome  and  because  mortality  following  
oesophagectomy  has  fallen  with  time.[155]    However,  both  early  and  late  ARDS  are  
associated  with  more   days   of   organ   failure,   spending  more   days   ventilated   and  
having  longer  ICU  and  hospital  stays  than  patients  who  do  not  develop  ARDS,  a  
finding  that  has  been  observed  elsewhere.[11]      
Improvements   in   pre-­operative,   intra-­operative   and   post-­operative   care   may   all  
have   contributed   to   apparent   reduction   in   harm   associated   with   ARDS   and   the  
reduction   in   the   frequency  and  severity  of  ARDS  observed   in  older  cohorts.[150]    
Another,   more   recent,   study   has   shown   that   post-­oesophagectomy   respiratory  
failure  and  ARDS  were  independent  risk  factors  for  in-­hospital  death.[156]    Overall,  
the  rates  of  mortality  and  respiratory  and  cardiovascular  complications  were  similar  
to  contemporary  studies  of  oesophagectomy  outcomes  elsewhere.[157]      
Scoring   systems,   such   as   the   Lung   Injury   Prediction   Score   (LIPS),   have   been  
developed  to  identify  high  incidence  ARDS  groups  a  priori  for  both  clinical  purposes  
and  to  provide  groups  with  high  ARDS  incidences   for  preventative   trials.[154]     A  
cohort  identified  using  the  LIPS  score  had  an  incidence  of  ARDS  of  7%.[154,  158]    
The   majority   of   ARDS   detected   in   BALTI-­P   occurred   in   the   first   72h   following  
surgery,  with  a  similar  pattern  seen  in  the  LIPS  validation  cohort,  which  identified  
only  25%  of  ARDS  on  or  after  day  4.[158]      
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Oesophagectomy   is   attractive   as   a   model   of   ARDS   as   the   timing   of   the   insult  
(surgery)  is  consistent  and  predictable.    Patients  can  be  identified,  approached  and  
consented  in  advance.  Systemic  and  alveolar  inflammatory  changes  are  similar  to  
those   observed   in   ARDS[159]   and   include   evidence   of   alveolar   and   endothelial  
damage,  neutrophil  infiltration  and  pulmonary  vascular  congestion.[148]  
One   limitation   to   the  model   is   that   although   the   ARDS   incidence  was   high,   the  
majority  was  classified  as  mild  to  moderate  and  this  is  partly  reflected  in  the  lower  
mortality  detected  in  this  study  than  others  focussing  on  more  severe  patients.[153]    
However,  the  increased  organ  failure,  increased  duration  of  ventilated  and  intensive  
care  and  hospital  stay  all  demonstrate  even  early  onset  mild  to  moderate  ARDS  has  
significant  adverse  implications  for  both  patients  and  healthcare  resource  utilisation  
and  it  would  therefore  be  beneficial  to  prevent  it.      
This  study  has   identified   increased  age  and  tumour  site  are  risk   factors  for  early  
ARDS.    Finding  no  significant  risk  factors  for  late  ARDS  probably  reflects  the  small  
numbers  in  this  group.    The  magnitude  of  the  increased  risk  of  ARDS  associated  
with  mid-­oesophageal  tumours  was  unexpected.      
Squamous  cell  carcinoma  (SSC)  is  the  predominant  histological  subtype  in  cervical  
and  mid-­oesophageal  tumours.    A  higher  risk  of  pulmonary  complications  with  more  
proximal   tumours   has   been   reported   previously,   with   one   study   suggesting   a  
relationship  with  increased  surgical  technical  difficulty  and  recurrent  laryngeal  nerve  
injury.[160]      In   one   small   study,   SCC   histology   was   associated   with   more   pre-­
operative  respiratory  disease  and  alcohol  use  and  with  more  severe  post-­operative  
complications  and  longer  ICU  stays.[161]    Similar  rates  of  COPD,  cardiac  disease,  
smoking   and   neoadjuvant   chemoradiotherapy   were   seen   for   SCC   and  
adenocarcinomas.[161]    Preoperative  radiotherapy,  more  commonly  administered  
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in   the   UK   for   SCC   (and   infrequently   for   adenocarcinoma),   is   associated   with  
increased  pulmonary   complications,[162]   and   salvage  oesophagectomy   for  SCC  
after   definitive   chemoradiotherapy   can   be   technically   challenging  with   increased  
post-­operative   morbidity.      These   factors   may   explain   the   higher   risk   of   ARDS  
observed  with  mid-­oesophageal  tumours.  
This  result   is  also  surprising  given   the  similar  ARDS  incidence  between  the  mid-­
oesophageal  and  gastro-­oesophageal  groups.    This  may  be  due  to  collinearity  with  
other   risk   factors   manifesting   in   the   multivariate   analysis,   or   a   type   one   error.    
Clearly,   caution  must  be  exercised   in   interpreting   these   results  and   this  requires  
validation  with  further  studies.  
It  has  been  suggested  that  cumulative  insults  may  aggregate  to  increase  ARDS  risk.    
McKevith  and  Pennefather[11]  discussed  the  possibility  that  the  combined  ‘hits’  of  
multi-­cavity  surgery  and  OLV  combine  to  give  higher  rates  of  ARDS  when  compared  
with   other  major   surgery.      An   incidence  of  ARDS   of   60%   has   been   reported   in  
patients   who   had   undergone   thoracoabdominal   surgery   and   developed   sepsis,  
compared  to  34.6%  in  those  with  sepsis  without  surgery,  which  suggests  ARDS  is  
more   likely  as  pathological   insults  aggregate.[145]     We  believe   in   this  study   that  
early  ARDS  was  driven  by  factors  at  the  time  of  surgery  such  as  OLV  lung  injury  
and/or  inflammation  induced  by  the  surgical  insult  whereas  ARDS  in  the  late  group  
was  more  frequently  caused  by  complications  following  surgery.      
A  similar  concept  has  been  proposed  elsewhere,  with  a  study  of  ARDS  following  
lung   resection   identifying   what   the   authors   termed   “primary   ARDS”   (i.e.   due   to  
surgery  and  OLV  alone,  without  another   identified  cause)  being  observed  shortly  
after  surgery  (median  onset  two  days),  whereas  “secondary  ARDS”  (where  a  causal  
factor  other   than   the   initial   surgery,  such  as  aspiration  or  sepsis,  was   identified)  
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tended  to  occur   later   (median  onset  of  5.5  days).[163]     This  again  suggests   that  
accumulated  insults  contribute  to  ARDS.  
There  are  limitations  in  this  study.    This  is  a  retrospective  observational  analysis,  
with  the  potential  bias  that  confers.    Furthermore,  the  ongoing  changes  in  both  the  
epidemiology  of  oesophageal  cancer  and  its  management  render  comparisons  with  
other,  especially  older,  cohorts  less  reliable.    The  total  number  of  participants  may  
have  resulted  in  a  lack  of  power  to  identify  trends,  particularly  mortality  but  this  is,  
nevertheless,   to   our   knowledge,   the   largest   cohort   of   patients   undergoing  
oesophagectomy   who   have   been   subject   to   systematic   screening   for   ARDS.    
Potentially   important   information,   such  as   tumour  histology,   use  of   radiotherapy,  
smoking  status  and  alcohol  consumption  were  not  collected.      
Both  early  and  late  ARDS  are  harmful  for  patients  following  oesophagectomy  and  
increase  ICU  and  hospital  resource  use.    New  preventative  strategies  to  reduce  the  
burden  of  perioperative  ARDS  would  be  valuable.    Because  of  the  high  incidence  
of  ARDS  in  patients  undergoing  oesophagectomy,  it   is  a  useful  model  for  trialling  
such  strategies  and,  compared  to  other  methods  for  finding  such  cohorts,  it  has  a  
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Patients   undergoing   oesophagectomy   have   high   rates   of   postoperative  
complications   [28]   including   the  acute  respiratory  distress  syndrome   (ARDS)   [8].  
We  have  previously  shown  that  ARDS  following  oesophagectomy  is  associated  with  
more  non-­respiratory  organ  failure,  longer  critical  care  and  hospital  stays  [164],  and  
other   groups   have   demonstrated   worse   short-­term   and   long-­term   outcomes  
associated  with  ARDS2  and  other  pulmonary  complications  [23].  Severe  infection  
and   cardiac   dysrhythmias   are   common.   However,   this   high   complication   rate,  
alongside  the  planned  nature  of  surgery  and  the  clear  timing  of  the  surgical  insult  
[9,   13],  makes  oesophagectomy  a   potentially   useful  model   to   undertake   trials   to  
reduce  perioperative  complications  [148].  
Both   the   Beta   Agonists   in   Lung   Injury   Trial-­Prevention   (BALTI-­P)   [159],   which  
completed   recruitment   in   2011,   and   the  Vitamin  D   to  Prevent  Acute  Lung   Injury  
Following   Oesophagectomy   (VINDALOO)   trials,   completed   in   2015,   [140]   used  
oesophagectomy  as  a  model  of  ARDS.  We  observed  that  the  incidence  of  ARDS  in  
the   VINDALOO   (8   out   of   68,   11.8%)   cohort   was   substantially   lower   than   in   the  
BALTI-­P  (83  out  of  331,  25.1%  and  14  out  of  61,  23%)  sub-­study  (see  the  Methods  
section   below),   independent   of   a   pharmacological   effect   of   the   agents   trialled,  
suggesting  that  there  had  been  changes  between  the  groups  that  were  expected  a  
priori  to  be  similar.  
The   aims   of   this   work   were   to   determine   which   clinical   features   were   different  
between  the  two  cohorts  that  might  explain  the  differences  in  postoperative  ARDS  
and  complications.  The  combined  cohorts  were  analysed  to  seek  further  risk  factors  
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not  apparent   in   the   individual  cohorts  and  potential   therapeutic  targets   for   further  
investigation.  
4.2  Methods  
See  Chapter  2.  
4.3  Results  
Table   4   shows   the  baseline   demographic   data   from   the  BALTI-­P   sub-­study  and  
VINDALOO  groups.  Patients  in  VINDALOO  were  heavier,  received  a  lower  mean  
tidal  volume,  received  more   intravenous   fluid,  more  were  on  beta-­blockers,  more  
received  ketamine  and  dexamethasone  and  fewer  remifentanil  and  thoracoscopic  
approach  was  more  common.  
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Table  4.  Demographic  data  from  the  BALTI-­P  and  VINDALOO  trials.  
   BALTI-­P  (n=61)   VINDALOO  (n=68)   P  value  
Age  (years)  Median  IQR   64  (65-­72)   67  (60-­72)   0.110  
Weight  (kg)  Median  IQR   75  (60-­84)   77  (68-­94)   0.049  
Height  (cm)  Median  IQR   171  (167-­175)   173  (168-­177)   0.413  
Current  Smoking   16  (26.7%)   9  (13.4%)   0.075  









Benign  0  (0.0%)  
0.134  
Hypertension  n  (%)   22  (40.7%)   27  (40.3%)   1.00  
Ischaemic  Heart  Disease  
n  (%)  
4  (7.40%)   5  (7.46%)   1.00  
Diabetes  Mellitus   5  (9.26%)   8  (11.9%)   0.771  
Chronic  Lung  Disease   5  (9.26%)   9  (13.4%)   0.574  
Venous  thromboembolic  
disease  
3  (5.56%)   9  (13.4%)   0.342  
Beta  blockers  n  (%)   4  (7.41%)   16  (23.9%)   0.025  
Aspirin  n  (%)   9  (16.7%)   11  (16.4%)   1.00  
Dihydropyridine   8  (13.1%)   7  (10.3%)   0.784  
Statin   11  (20.4%)   22  (32.8%)   0.153  
Angiotensin  converting  
enzyme  inhibitor  or  
angiotensin  II  receptor  
antagonist  
11  (20.4%)   13  (19.6%)   1.00  
Pre-­operative  
haemoglobin  (g/dl)  Mean  
(SD)  
121  (15)   126  (18)   0.080  
Mean  Tidal  Volume  ml/kg,  
(Mean  (SD))  
6.9  (1.9)   6.1  (1.4)   0.011  
Duration  of  surgery   385  (318-­454)   373  (321-­419)   0.494  
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Duration  of  OLV  (minutes)  
Median  (IQR)  
155  (130-­188)   150  (130-­195)   0.794  
Fluid  administered  (ml/kg)  
Median  (IQR)  
31  (24-­46)   41  (30-­52)   0.012  
Regional  analgesia  used  n  
(%)  
51  (92.7%)   55  (84.6%)   0.254  
Remifentanil   13  (24.5%)   5  (8.33%)   0.022  
Dexamethasone   8  (15.0%)   20  (66.7%)   0.030  
Ketamine   0  (0.0%)   14  (22.2%)   P<0.0001  
Thoracoscopy   10  (17.9%)   22  (35.5%)   0.039  
Laparoscopy   10  (21.7%)   8  (12.7%)   0.455  
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Staging  of  malignancy  was  both  more  widely  distributed  and  overall  higher  in  the  
VINDALOO  cohort  (figure  5).  Pre-­existing  Charlson  Index  was  not  different  between  
groups   (BALTI-­P   median   2   (IQR   2–3),   VINDALOO   2   (IQR   2–3),   P=0.872).  
Perioperative   risk   scores   were   not   different   between   the   groups   (P-­POSSUM  
Mortality   (BALTI-­P   median   2.4   (IQR   1.9–37)   vs   VINDALOO   2.4   (IQR   1.5–5.4),  
P=0.759),  P-­POSSUM  Morbidity  (BALTI-­P  median  8.5  (IQR  4.6–13)  vs  VINDALOO  
8.7   (IQR  6.3–17),  P=0.141),  O-­POSSUM   (BALTI-­P  median  8.5   (IQR  4.6–13)   vs  
VINDALOO  8.7  (IQR  6.3–17),  P=0.141)).     
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Figure  5:  Percentage  of  patients  per  stage  of  oesophageal  cancers  in  the  BALTI-­P  
and  VINDALOO  trials  (***p<0.001).    Patients  recruited  to  the  VINDALOO  trial  had  
overall  higher  staged  cancers.  
  

































To   assess   risk   factors   further,   the   two   cohorts   were   combined   and   assessed  
according   to   ARDS   status   (table   5).   Univariate   analysis   showed   that   current  
smoking  and  dihydropyridine  use  were  associated  with  the  development  of  ARDS  
postoperatively.  These  variables  were  then  subject  to  multivariate  analysis,  which  
showed   that   both   active   smoking   (OR   3.91;;   95%   CI   1.33   to   11.5)   and  
dihydropyridine  use  (OR  5.34;;  95%  CI  1.56  to  18.3)  remained  associated  with  ARDS  
risk.     
76  
  
Table   5.   Comparison  of   patients  with   and  without   ARDS   from   the   BALTI-­P   and  
VINDALOO  combined.  
Factor   No   ARDS  
(n=108)  
ARDS  (n=21)   P  
value  
Age  Median  (IQR)   66  (58-­72)   61  (57-­70)   0.367  
Current  Smoking  n  (%)   17  (16.0%)   8  (38.1%)   0.033  
Histology  n  (%)  
Adenocarcinoma  










Hypertension  n  (%)   40  (38.8%)   9  (50%)   0.439  
Ischaemic  Heart  Disease  n  (%)   9  (8.7%)   0  (0.0%)   0.353  
Diabetes  Mellitus  n  (%)   9  (8.7%)   4  (22.2%)   0.103  
Lung  disease  n  (%)   12  (11.7%)   2  (11.1%)   1.00  
Venous   thromboembolic   disease   n  
(%)  
11  (10.7%)   0  (0.0%)   0.367  
Weight  (kg)  median     75  (65-­88)   81  (62-­93)   0.485  
Height  Median  (IQR)   173   (167-­
176)  
172  (169-­176)   0.915  
Haemoglobin  Mean  (SD)   125  (16)   120  (19)   0.260  




170  (124-­205)   0.457  
Mean  Tidal  Volume  (mlkg-­1)  Median  
(IQR)  
6.1  (5.4-­7.7)   5.8  (5.4-­6.9)   0.458  
Beta-­blocker  n  (%)   17  (16.7%)   3  (15.8%)   1.00  
Dihydropyridine  n  (%)   9  (8.3%)   6  (28.6%)   0.0173  
Benzothiazepine  n  (%)   3  (2.78%)   0  (0.0%)   1.00  
Statin  n  (%)   28  (27.5%)   5  (26.3%)   1.00  
Aspirin  n  (%)   16  (15.7%)   4  (21.1%)   0.517  
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Angiotensin   converting   enzyme  
inhibitor   or   angiotensin   II   receptor  
antagonist  
20  (19.8%)   4  (21.1%)   1.00  
Regional  anaesthesia  n  (%)   11  (10.9%)   3  (15.8%)   0.464  
Remifentanil  n  (%)   14  (14.7%)   4  (22.2%)   0.483  
Ketamine   12  (12.5%)   2  (11.1%)   1.00  
Thoracoscopic  approach  n  (%)   29  (29.0%)   3  (16.7%)   0.392  
Laparoscopic  approach  n  (%)   84  (83.1%)   17  (94.4%)   0.302  
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The   effect   of   these   factors   on   length   of   stay   as   a   measure   of   outcome   was  
assessed,   as   this   outcome  was   collected   in   both   trials.   This   showed   that   those  
patients  on  dihydropyridines  had  longer  hospital  stays  (dihydropyridine  median  29  
days  (IQR  17–42),  no  dihydropyridine  13  days  (IQR  10–18),  P=0.0007),  as  did  those  
with  diabetes  mellitus  (diabetes  median  25  (IQR  14–39)  vs  no  diabetes  13  (IQR  10–
19),  P=0.023).  There  was  no  difference  in  length  of  stay  related  to  smoking  (median  
in  never/ex-­smokers  13  (IQR  10–23)  vs  active  smokers  15  (IQR  11–20),  P=0.73).  
4.4  Discussion  
Lower  tidal  volume  is  now  well  established  in  the  management  of  ARDS  following  
the  landmark  ARDS  Clinical  Network  trial  [49]  and  there  is  increasing  evidence  of  
its   role   in   intraoperative   ventilation   [32,   165].   Tidal   volumes   were   lower   in   the  
VINDALOO   trial,   which   is   likely   to   represent   the   increasing   adoption   of   lung  
protective  strategies,  including  lower  tidal  volumes,  higher  positive  end-­expiratory  
pressure  and  permissive  hypercarbia   [12].  Whether   the  reduction  of  0.8  mL/kg   is  
clinically   significant   is   not   certain,   but   may   be   in   the   context   of   OLV   during  
oesophagectomy,  where   less   than  half   the   lung  volume   is  subject   to   intermittent  
positive  pressure  ventilation   [42].  This  may  have  played  an   important   role   in   the  
change   in  ARDS   incidence.  However,  neither  mean   tidal  volume  nor  duration  of  
OLV  were  associated  with  a  higher  risk  of  ARDS.  It  may  be  other  factors  may  be  
more  revealing  about  the  effects  of  ventilation  on  the  lung,  such  as  driving  pressure  
[166]  or  mechanical  power  [167].    
More   fluid   was   administered   to   the   VINDALOO   cohort;;   this   might   represent   a  
reduction  in  colloid  and  increased  crystalloid  administration  and/or  more  balanced  
fluid   use   improving   anastomosis   perfusion   [13].   Similarly,   increasing   the   use   of  
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thoracoscopic  techniques  and  anaesthetic  agents  with  immunomodulatory  effects  
may  reduce  the  inflammatory  response  to  surgery  and  so  the  risk  of  ARDS  [12].  
This   study   has   indicated   that   there   are   two   major   targets   for   reduction   in  
postoperative  ARDS:  cigarette  smoking  and  diyhdropyridines.  Smoking  has  been  
previously   demonstrated   to   be   a   risk   factor   for   ARDS   [25,   168],   and   the   fewer  
current   smokers   in   VINDALOO   may   have   had   a   marked   effect   on   the   ARDS  
incidence   between   the   two   trials.   Smoking   has   been   associated   with   severe  
perioperative   complications   in   another   oesophagectomy   cohort   [169].   This   work  
supports   the   premise   of   efforts   to   reduce   smoking   perioperatively   [170].   Use   of  
nicotine  replacement  therapy  in  critical  care  medicine  is  controversial,  and  trials  in  
the   perioperative   setting   are   required   to   ensure   safety   as  well   as  efficacy   [171].  
Evidence  of  the  safety  and  effectiveness  of  e-­cigarettes  and  nicotine  replacement  
in  the  perioperative  period  also  need  to  be  confirmed  by  randomised  trials  [172].  
The  association  between  dihydropyridine  calcium  channel  blockers  and  ARDS  was  
unexpected.   ARDS   has   been   reported   following   dihydropyridine   overdose   [173].  
Pulmonary  oedema  following  administration  of  the  dihydropyridine  nimodipine  has  
been   described   in   the   context   of   subarachnoid   haemorrhage   [174].   Potential  
mechanisms  include  worsened  ventilation-­perfusion  mismatching  due  to  pulmonary  
arterial   dilatation,   reduced   cardiac   function   and   pulmonary   or   inflammatory  
modulatory   effect.   Calcium   channel   blockade   has   been   associated   with  
immunomodulation,  although  mostly  downregulating  inflammatory  processes  [175-­
177].  It  may  be  that  dihydropyridine  use  is  a  marker  of  worse  systemic  disease  and  
therefore  perioperative  risk,  although  we  did  not   find  an  association  with  aspirin,  
beta-­blockers   or   statins.   It   would   be   premature   to   recommend   not   using  
dihydropyridines  in  the  perioperative  period,  but  there  is  a  need  for  further  studies  
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on  the  effects  of  concurrent  medications  on  patients  undergoing  surgery.  Identifying  
the  mechanisms   through   which   dihydropyridines   have   this   effect   would   also   be  
useful.  
A  major  problem  in  ARDS  prevention  trials  is  identifying  a  cohort  with  a  high  ARDS  
risk  [148].  Even  in  the  VINDALOO  cohort,  the  ARDS  incidence  remains  higher  than  
that   defined   by   the   Lung   Injury   Prediction   Score   [158]   and   the   postoperative  
complication  incidence  is  very  high,  with  the  advantages  of  an  initial  insult  of  surgery  
at  a  specific  time  and  a  defined  postoperative  care  pathway  [164],  which  facilitates  
the   conduct   of   efficacy   trials.   We   believe   this   work   demonstrates   that  
oesophagectomy   continues   to   be   a   useful   model   for   trialling   translational  
therapeutic   and   preventative   strategies   for   critical   illnesses   prior   to   engaging   in  
larger,  more  complex  and  expensive  trials  [148].  Examples  include  the  Prevention  
of   Postoperative   Pulmonary   and   Cardiac   Complications   By   Using   HMG-­CoA  
Reductase   Inhibitor   in  Patients  Undergoing  Oesophagectomy  (EudraCT  Number:  
2007-­002454-­37)   and   a   trial   of   novel   agent   GSK2862277   (TFR116341   Trial  
EudraCT  Number:  2014-­000643-­33).  
There  are  several  weaknesses  with  this  investigation.  This  is  a  retrospective  study  
and  may  well  be  underpowered  for  some  factors,  although  this  work  was  intended  
only   to  be  exploratory  and  hypothesis  generating.  Much  of   the  data  we  collected  
were  retrospective  and  full  data  were  not  available  for  every  patient.  Additionally,  
some  factors  that  may  be  important  risk  factors  for  both  ARDS  and  oesophageal  
cancer,   including   alcohol   consumption   [25],   were   not   recorded.   There   were  
significant  differences  in  potentially  important  factors  in  anaesthetic  management,  
discussed  above,  which  potentially  complicate  comparisons  made  over  time  without  
protocolised  surgical  or  anaesthetic  management.  
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In  conclusion,  smoking  has  been  associated  with  higher  rates  of  ARDS  following  
oesophagectomy.   The   association   of   dihydropyridines   and   ARDS   requires  
validation   in   a   larger   cohort   and   mechanistic   elucidation.   Oesophagectomy  
continues  to  have  a  high  risk  of  ARDS,  which  continues  to  offer  a  useful  model  for  
perioperative  studies.  




THE  TFR116341  TRIAL:  CHALLENGES  TO  RECRUITMENT  




ARDS  is  a  serious  complication  of  major  surgery  which  continues  to  have  adverse  
consequences   for  patients   [2].     ARDS   rates  are   falling   [47],   but   apart   from   lung  
protective   ventilation   [49],   muscle   relaxants   [54]   and   the   prone   position   [52],  
preventative   and   therapeutic   strategies   are   lacking   [56,   178].      Following  
oesophagectomy,   ARDS   is   both   common   and   associated   with   severe   adverse  
outcomes  [8,  23].    Reductions  in  ARDS  incidence  have  been  associated  with  lower  
post-­operative  mortality  in  this  cohort  [28].  
The  novel  domain  antibody  GSK2862277  was  developed  by  GlaxoSmithKline  as  a  
TNFR1  receptor  antagonist.    TNFR1  blockade  has  been  shown  to  be  effective  in  
protecting  the  lung  in  a  number  or  pre-­clinical  models,  including  ventilator  induced  
lung  injury  in  TNFR1  knockout  mice  [132],  poly-­microbial  sepsis  in  mice  [179]  and  
a   human  model   of   ARDS   induced   in   healthy   volunteers  with   lipopolysaccharide  
[133].    Theoretically,  GSK2862277  could  be  of  benefit  to  patients  with  established  
hyperinflammatory   ARDS   and/or   preventing   post-­operative   pulmonary  
complications  in  those  at  high-­risk  [132,  137].  
TFR116341  was  a  double-­blind  randomised  placebo  controlled  trial  to  evaluate  the  
effect   of  GSK2862277   on   the   lung,   using   oesophagectomy   of   a   high-­risk   group  
(EudraCT   Number:   2014-­000643-­33).      This   chapter   aimed   to   evaluate   the   trial,  
focussing  on  the  barriers  to  trial  (and  therefore  translational  sub-­study)  recruitment.  
5.2  Methods  




The  TFR116341  trial  had  failed  to  recruit  to  half  its  target  numbers  nationally  and  
was   terminated   for   futility   in   August   2017.      The   Data   Monitoring   Committee  
remarked   upon   excessive   baseline   variability   in   the   patients’   extravascular   lung  
water   and   pulmonary   vascular   permeability   index,   and   inadequate   pre-­   to   post-­
operative   change   (A   Bayliffe,   personal   communication).      Details   of   the   trial  
nationally  (to  January  2017)  are  shown  in  table  6,  compared  to  data  from  the  BALTI-­
P  trial  [138]  and  the  VINDALOO  trial  [143].      
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Table   6.      Recruitment   into   TFR116341,   BALTI-­P   and   VINDALOO,   number   of  
patients  (%).  
Trial   Screened   Screen  
Failures  




BALTI-­P   362  
(randomised)  
0  (0.0%)   338  
(93.4%)  
2  (0.6%)   22  (6.1%)  
VINDALOO   79   0  (0.0%)   68  
(86.1%)  
3  (3.7%)   8  (10.1%)  




1  (2.3%)   1  (2.3%)  
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Figure   6.      Outcomes   of   patients   recruited   to   the   BALTI-­P,   VINDALOO   and  
TFR116341  trials   (percentage  of  patients  recruited).     In   the  TFR116341  trial,   the  
proportion  of  patients  who  withdrew  consent  or  were  screen  failures  was  higher  than  
the  earlier  trials.    Conversely,  cancelled  surgery  and  abandoned/alternative  surgery  
were  higher  in  BALTI-­P  and  VINDALOO.  
  






























When   the   three   trials   were   compared,   there   were   significant   differences   in   the  
outcome  of  those  screened/randomised  (p<0.0001)  (figure  6).    Four  patients  (9.5%)  
of  42  screened  for  ADAs  were  positive.  
Across  the  two  Birmingham  sites,  a  total  of  118  patients  had  been  considered,  of  
whom  17  had  been  formally  screened.    12  patients  had  been  dosed,  the  primary  
endpoint  (PVPI  reading  at  the  end  of  surgery)  had  been  obtained  for  11.    Screen  
failure  was  for  positive  Quantiferon™  tuberculosis  test  in  two  patients,  two  had  anti-­
drug  antibodies  and  one  a  prolonged  QTc  interval.    One  patient  was  withdrawn  as  
he   underwent   transhiatal   oesophagectomy,   which   did   not   require   one-­lung  
ventilation.      Two   patients   were   not   screened   due   to   exposure   to   concurrent  
experimental  medications.  
101   patients   were   considered   for   approach   for   formal   screening   but   were   not  
screened.      Reasons   for   inability   to   approach   and/or   screen  were   collected   from  
ongoing  trial  meetings  and  local  quality  assurance  processes.    These  included:  
•   Exclusion  criterion  apparent  prior  to  screening  (premenopausal,  pre-­existing  
tuberculosis,  hepatitis  C,  high-­dose  steroids,  other  investigational  therapy)  (8  
(7.9%)).  
•   Invited  to  attend  but  did  not/unable  to  attend  (9  (8.9%)).  
•   Alternative  medical   and/or   surgical   therapy  was   subsequently   pursued   (9  
(8.9%)).  
•   Surgical  consultation  too  soon  for  consent  and  screening  (20  (19.8%)).  
•   Approached  but  declined  (34  (33.6%)).  
•   Unable  to  recruit  due  to  trial  suspension  (17  (16.8%)).  
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•   One  patient  was  psychologically  distressed  and  approach  for  consent  was  
judged  not  to  be  in  her  best  interests  (1  (1.0%)).  
•   Not  recorded  (1  (1.0%)).  
The  majority   of   approached   patients   declined.      Although   not   every   patient   was  
asked  for  or  gave  reasons,  where  they  did,  these  were:  
•   Trial  participation  being  too  burdensome.  
-   Psychological  stress  of  considering  the  trial.  
-   Additional  visits   to   the  hospital/distance  to   travel   to   the  hospital   too  
great.  
-   Excess  blood  taken.  
•   Concurrent  significant  life  events.  
-   Death  of  partners  close  to  surgery.  
-   Requirement  to  close/sell  a  business.  
-   Carer  to  dependent  relatives.  
•   Patients  did  not  want  to  be  exposed  to  experimental  therapy.  
•   Individuals  perceived  they  were  too  old  (despite  being  within  the  age  range  
for  inclusion).  
•   Strong  opposition  from  close  family  members.  
Recruitment   in  Birmingham  was  undertaken  by   a   number   of   doctors  working  as  
investigators  and  research  nurses,  all  of  whom  were  experienced   in  both  clinical  
perioperative   care   and   in   conducting   clinical   trials,   and   one   experienced   clinical  
trials  coordinator  with  a  background  in  health  science.    Additional  potential  barriers  
were   discussed   on   a   number   of   occasions   with   the   trials   senior   investigators.    
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Consensus   included   the   following   factors,   beyond   those   given   by   the   patients  
above,  were  important:  
•   Short-­notice  scheduling  of  surgery  was  the  single  biggest  limiting  factor.  
•   Participation   in  a   trial  of  a  novel  agent   from  a  commercial  pharmaceutical  
company  was  more  difficult  to  recruit  to  than  to  drugs/vitamin  supplements  
already   in   routine   use,   particularly   when   sponsored   by   a   non-­commercial  
entity.  
•   The  patient  information  leaflet  was  off-­putting.  
•   Patients,   despite   efforts   from   the   research   team,   struggled   to   accurately  
perceive  perioperative  and  anaesthetic  risk.    
•   Patients  were  better  empowered  to  direct  their  care  and  were  more  sceptical  
of  participation  than  previously.  
•   Patients  wanted  explicit  approval  from  their  surgeon  and/or  anaesthetist,  and  
were  sometimes  perplexed  it  was  not  their  clinical  team  leading  recruitment.  
5.4  Discussion  
Recruitment  and  retention  of  clinical  trial  participants  is  challenging  and  a  range  of  
factors   affected   TFR116341.      Recruitment   in   cancer   trials   is   often   slower   than  
anticipated   [180]   and   some   large   and   important   critical   care   trials   have   taken  
substantial  periods  of   time  to  complete   [181].     Older  patients  are  generally  more  
likely   to   decline   [182],   which   has   implications   for   trials,   such   as   TFR116341,  
targeting  diseases   in  which   increasing  age   is  a  risk   factor   [13].     A  study  of  older  
adults   in   the   USA   found   pharmacological   agents   were   likely   to   discourage  
participation   than  non-­pharmacological   trials  [183].     Patients  declining  consent   to  
trial  participation  were  also  often  unwilling  to  participate  in  research  as  to  why,  and  
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those  who  did  often  did  not  disclose  or  did  not  have  specific  reasons  [182].    Being  
unable   to   clearly   identify   patients’   barriers  makes   it   very   difficult   to   optimise   trial  
design  to  improve  recruitment.  
A  “general  discomfort  with  the  research  process”,  randomisation  (instead  of  choice  
to   receive  a  drug),   inclusion  of  placebo  and  trial   setting  have  been  shown   to  be  
important   deterrents   to      trial   participation   [184].      Fear   of   further   deterioration   in  
health  status  is  a  factor  against  trial  participation  in  cancer  patients,  as  is  inadequate  
prior  research  awareness  [185].    Long  and  jargon-­filled  patient  information  leaflets  
may  be  off-­putting  [186].    Patients  frequently  stated  the  burden  of  TFR116341  trial  
participation   to   be   “too   much.”      This   reflects   the   overwhelming   psychological  
demands   of   participation   in   the   face   of   major   surgery,   uncertainty   of   the  
experimental  drug  and  perhaps  feelings  of  loss  of  control  [184].    Major  surgery  is  
associated  with  higher   level  of  anxiety   in  patients   [187]  and  perception  of   risk   is  
often  poor  [188,  189].    Declining  to  participate  in  research  may  be  a  way  of  relieving  
anxiety  by  exercising  self-­determination  [190].      
General   education   about   research   before   an   approach   for   a   specific   trial   and  
innovative  approach  styles  (such  as  in  groups)  may  be  beneficial  [185].    Whether  
patients   had   previously   been   approached   for   chemotherapy   or   involvement   in  
observational  studies   that  were  also   running  at   the  Birmingham  centres  was  not  
recorded  but  patients  who  had  already  been  involved  in  these  trials  seemed  more  
receptive  to  TFR116341,  perhaps  by  being  more  research  aware.      
Clinical  decision  making  has  moved  from  doctor-­centred  directive  treatment  plans  
to  the  shared  decision  making  model,  where  integration  of  the  patient’s  expectations  
and   goals   is   paramount   [191].      Patients   are   supported   to   choose   between   their  
91  
  
treatment  options  and  may  have  implications  for  trial  participation.    The  role  of  nurse  
specialists  may  have  a  profound  influence,  but  study  of  this  in  relation  to  research  
participation  is  limited,  as  most  studies  have  focussed  on  doctors  [180].    For  many  
patients   participation   in   research   offers   benefits   include   the   positive   self-­image  
driven  by  their  altruism  and  education  about  their  own  health  [180,  182,  191],  which  
could  be  used  to  enhance  recruitment  [183].    Despite   this,  clinicians  (rather   than  
investigators)   are   remarkably   reluctant   to   raise   trial   participation   with   eligible  
patients  and  several  major  trials  have  relied  on  a  few  clinicians  for  the  majority  of  
consents  [180].      
Protocol  complexity  can  be  a  major  problem  for  trials  [192].    In  TFR116341,  a  large  
number  of  patients  could  not  be  approached  due  because  of  inadequate  time  for  
screening  for  ADAs,  in  comparison  to  VINDALOO,  in  which  there  were  few  patients  
who  met  its  less  stringent  exclusion  criteria  and  patients  could  be  enrolled  at  shorter  
notice   [140].     Patients   in  VINDALOO  were  dosed  at  a  mean  of  10  days  prior   to  
surgery,  with  the  shortest  being  3  days  [143],   indicating  that  the  typical  time  from  
surgical  consultation   to  surgery  has  shortened  since  VINDALOO  was  completed.    
The   higher   than   expected   latent   tuberculosis   prevalence   probably   reflects  
insufficient  epidemiological  study  [193].  
The  TFR116341  trial  suffered  slower  than  expected  recruitment  across  all  sites  (K  
Hardes,  personal  communication).    Clinician,  researcher,  patient  and  organisational  
factors  may  all  played  a  role  [180,  182].    If  patients  and  their  clinical  teams  [184]  are  
willing   to   participate,   oesophagectomy   provides   a   predictably   high   incidence   of  
severe  post-­operative  complications  [12,  13].    Future  trials  need  to  be  designed  to  
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Data  from  this  chapter  have  been  published  as  an  abstract.  
P  Howells,  D  Dosanjh,  D.  McWilliams,  E.  Reeves,  C.  Snelson  and  D  Thicket.    Peri-­
operative  modulation  of  neutrophil  extracellular  trap  production:  a  translational  sub-­




The  neutrophil  plays  a  major  role  in  the  pathogenesis  of  ARDS  [65].    The  modulation  
of  neutrophil  function  by  TNF  alpha  has  previously  been  demonstrated  [194]  and  
the   novel   anti-­TNFR1  agent  GSK2862277  has  been   shown   to   reduce   indices   of  
pulmonary  inflammation  in  a  human  pre-­clinical  ARDS  model  [133].      
A  precursor  molecule  to  GSK2862277,  namely  GSK1995057,  has  been  shown  to  
reduce   reactive   oxygen   species   production,   reduce   neutrophil   migration   and  
reduced  bronchoalveolar  lavage  neutrophil  counts  in  primate  and  human  models  of  
acute  respiratory  distress  syndrome  [133].    This  work  with  GSK1995057  indicated  
that   pulmonary-­endothelial   interactions   were   important   ARDS   models   for   the  
observed  reduction  in  pulmonary  injury  and  via  TNFR1  signalling.      
Neutophils  cause  tissue  damage  through  the   formation  of  neutrophil  extracellular  
traps   (NETosis)   and/or   via   phagocytosis   being  modulated   [195,   196].      There   is  
increasing  evidence  of  their  importance  in  the  pathology  of  ARDS  [197-­203].    The  
aim  of  this  chapter  was  to  identify  the  effects  of  DAB  on  neutrophil  function  in  healthy  
and   critically   unwell   individuals,   specifically   looking   at   neutrophil   extracellar   trap  
production  and  phagocytosis.    Unfortunately  it  was  not  possible  to  study  the  effects  
of  DAB  on  neutrophil  function  in  vivo  from  TFR116341,  due  to  the  small  numbers  
recruited  and  the  trial  remaining  blinded  at  the  time  of  completion  of  this  work.  
The  original  planned  research  question  was  to  compare  the  neutrophil  function  in  
patients  having  undergone  oesophagectomy  in  those  patients  given  GSK2862277  
versus  placebo.    Because  of  poor  recruitment  to  the  trial,  this  was  not  possible.  
Therefore,  experiments  were  undertaken  to  attempt  to  ellucidate  in  vitro  the  effects  
of  GSK2862277  on  neutrophil  function,  comparing  healthy  young  and  older  adults,  
patients  undergoing  oesophagectomy  and  patients  with  established  critical  illness.    
94  
  
This  also  provided  the  opportunity  to  study  the  effects  of  major  surgery  and  critical  
illness  on  the  neutrophil  functions  being  investigated.  
6.2  Methods.  
See  Chapter  2.  
6.2.1  NETosis  assay  
For  experiments  with  DAB,  either  DAB,  Dummy  DAB  or  vehicle  control  were  applied  
during  the  15  minute  period  for  priming  (referred  to  as  “priming  phase”)  or  during  
the  three  hour  incubation  (referred  to  as  “incubation  phase”),  (see  section  2.4.2).  
6.2.2  Phagocytosis  assay  
Phagocytosis   was   assessed   as   described   in   section   2.4.3.      To   investigate   the  
effects  of  DAB,  neutrophils  were  exposed  to  DAB,  Dummy  DAB  or  Vehicle  Control  
for   15   minutes   prior   to   exposure   to   the   labelled   PHRODO™   particles.      This  
remained  in  their  media  for  the  duration  of  the  incubation.    In  these  experiments,  
intrinsic  TNF  from  the  neutrophils  was  relied  upon  for  stimulation.  
6.2.3  Additional  trial  data  
Patients  were  recruited  to  the  Critical  Care  Rehabilitation  Trial  on  their  fifth  day  of  
mechanical  ventilation  (this  is  Day  0,  their  first  day  of  participation;;  Day  7  refers  to  
their  seventh  day  of  participation  and  Day  14  their  fourteenth).  
White  cell  counts  were  available  from  trial  samples  for  TFR116341  (produced  by  a  
laboratory  for  the  sponsor)  and  were  available  from  the  hospital  laboratory  for  the  
Critical  Care  Rehabiliation  Trial.  
Patients  in  the  Critical  Care  Rehabilitation  trial  had  their  illness  severity  assessed  
by  SOFA  score[204],   recorded  at  baseline  and  daily  until   ICU  discharge.     SOFA  
scores  were  correlated  with  recruitment  and  nearest  day  of  discharge  to  week  one  
functional  neutrophil  studies.  
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SOFA   scores   for   TFR116341   particpants   were   not   available   at   the   time   of   the  
preparation  of  this  work.  
6.3  Results  
Patient  ages  are  shown  in  table  7.     
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Table   7.      Baseline   demographics   numbers   of   patients   contributing   to   neutrophil  
translational  substudies.  




TFR116341   Critical   Care  
Rehabilitation  
Trial  
Age   Range  
(Years)  
19-­41   45-­75   41-­75   26-­78  
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6.3.1  Neutrophil  expression  of  TNFR-­1  and  TNFR2  
Identification   of   receptor   expression   on   neutrophils   was   undertaken   using   flow  
cytometry,  using  healthy  and  critical  care  neutrophils.    Due  to  other  samples  taken  
for  the  TFR116341  and  MARTINI  trials,  insufficient  blood  was  available  for  sampling  
from  the  Healthy  Elderly  cohort  for  these  experiments.    There  were  no  significant  
differences   in  TNFR1  or  2  receptor  expression  between  healthy  controls  and  the  
critical   care   cohort   (one   value   excluded   as   outlier   by   Grubb’s   test),   but   high  
variability  was  observed  in  the  critical  care  cohort,  especially  for  TNFR1  (figure  7).  
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Figure  7:  (A)  Flow  cytometry  plot  demonstrating  presence  of  TNFR1  (pink  line)  and  
TNFR2  (black  line)  on  neutrophils  versus  isotype  control;;  median  fluorescent  index  
of  TNFR1  and  TNFR2  in  controls  and  ongoing  critical  illness  (Healthy  Young  n=13,  
Critical  Care  Rehabilitation  Trial  Day  0  n=10,  Critical  Care  Rehabilitation  Trial  Day  
7  n=7).      
(B)  No  difference  in  the  distribution  of  TNFR1  or  TNFR  2  was  detected  (Kruskal-­


























































6.3.2  Neutrophil  extracellular  trap  release  is  dysregulated  in  the  perioperative  
period  and  in  patients  with  critical  illness  
6.3.2.1  Baseline  NETosis    
Comparison  of  the  young  and  elderly  healthy  controls,  critical  care  rehabilitation  trial  
and  the  TFR116341  trial  were  analysed  (figure  8).    The  unstimulated  group  were  
significantly  different  (Kruskal-­Wallis  0.0125).    NETosis  on  entry  to  the  Critical  Care  
Rehabilitation   trial   was   significantly   lower   than   Young   Healthy   Controls   (CCRT  
Median   6506   (IQR   5779-­7701)   versus   Young   Healthy   9376   (IQR   8415-­9823)  
p=0.0047).      Healthy   elderly   controls   had   higher   NETosis   that   the   Critical   Care  
Rehab  Group   at   Recruitment   (Healthy   Elderly  Median   10666   (IQR   7660-­13095)  
versus  CCRT  Median  6506  (IQR  5779-­7701)  p=0.0125)  and  Day  7  (Median  6457  
(IQR  6108-­9240,  p=0.0462).    There  was  no  difference  in  pre-­operative  versus  post-­
operative  NETosis  levels,  but  pre-­operative  and  post-­operative  levels  were  higher  
than   the   baseline   Critically   Ill   (Pre-­operative   Median   10312   (IQR   7478-­11469),  
p=0.0125;;  Post-­operative  Median  9021  (IQR  5779-­7701),  p=0.0066).  
6.3.2.2  NETosis  post  stimulation  
The  same  groups  with  PMA  stimulation  were   then  analysed.     Overall  differences  
were  significant  (Kruskal-­Wallis  p=0.0288).    NETosis  was  higher  in  Elderly  (Median  
40630  (IQR  34783-­45456))  versus  Young  (Median  31855  (27462-­34129))  Controls  
(p=0.0350).      Young  Controls   were   lower   than   the   post-­operative   group   (Median  
49338  (IQR  39748-­62827),  p=0.0023).  
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Figure   8:   NETosis   in   unstimulated   and   stimulated   neutrophils   (A)   and   with  
unstimulated  only  (B,  expanded  for  clarity)  (n=6-­13),  *p<0.05,  **p<0.01.    Baseline  
NETosis   was   suppressed   in   early   critical   illness,   but   was   unchanged   in   the  































































































































































































































6.3.3  Correlation  of  NETosis  and  severity  of  critical  illness  
Illness  severity  in  the  Critical  Care  Rehabilitation  group  was  defined  by  using  serial  
SOFA  scores.    There  was  no  correlation  between  the  SOFA  scores  at  recruitment  
and   day   7   and   concurrent   NETosis   (Spearman’s   r=0.272,   p=0.365).      Only   the  
recruitment  SOFA  score  was  moderately   inversely   correlated  with   day  7   primed  
unstimulated  NETosis  (Spearman’s  p=-­0.463,  p=0.023).  
6.3.4.1  Cell-­free  DNA  in  the  perioperative  period  and  in  critical  illness  
Cell-­free  DNA  has  been  used  as  a  surrogate  for  NETosis  in  clinical  studies  [205,  
206]   and   is   being   investigated   as   a   potential   near-­patient   test   in   a   number   of  
respiratory  illnesses  (D  Thickett,  personal  communication).    Samples  for  analysis  
were   limited,   but   were   available   from   a   cohort   of   young   healthy   individuals,  
TFR116341   pre-­   and   post-­operatively,   and   Critical   Care   Rehabilitation   Trial  
participants  on  Day  Zero.     Analysis  of  cell-­free  DNA  showed   in   the  TFR116341,  
cfDNA  was  lower  than  young  healthy  inviduals,  at  baseline  (median  in  TFR116341  
80ngml-­1  (IQR  53-­103)  versus  young  healthy  median  109  (IQR  104-­122),  p=0.0225)  
but  was  no  different  to  young  healthy  post-­operatively  (median  101  (IQR  75-­124),  
compared   to   control   p=0.3972,   compared   to   baseline   p=0.1563).      In   the  
Rehabilitation   Trial   patients,   there   was   much   higher   cell-­free   DNA   in   the  
Rehabilitation  patients  (median  1648ngml-­1  (IQR  1200-­1997)  versus  109  (104-­122),  
p<0.0001)  (figure  9).         
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Figure   9:   Cell-­free   DNA   in   TFR116341   (upper   figure)   and   the   Critical   Care  
Rehabilitation  Trial  Day  Zero  of  Mechanical  Ventilation  (lower  figure)  (Young  healthy  
n=8,   TFR116341   n=7,   Critical   Care   Rehabilitation   Trial   n=18)   *p<0.05,  
****p<0.0001.    These  data  indicate  significantly  lower  cfDNA  in  the  TFR116341  trial  
prior  to  surgery,  but  no  difference  in  the  post-­operative  samples.    In  contrast,  cfDNA  




















































































6.3.4.2  Association  of  cfDNA  with  illness  severity  
In  the  Critical  Care  Rehabilitation  trial  patients,  there  was  no  correlation  between  
cfDNA   and   neutrophil,   lymphocyte,   monocyte   or   eosinophil   count,   nor  
neutrophil:lymphocyte  ratio  or  SOFA  score  (table  8).      
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Table  8:  Correlation   of   cfDNA  and   various   clinically-­used  biomarkers   and  SOFA  
score   in   the   Critical   Care   Rehabilitation   Trial   (Spearman’s   Rank   Correlation  
Coefficient)  (n=18).  
  
Parameter   Correlation  Coefficient   P-­value  
White  cell  count   0.13   0.60  
Neutrophil  count   0.22   0.39  
Lymphocyte  count   0.17   0.51  
Monocyte  count   -­0.12   0.63  
Eosinophil  count   -­0.10   0.69  
C-­reactive  protein   0.35   0.27  
Neutrophil:Lymphocyte  
ratio  
-­0.06   0.80  
SOFA  score   0.03   0.92  
  
  
     
105  
  
6.3.5  Phagocytosis  in  the  perioperative  period  is  not  modulated  
The  phagocytic  index  for  both  E  coli  and  S  aureus  stimuli  were  determined  for  young  
and   elderly   controls   and   patients   from   the   TFR116341   and   Critical   Care  
Rehabilitation  Trials  (n=3-­10).    Regarding  the  PI  for  E  coli,  there  was  no  significant  
overall   difference   (Kruskal-­Wallis   p=0.13).   Similarly   For  S   aureus,   there  was   no  
significant  overall  difference  difference  (Kruskal-­Wallis  p=0.53)  (figure  10).    
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Figure  10:  Phagocytic  index  using  E  coli  (A)  and  S  aureus  (B)  particles.    There  were  
no   significant   differences   in   either   group   (Kruskal-­Wallis   for  E  coli   p=0.13,   for  S  
aureus  p=0.53  (Healthy  Young  n=7,  Healthy  Elderly  n=6,  TFR116341  n=8,  Critical  



















































































































































6.3.6  Phagocytosis  is  not  related  to  illness  severity  
There  was  no  signficant  correlation  between  SOFA  score  and  Phagocytic  Index  for  
participants  in  the  Critical  Care  Rehabilitation  Trial  (Day  0,  table  9;;  Day  7  Table  10  
and  SOFA  Score  (Day  0)  in  patients  in  the  Critical  Care  Rehabilitation  Trial)  (note  
day  14  SOFA  scores  were  not  collected,  as  per  the  trial  protocol).  
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Table  9:  Correlation  of  Day  0  SOFA  Score  and  Phagocytic  Index  for  participants  in  
the   Critical   Care   Rehabilitation   Trial   (Spearman’s   Rank   Correlation   Coefficient)  
(Day  0  n=11,  Day  7,  n=7,  Day  14  n=3).  
Phagocytic  stimulus   Time  point   Correlation  
Coefficient  
P-­value  
E  coli   Day  0   0.25   0.45  
E  coli   Day  7   -­0.06   0.93  
E  coli   Day  14   0.50   1.00  
           
S  aureus   Day  0   -­0.41   0.21  
S  aureus   Day  7   0.29   0.60  
S  aureus   Day  14   -­0.50   1.00  
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Table  10:  Correlation  of  Day  7  SOFA  Score  and  Phagocytic  Index  for  participants  
in  the  Critical  Care  Rehabilitation  Trial  (Spearman’s  Rank  Correlation  Coefficient)  
(Day  0  n=11,  Day  7,  n=7,  Day  14  n=3).  
Phagocytic  stimulus   Time  point   Correlation  
Coefficient  
P-­value  
E  coli   Day  0   0.25   0.28  
E  coli   Day  7   -­0.06   0.17  
E  coli   Day  14   No  data  available     
           
S  aureus   Day  0   -­0.22   0.57  
S  aureus   Day  7   0.32   1.0  
S  aureus   Day  14   No  data  available     
  
Note:  “No  data  available”  for  the  day  14  group  reflects  the  small  number  of  patients  
still  alive  and  in-­patients  at  this  time  with  complete  SOFA  scores.  
     
110  
  
6.3.7  Modulation  of  NETosis  by  DAB  and  Dummy  DAB  
The   in-­vivo   administration   of   DAB   versus   placebo   on   NETosis   was   studied   by  
comparing  those  receiving  GSK2862277  (n=3)  to  placebo  (n=4)  (these  data  were  
made  available  by  GSK  after  completion  of  the  trial  but  before  its  publication).    There  
was  no  difference  in  baseline  NETosis    (Table  11).  
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Table   11:   Comparison   of   post-­operative   NETosis   in   patients   having   undergone  
oesophagectomy,  treated  with  GSK2862277  (n=3)  or  placebo  (n=4).  
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The  effects  of  DAB  were  analysed  on  neutrophils  from  young  healthy  volunteers,  
looking  at  the  effects  on  NETosis  whilst  applied  during  for  three  hours  during  the  
incubation  phase,   initially  at  10nM   (figure  11).     Across  all   conditions,   there  were  
significant   differences   (Friedman’s   test   p<0.0001).      When   each   condition   was  
analysed   individually,   Unprimed   Unstimulated   was   significant   (Friedman’s  
p=0.0120),  there  was  a  significant  difference  between  vehicle  control  and  dummy  
DAB  (median  vehicle  control  9376  (8415-­9823)  versus  Dummy  DAB  11057  (IQR  
10483-­13056),   p=0.0313).      Unprimed   stimulated   was   significant   (Friedman’s  
0.0120);;  vehicle  control  versus  DAB  was  significant  (vehicle  control  median  31673  
(IQR  27156-­35420)  versus  dummy  DAB  34491  (30405-­41072),  p=0.0313).    In  the  
primed  unstimulated  group,  Friedman’s  test  was  significant  (p=0.0055).    Individual  
comparison   showed   DAB   was   significantly   higher   than   vehicle   control   (vehicle  
control   median   12343   (IQR   9167-­13745)   versus   DAB   14689   (10551-­16070),  
p=0.0313)  and  Dummy  DAB  higher  than  vehicle  control  (median  14618  (IQR  11006-­
17240),   p=0.0313).      There   were   no   differences   in   the   Primed   PMA   conditions  
(Friedman’s  p=0.1416).  
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Figure  11:  effect  of  DAB  10nM  on  NETosis  when  exposed  for  the  incubation  phase  
in  healthy  volunteers  (n=6,  *p<0.05).    PMA  predictably  increased  NETosis.    In  the  
unpimed  group,  Dummy  DAB  also  increased  NETosis  compared  to  VC.  
   Primed   -­                -­                  -­              -­                -­              -­                +          +              +            +            +            +  
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When   incubated   with   100nM   DAB   or   Dummy   DAB,   the   absolute   values   were  
significantly   different   (Friedman’s   p=0.0006)   (figure   12).      The   unprimed  
unstimulated  group  were  significantly  different  (Friedman’s  p=0.028),  but  there  were  
no  significant  differences  between  groups.    The  unprimed  stimulated  groups  were  
significantly  different  (Friedman’s  p=0.028),  but  there  were  no  significant  differences  
between  individual  groups.    Neither  of  the  primed  groups  were  significantly  different.  
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Figure  12:  effect  of  DAB  100nM  on  NETosis  when  exposed  for  the  incubation  phase  
in  healthy  volunteers  (n=5).    No  significant  differences  were  observed  within  groups  
at  this  concentration  (p>0.05  for  all).  
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Neutrophils  were  primed  with  TNF  alongside  10nM  DAB,  Dummy  DAB  or  Vehicle  
Control   (figure   13).      Friedman’s   tests   was   only   significant   for   Unprimed  
Unstimulated   (Friedman’s   test   p=0.039)   but   tests   between   individual   conditions  
were  not.      
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Figure  13:  effect  of  DAB  100nM  on  NETosis  when  exposed  for  the  priming  phase  
in  young  healthy  samples  (n=5).    PMA  stimulation  increased  NETosis  as  expected.    
There  were  no  significant  differences  within  groups  (p>0.05  for  all).  
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PMA      -­                -­                -­                +              +            +                -­            -­                -­            +            +            +  
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To  investigate  neutrophils  in  sick  patients,  samples  were  used  from  the  Critical  Care  
Rehabilitation  Trial  on  days  0  and  7.    With  respect  to  day  0  (figure  14),  the  Unprimed  
Unstimulated   group,   NETosis   was   lower   in   VC   than   both   DAB   (p=0.0018)   and  
Dummy  DAB  (p=0.0011),  and  Dummy  DAB  was  higher  than  DAB  (p=0.027).    In  the  
Unprimed  PMA  group,  DAB  was  higher   than  VC  (p=0.0018),  Dummy  was  higher  
than  VC  (p=0.0058)  but  there  was  no  difference  between  DAB  and  Dummy  DAB.    
In  the  Primed  Unstimulated  group,  DAB  was  not  different  to  VC,  however  DAB  was  
significantly   lower   than   Dummy   DAB   (p=0.013)   and   Dummy   versus   control  
(p=0.012).    Primed  PMA-­stimulated  showed  no  difference  between  DAB  and  VC,  
however  Dummy  DAB  was  higher  than  VC  (p=0.024)  and  DAB  (p=0.0021).  
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Figure   14:   the   effects   of   DAB   on   neutrophils   recovered   from   patients   from   the  
Critical  Care  Rehabilitation  Trial  Day  0  (n=11),  *p<0.05,  **p<0.01.    PMA  stimulation  
increased  NETosis  as  expected.    Both  DAB  and  Dummy  DAB  increased  NETosis  
compared  to  VC.  
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This  was  repeated  with  the  Day  7  data  (figure  15).    Several  groups  showed  non-­
normal  distribution  (D'Agostino  &  Pearson  omnibus  normality  tests  were  significant).    
Unprimed  unstimulated  neutrophils  were  different  overall   (Friedman’s  p<0.0001).    
When  compared  individually,  NETosis  was  higher  in  the  DAB  group  compared  to  
VC   (p=0.0059),  Dummy  DAB  was  higher   than  DAB   (p=0.002)  and  Dummy  DAB  
higher  than  VC  (p=0.0020).    In  the  Unprimed  PMA-­stimulated  group,  VC  was  lower  
than  both  DAB  (p=0.0020)  and  Dummy  DAB  (p=0.0059)  but  no  difference  between  
DAB  and  Dummy  DAB.    In  the  Primed  Unstimulated  group,  overall  differences  were  
significant   (Friedman’s   test   p<0.0001).      DAB   was   significantly   higher   than   VC  
(p=0.002),   as   was   Dummy   DAB   (p=0.002),   Dummy   DAB   higher   than   DAB  
(p=0.014).    For  the  Primed  PMA-­stimulated  group,  overall  significance  was  found  
(p=0.012).    VC  was  lower  than  DAB  (p=0.027)  and  Dummy  DAB  (p=0.0039),  whilst  
DAB  versus  Dummy  DAB  was  not  significant.  
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Figure   15:   the   effects   of   DAB   on   neutrophils   recovered   from   patients   from   the  
Critical   Care   Rehabilitation   Trial   Day   7   (n=10).      PMA   increased   NETosis   as  
expected.    DAB  and  Dummy  DAB  increased  NETosis  compared  to  controls,  in  the  
Unprimed  Unstimulated  and  Primed  Unstimulated,  Dummy  DAB  increased  NETosis  
significantly  more  than  DAB.  
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6.3.8  DAB  does  not  modulate  phagocytic  activity  of  neutrophils  
Healthy  elderly  controls  were  used  to  assess  the  effects  of  DAB  on  phagocytosis  
(given  the  results  below,  it  was  decided  not  to  repeat  these  experiments  in  other  
groups).    Neutrophils  were  exposed  to  DAB,  Dummy  DAB  or  vehicle  control  for  15  
minutes  prior  to  running  the  PHRODO  assay.    Phagocytosis  experiments  were  run  
relying  on  intrinsic  neutrophil  TNF  secretion.    Plans  to  study  exogenous  TNF  and  
other   methods   for   eliciting   TNFR   signalling   pathways   were   not   pursued   due   to  
limited  samples.  
Comparison  was  made  between  vehicle  control,  DAB  and  Dummy  DAB  was  made  
and   there   were   no   differences   at   any   time   point,   to   either   S   aureus   or   E   coli  
(assessed   by   multiple   Kruskal-­Wallis   tests).      One   data-­point   was   missing,   for  
analyses   requiring   complete   data,   last   observation   carried   forward   was   used   to  
interpolate  this.  
Analyses  of  the  phagocytic  index  were  undertaken  with  Friedman’s  test  at  each  time  
point.  
For   those   with   E   coli   PHROD   particles,   these   showed   no   difference   (t=0min  
p=0.956,   t=30min  p=0.430,   t=60min  p=0.956)   (figure  16  upper).     Similarly,   for  S  
aureus,  no  difference  was  observed  (for  the  60  minute  time  point,  Friedman’s  test  
0.6425)  (figure  16  lower).     
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Figure  16:   phagocytic   index  of  E  coli   (upper   figure)  and  S  aureus   (lower   figure)  
PHRODO   in  neutrophils  exposed   to  DAB   (n=6).     No  significant  differences  were  
seen  between  VC,  DAB  and  Dummy  DAB  at   any   time  point   for   either   condition  
(p>0.05).  
  






































































































































6.3.9   DAB   does   not   alter   phagocytosis   in   vivo   when   administered   pre-­
operatively.  
The   effect   of   GSK2862277   was   compared   to   placebo   in   the   post-­operative  
phagocytosis  assays  of  patients  exposed  to  drug  (n=3)  and  control  (n=4).    There  
were  no  significant  differences  between  groups,  regardless  of  stimulus  or  time  point  
(Table  12).  
     
125  
  
Table   12:   Effect   of   GSK2862277   (n=3)   versus   placebo   (n=4)   on   neutrophil  
phagocytosis  in  patients  in  the  TFR116341  trial.  
Time  point  
(minutes)  




















0   S  aureus   60.5  (5.3-­183)   46.0  (27.0-­
81.0)  
>0.99  
















As  was  shown  previously  [148],  neutrophils  expressed  both  TNFR1  and  2,  although  
this  chapter’s  experiment  showed  TNFR2  expressed  more  consistently.    Given  the  
modulation  of  TNF  and  TNFR  in  sepsis  [207]  and  ARDS  [208],  substantially  lower  
receptor  levels  were  expected  in  sick  patients.    As  the  critical  care  patients  had  been  
ventilated  on   the  ICU  for   five  days  prior   to  recruitment,  and  potentially  unwell   for  
some   time   prior   to   admission,   it   is   possible   the   nadir   in   TNFR   expression   was  
missed  or  regulation  of  TNF  pathways  is  primarily  at  the  intracellular  level.  
This  study  showed  no  change  in  baseline  NETosis  between  pre-­operative  and  post-­
operative   phases,   but   that   PMA-­stimulated   post-­operative   NETosis   was   much  
higher,   suggesting   that   surgery   has   a   priming   effect.      This   may   be   biologically  
desirable  in  providing  an  aggressive  immune  response  to  a  second  insult  following  
surgery  (such  as  infection  or  haemorrhage),  or  may  contribute  to  excessive  immune  
activity   and   collateral   tissue   damage   [209].      Lower   NETosis   in   unstimulated  
neutrophils   in   established   critical   illness   is   consistent   with   other   features   of  
immunoparesis  previously  described  [207,  210].      
Raised  NETosis  has  been  reported  in  a  range  of  diseases  [98,  196,  199,  206,  211,  
212].    Currently,  debate  continues  about  whether  NETs  are  important  mediators  of  
the  pathophysiological  processes  of   these  diseases   [90,  98]  or  whether  NETosis  
may  be  a  biologically  useful   immunological   response,  but   its  high   level   in  critical  
illness  may  be  an  epiphenomenon  of  upregulated  neutrophil  activity  [196].  
NETosis  has  not  only  been  implicated  in  inflammation,  but  also  thrombosis  [212],  
cancer   metastasis   [97]   and   acute   kidney   injury   [206].      A   comprehensive  
understanding  of  their  biology  remains  elusive,  in  part  due  to  their  recent  discovery  
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[85]  but  also  because  of  the  various  different  methodologies  used  for  their  detection,  
making  direct  comparisons  more  challenging  [196].  
Nevertheless,   NETosis   increasingly   seems   important   in   ARDS   [197,   199,   202].    
Their  upregulation  by  infective  and  non-­infective  triggers  and  their  potential  cross-­
activity  with  the  immune  and  coagulation  system,  both  of  which  are  key  components  
of  the  pathophysiology  of  ARDS  [213]  adds  mechanistic  plausibility  to  clinical  [202]  
and  animal  model  data  [92].  
These  experiments  showed  increased  NETosis  in  response  to  PMA  in  the  healthy  
elderly  compared  to  young  individuals.    The  opposite  effect  is  reported  elsewhere  
[194].     This  may  be  an  effect  of   the  smaller  number  of  subjects   in   this  study,  or  
perhaps  the  more  stringent  definition  of  healthy  used  in  preceding  investigations.      
Assessment   of   baseline   NETosis   in   disease   has   shown   variable   results.      In   a  
longitudinal  study  of  burns  patients,  neutrophil  function  overall  was  suppressed  from  
the   day   after   the   burn   to   one   year   (completion   of   the   study),   but   NETosis   was  
increased  during  septic  episodes   [214].     Baseline  NETosis   is  up-­regulated   in   the  
first  hour  after  major  trauma  (albeit  with  markedly  increased  variability)  but  down-­
regulated  from  4-­48  hours,  whereas  PMA-­stimulated  NETosis  was  suppressed  at  
all  time-­points  [215].    This  is  one  of  the  first  reports  of  the  hyper-­acute  regulation  of  
NETosis  but  indicates  baseline  NETosis  is  subject  to  rapid  changes  in  response  to  
pathological  stimuli.  
NETosis  in  the  perioperative  period  is  yet  to  be  characterised  in  detail.    The  role  of  
neutrophil   extracellular   traps   is   being   investigated   in   organ   transplant,   where  
neutrophil   function   is  complex  with  both  pro-­  and  anti-­inflammatory  effects   [216].  
NETosis  may  be  an  important  mechanism  driving  surgical  complications,  including  
inflammation  [93,  195,  196],  thrombophilia  [212]  and  tumour  metastasis  [97]  and,  
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therefore,   patient   harm   following   surgery   [2].      As   described   above,   NETosis   is  
subject  to  very  rapid  regulation  in  the  immune  system  [214],  moreover  NETosis  and  
reactive  oxygen  species  production  was  further  modulated  by  exposure  to  a  number  
of  damage-­associated  molecular  patterns  [214].    In  the  perioperative  phase,  given  
the  complex  interaction  of  patients  with  comorbidities  and  pharmacological  therapy,  
anaesthesia,   the   surgical   insult   and   subsequent   management   [12,   13],   it   is  
conceivable  a  number  of   factors  may   influence  perioperative  neutrophil   function,  
contributing  to  a  complex  response  to  the  surgical  insult.  
Cell-­free  DNA  has  been  proposed   to  be  a  proxy   for  NETosis   [84,  206]  and  was  
associated  with  a  risk  of  post-­operative  renal  failure  [206].    In  the  TFR116341  group,  
baseline  cfDNA  was  lower  than  healthy  controls.    This  may  reflect  these  patients  
being  post-­chemotherapy  and  having  subtle  ongoing  impairment  in  haemopoiesis  
or   immune   function.     However,  cell-­free  DNA  was   far  higher   in   the  Critical  Care  
Rehabilitation  Trial  patients  than  healthy  controls  in  the  presence  of  lower  baseline  
NETosis   in   the   critically   unwell,   indicating   it   likely   arises   from   sources   besides  
NETosis,   or   NETosis   is   increased   in   vivo   in   the   critically   unwell   [205].      These  
patients   had   heterogeneous   presenting   pathologies   in   the   Critical   Care  
Rehabilitation  group,  which  would  be  expected  to  be  associated  with  heterogeneous  
immune  modulation  [84,  210].  
These  experiments  showed  a  modulatory  effect  of  both  DAB  and  Dummy  DAB  on  
neutrophils  from  healthy  or  critically  unwell  individuals  in  vitro  [133].    This  is  likely  
an  off-­target  effect  of  novel  domain  antibodies.    Toll-­like  receptors  (TLR)  are  present  
on  neutrophils  but  their  function  is  not  yet  as  well-­described  as  in  other  cell  types  
[217],  which  is  an  avenue  for  future  work.    TLRs  are  important  in  ARDS  [68]  and  
they  may  drive  NETosis  [218].    The  response  seen  to  Dummy  DAB  could  be  via  this  
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mechanism.    In  macrophages,  the  TNF  and  PAMP  signalling  pathways  converge  
onto  the  MAPK-­NF-­κB  system  [72].    Potentially,  an  immunogenic  dummy  agent  may  
inadvertently  be  acting  in  this  way.      
Multiple   factors,   including   time  and  environmental  mileau   influence  whether  TNF  
signal  transduction  leads  to  increased  or  decreased  apoptosis  [217].    A  much  more  
sophisticated  model  may  be   required   to   ellicudate   the   biological   effects   of  DAB.    
Most  of  the  beneficial  effects  of  DAB  were  demonstrated  in  animal  models  [137].    It  
may  well   the  down-­regulation  of  neutrophil  effects  by  TNFR1  modulation  models  
are   driven   by   regulatory   cells   such   as  macrophages   [82],   lymphocytes   [219]   or  
endothelium  [133],  with  potential  temporal  effects  and/or  sequence  of  stimuli  being  
important   [108].      Signalling   related   to   the   differential   effects   of   soluble   and  
membrane  bound  TNF  may  well  affect  the  model  as  well  [108,  220].      
Modulation   of   phagocytosis   by   DAB   was   not   demonstrated.      TNF   has   been  
associated  with  a  range  of  functions,  but  is  not  canonical  in  relation  to  phagocytosis,  
so  this  is  perhaps  not  surprising  [221].    Granulocyte  Colony-­Stimulating  Factor  (G-­
CSF),   generally   taken   as   an   immune   enhancing   agent,   has   mixed   effects   on  
neutrophils,   enhancing   chemotaxis,   phagocytosis   and   bacteriocidal   activity   but  
reduced  scretion  of  TNF  alpha,  but  increased  soluable  TNF-­receptor  and  increased  
IL-­1ra   release   [222].      TNF   alpha  was   higher   in   poor   responders   to  G-­CSF,   but  
patients  had  similar  neutrophil  counts,  phagocytic  and  bacteriocidal  effects   [222].    
Therefore,  TNF  alpha  may  not  play  a  decisive  role  in  regulating  phagocytosis  via  
neutrophils  directly.  
There  are  a  number  of  limitations  to  this  work.    Insufficient  recruitment  to  both  the  
main  and  translational  sub-­study  of  TFR116341  resulted  in  insufficient  participants  
for  the  original  experiments  planned,  and  delayed  termination  of  the  trial  prevented  
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comparison  of   this   to  clinical  and  biomarker  data   from   trial  participants.     This,   in  
particular,   led   to   the   study   of   a   simplistic   model   of   direct   neutrophil   functions,  
especially  phagocytosis,  whereas  regulation  in  an  in  vivo  system  may  be  of  greater  
biological   interest   and   link   to   the   TNF   alpha   signalling   system   [201].      Limited  
availability   of   blood   from   participants   in   other   trials   limited   which   groups   could  
contribute  to  which  experiments,  as  did  a  limited  supply  of  both  DAB  and  Dummy  
DAB.      
Attrition   (by   death   or   hospital   discharge)   in   the  Critical   Care  Rehabilitation  Trial  
limited  sample  size  in  patients  beyond  a  week  of  established  critical  illness.    This  is  
an  important  factor  to  be  considered  in  future  trial  design  where  prolonged  follow-­
up  is  considered,  as  loss  to  follow-­up  substantially  weakens  the  data  derived.  
Dummy  DAB’s  apparent  off-­target  effect  suggests  unanticipated  biological  activity.    
In  one  sense,  this  was  its  role,  and  future  work  will  need  to  ellicidate  how  Dummy  
DAB   (and   perhaps   DAB   too)   exerted   this   effect.      Unfortunately   the   laboratory  
infrastructure  to  determine  this  were  not  available  during  these  studies.  
Future  work   also   needs   to  map   in   vivo  NET  activity.     Clinical   tissue   sampling   is  
difficult  in  ARDS  studies  [148]  and  so  an  animal  model  may  be  more  appropriate.    
This   would   allow   a   controlled   surgical   stimulus   and   reliable   sampling,   including  
during   and   immediately   after   the  ARDS  and/or  OLV   stimulus,   and  post-­mortem.    
However,  the  applicability  of  animal  models  to  humans,  the  challenges  accurately  
modelling   oesophagectomy   as   an   operation   in   even   a   large   mammal   and   the  
reliability  of  animal  ARDS  models  all  make  this  a  difficult  undertaking  [223].  
There  are  now  some  established  blood  biomarkers  [214],  but  as  demonstrated  here,  
cfDNA   does   not   seem   to   fulfil   this   role,   at   least   in   this   cohort.      Sampling   for  
established  NETosis  biomarkers  in  future  trials  may  be  useful.    
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One  strategy  may  be  to  establish  Dummy  DAB’s  (and  also  perhaps  DAB’s)  off-­target  
effects  using  binding  studies,  confirming  its  mechanism  with  agonist  and  antagonist  
studies.      It   would   be   possible   to   study   DAB’s   effects   in   a   large   animal   model,  
following   adminstration   and   a   surgical   stimulus,   followed   by   analysis   of  multiple  
neutrophil  functions  and  upstream  regulators.    This  would  permit  a  more  focussed  
clinical  study  in  humans  and  perhaps  allow  more  sophisticated  targeting  of  the  drug  
to  particular  diseases  and/or  clinical  phenotypes.  
Translational  substudies  need  to  be  undertaken  with  the  challenges  to  recruitment  
considered  and  addressed,  as  discussed  in  Chapter  5.    Planning  experiments  which  
can  either  utilise  stored  and  transported  samples  and/or  near-­patient  analysis,  may  
be  necessary  for  trials  with  small  numbers  of  participants.  
In   conclusion,   neutrophil   responses   to   NETosis   promoters   are   up-­regulated  
following  oeosphagectomy,  whilst  being  depressed  in  patients  with  onging  critical  
illness.    Phagocytosis  was  not  affected.    The  effect  on  NETosis  may  be  important  
in   contributing   to   post-­operative   complications   following   major   surgery.    
GSK2862277   was   not   demonstrated   to   modulate   phagocytosis.      Inadequate  
replication  of  the  biological  system  in  the  in  vitro  models  limit  the  ability  of  models  
to   ellucidate   the  mechanisms  of   effects   seen   in   the   pre-­clinical  models   in  which  
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A   precursor   molecule   of   GSK2862277   has   been   shown   to   reduce   indices   of  
inflammation   in   a   human   pre-­clinical   LPS   model   of   ARDS   [133],   and   there   is  
mechanistic  work  to  suggest  down-­regulation  of  TNFR1  signalling  may  be  beneficial  
in   pre-­clinical   ARDS   models   [132,   179],   but   how   different   immune   cells   are  
modulated  remains  to  be  more  fully  defined.      
Macrophages  are  an  important  cell  in  the  innate  immune  response  and  ARDS  [65].    
They  have  roles  as  immunomodulators,  secreting  cytokines  [224]  and  undertaking  
phagocytosis  [225].    The  immune  response  associated  with  ARDS  involves  a  range  
of  cytokines  with  local  and  systemic  effects  [65].    They  are  important  in  both  in  the  
inflammatory  and  recovery  phases  [65,  213],  with  their  secretion  of  TNF  alpha  being  
proposed  as  a  key  cytokine  in  the  acute  phase  [125].    Work  in  this  thesis  showed  
neutrophil  NETosis  and  phagocytosis  are  not  modulated  by  GSK2862277,  whilst  
reactive  oxygen  species  have  previously  been  shown  to  down-­regulated  [148].  
The   original   intention   had   been   to   firstly   characterise   cytokine   profiles   in   the  
TFR116341  trial  for  comparison  with  BALTI-­P  and  VINDALOO,  secondly  to  recover  
alveolar  macrophages  and  assess  their  function  cytokine  secretion  and  functional  
behaviour  in  the  context  of  DAB  administration  and  thirdly  to  assess  DABs  effects  
on  recovered  alveolar  macrophages   in  a  series  of   in  vitro  experiments.     The  first  
was  not  possible  as  data  from  the  trial  were  not  available  at  the  time  of  preparation  
of  this  thesis.    The  second  was  not  possible  due  to  poor  rates  of  recruitment  to  the  
TFR116341  trial.    The  third  was  hampered  by  limited  sample  availability.  
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The  aim  of   this  study  was   to  characterise  TNF  alpha  and  other  cytokines   in   the  
perioperative  phase,  using  data  from  the  BALTI-­P  sub-­study  [138]  and  VINDALOO  
trials  [143],  and  assess  the  effects  of  GSK2862277  on  macrophage  function.  
7.2  Methods  
See  Chapter  2.  
7.3  Results  
7.3.1  Cytokine  Data  from  BATLI-­P  and  VINDALOO  
Results  of  the  cytokine  data  are  presented  in  Table  13  and  14.    For  TNF  alpha,  there  
was   an   overall   difference   in   absolute   levels   (Kruskal-­Wallis   p<0.0001).      When  
compared  individually,  in  both  BALTI-­P  and  VINDALOO  TNF  alpha  fell  from  pre-­  to  
post-­operatively,  but  recovered  to  pre-­operative  levels  on  day  1.    When  the  two  trials  
were  compared,  plasma  TNF  alpha  was  significantly  lower  in  VINDALOO  at  all  three  
time  points.  
For  TNFR1,  there  was  an  overall  difference  (Kruskal-­Wallis  p<0.0001).    Levels  were  
higher  post-­operatively  and  on  day  one   in  both   trials,  whilst   levels  were   lower  at  
each  time  point  in  VINDALOO  compared  to  BALTI-­P  (p<0.0001).    When  fold-­change  
was  analysed,  there  were  overall  differences  (Kruskal-­Wallis  p<0.0001).    In  BALTI-­
P,   there   was   a   fold-­change   rise   from   pre-­   to   post-­operatively,   but   returned   to  
baseline  on  day  1,  whereas  in  VINDALOO,  pre-­  to  post-­operatively  and  pre-­  to  day  
1  both  rose  significantly  (p<0.0001).      
For   TNFR2,   overall   differences   were   significant   (Kruskal-­Wallis   p<0.0001).      In  
BALTI-­P,   TNFR2   rose   post-­operatively   (p=0.0017)   and   on   day   one   (p<0.0001)  
compared  to  pre-­operatively,  with  a  similar  pattern  in  VINDALOO  (post-­operatively  
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p=0.0051,  day  1  p<0.0001).    Levels  were  lower  in  VINDALOO  at  each  time  point  
compared   to   BALTI-­P   (p<0.0001).      For   fold   change,   there   were   significant  
differences  overall  (Kruskal-­Wallis  p<0.0001).    In  both  trials,  there  were  significant  
fold-­rises  in  TNFR2  levels  from  baseline  post-­operatively  and  on  day  1  (p<0.0001  
for  all).    In  BALTI-­P,  there  was  also  a  significant  rise  from  post-­operative  to  day  1  
(p=0.0065).  
IL6   levels   rose   in   both   trials   post-­operatively   and   fell   but   remained   higher   than  
baseline,  but  there  was  not  a  significant  difference  between  the  two  trials,  in  contrast  
to  other  cytokines.    IL1-­ra  was  higher  in  the  VINDALOO  group,  but  fold  change  was  
greater  in  BALTI-­P.    IL  10  levels  were  higher  in  the  VINDALOO  group,  but  showed  
less  fold-­change,  again  indicating  a  more  stable  cytokine  profile.    IL8  was  modestly  
but  significantly  higher  in  VINDALOO,  but  the  two  trials  showed  a  similar  trajectory  
of  change  over  the  three  time  points.      
Soluble  RAGE   (a  marker  of   respiratory   type  one  epithelial   cell  damage)  showed  
overall   significant   differences   (p<0.0001).      Interestingly,   levels   were   higher   at  
baseline  in  VINDALOO  versus  BALTI-­P  (BALTI-­P  median  31  (IQR  16-­59)  versus  
VINDALOO  42  (35-­42),  p=0.0047),  but  BALTI-­P  was  much  higher  than  VINDALOO  
post-­operatively  (BALTI-­P  469  (IQR249-­1016)  versus  VINDALOO  52  (IQR  39-­72),  
p<0.0001),  and  remained  elevated  but  less  markedly  on  day  1  (BALTI-­P  55  (IQR  
35-­95)  versus  VINDALOO  38  (IQR  30-­49).    When  analysed  for  fold-­change,  there  
were  significant  differences  overall  (Kruskal-­Wallis  p<0.0001).    In  both  trials,  there  
was  a  fold-­change  rise  from  pre-­  to  post-­operatively,  then  a  significant  fall  to  day  
one,  but  remained  higher  on  day  1  than  baseline  (p<0.0001  for  all).  
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Pre-­day  1  0.0025  
Post-­day  1  <0.0001  
   0.86  (0.81-­0.97)   0.96  (0.88-­
1.0)  
Pre-­post  <0.0001  
Pre-­day  1  0.029  
Post-­day  1  0.0014  






Pre-­day  1  0.39  
Post-­day  1  <0.0001  
   2.3  (1.4-­3.2)  
  
2.0-­(1.5-­2.6)   Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  0.49  





Pre-­day  1  <0.0001  
Post-­day  1  0.0065  
   1.3  (0.99-­1.5)   1.3  (1.1-­1.7)   Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  0.063  





Pre-­day  1  <0.0001  
Post-­day  1  0.20  
   34  (20-­58)   24  (13-­45)   Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  0.037  





Pre-­day  1  <0.0001  
Post-­day  1  0.6146  
   2.0  (1.5-­2.9)   2.0  (1.5-­2.5)   Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  0.70  





Pre-­day  1  <0.0001  
Post-­day  1  0.64  
   2.8  (1.9-­5.9)   1.7  (1.4-­2.3)   Pre-­post  <0.0001  
Pre-­day  1<0.0001  
Post-­day  1  <0.0001  







Pre-­day  1  0.25  
Post-­day  1  0.37  
   1.2  (1.1-­1.4)   1.1  (1.0-­1.3)   Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  0.12  





Pre-­day  1  <0.0001  
Post-­day  1  0.19  
   8.4  (3.0-­12)   2.9  (2.0-­3.9)   Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  <0.0001  





Pre-­day  1  <0.0001  
Post-­day  1  <0.0001  
   1.2  (0.95-­1.5)   0.90  (0.73-­
0.99)  
Pre-­post  <0.0001  
Pre-­day  1  <0.0001  
Post-­day  1  <0.0001  
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7.3.2  Macrophage  phagocytosis  and  DAB  
Phagocytosis   was   analysed   using   recovered   alveolar  macrophages   (n=8).      This  
showed   an   overall   difference   (Kruskal-­Wallis   p<0.0001).      Cytocholasin   inhibited  
phagocytosis  as  expected  (1.0  versus  -­88  (-­92  to-­83%),  p=0.0078).    DAB  100nM  
promoted   phagocytosis   compared   to   baseline   versus   baseline   (p=0.039)   and  
Dummy  DAB  (DAB  42%  (IQR  5.8  to  102)  versus  Dummy  DAB  18%  (IQR  -­18  to  24)  
p=0.0078).    5nM  Dummy  DAB  reduced  phagocytosis  compared  to  baseline  (-­29%  
(IQR  -­48  to  -­11,  p=0.016)  and  5nM  DAB  was  higher  (Median  17%  (IQR  -­6.1  to  24),  
p=0.016),  (figure  17).  
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Figure   17:  Macrophage   phagocytosis   as  modulated  by  DAB,   *p<0.05,   **p<0.01.    
Cytocholasin  C   significantly   decreased  phagocytosis   as   expected.      100nM  DAB  
increased  phagocytosis  compared  to  control  and  Dummy  DAB  100nM.    DAB  5nM  
was  significantly  higher  than  Dummy  DAB  5nM,  but  not  different  from  control.  
  








































































7.3.3  Macrophage  survival  and  function  
To   see   if   effects   might   be   mediated   by   macrophage   death,   cell   survival   was  
analysed   using   CellTitre™   assay   utilising   a   macrophage-­like   cell   line,   THP-­1.    
Adequate   supplies   of   human  macrophages  were   not   available   at   the   time   these  
experiments  were  undertaken.      
Viability  was  not  altered  by  DAB  (figure  18).     
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Figure  18:  Cell  survival  of  THP-­1  derived  cells,  with  absolute  and  percentage  
change  compared  to  vehicle  control  (n=6).    There  were  no  differences  at  two  
hours  absolute  (p=0.29)  or  in  percentage  change  (p=0.30),  or  at  four  hours  
absolute  (p=0.24)  or  percentage  change  (p=0.24).  
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To  further  investigate  the  modulatory  effects  of  DAB  on  macrophages,  the  effects  
on  THP-­1  cells  were  analysed  using  the  DCFDA  assay  to  study  reactive  oxygen  
species  production.    No  effects  at  two  or  four  hours  were  elucidated  (figure  19).  
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Figure  19:  Reactive  oxygen  species  production  produced  by  THP-­1  cells  at  two  and  
four   hours,   determined   by   DCFDA   assay   (n=6).      None   of   the   experiments   had  
significant  differences  (ROS  2  hours,  p=0.15,  ROS  2  hours  percentage  p=0.11,  4  
hours  p=0.21,  4  hours  percentage  p=0.23).  
  























































































































































































































































Receptor  expression   in  alveolar  macrophages  was  attempted  with   the  recovered  
macrophages.      However,   repeated   samples   had   high   autofluorescence   which  
prevented  receptor  analysis  (figure  20).    
  
Figure  20.  Autofluorescence  in  recovered  alveolar  macrophages.  
  
  




TNF  alpha  is  elevated  at  presentation  in  patients  who  present  to  hospital  with  sepsis  
but  falls  rapidly  [207].    Baseline  TNF  levels  were  lower  in  oesophagectomy  patients  
preoperatively  (as  expected)  but  fell  further  by  the  end  of  surgery,  with  a  trend  to  
return  to  baseline  on  the  day  following  surgery.    It  may  be  TNF  alpha’s  peak  plasma  
levels   occur   in   the   early   phase   of   the   operation,   or   TNF   alpha   production   is  
suppressed,   perhaps   due   to   volatile   anaesthetic   agents   (although   this   effect   in  
animal  models  is  not  consistent  [226]).    Absolute  levels  of  TNFR1  and  2  were  lower  
in   VINDALOO,   but   TNFR1   fold-­change   was   higher.      There   is   clearly   complex  
regulation  of  TNF  alpha  in  the  perioperative  phase  [108].      
Given  the  reduced  ARDS  rates,  it  was  surprising  that  TNF  alpha  levels  were  higher  
in  the  VINDALOO  cohort,  especially  as  ARDS  with  a  hyperinflammatory  phenotype  
has   been   associated  with  worse   outcome   [208].     Whether   the  modest   absolute  
increase   was   physiologically   significant   is   not   clear.      Higher   levels   of   anti-­
inflammatory  cytokines  were  observed  (IL-­8,  IL-­10  and  IL-­1ra),  perhaps  indicating  
better  immune  regulation  in  response  to  surgery.    This  may  be  because  of  higher  
levels  of  baseline  vitamin  D  that  were  present   in   the  VINDALOO  trial   [143]  have  
modulated  the  immune  response.    Alternatively,  plasma  cytokine  levels  may  not  be  
representative   of   cellular   level   effects   or   regulation   by   downstream   signal  
transduction  [227].      
DAB  had  modulatory  effects  on  macrophage  phagocytosis.    Previous  work  showed  
modulatory   effects   on   reactive   oxygen   species   in   neutrophils   [133]   but   not   in  
NETosis  or  phagocytosis  (as  described  in  chapter  6).    This  suggests  that  immune  
regulatory   cells   such   as   macrophages   may   more   important   in   the   effect   of  
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GSK2862277  than  neutrophils  [73,  75,  76].    A  re-­analysis  of  a  trial  of  IL-­1  inhibition  
in   sepsis   has   suggested   a   subset   of   patients   with   “macrophage   activation  
syndrome”  may  have  benefitted,  implying  the  targeting  of  immune-­regulating  cells  
may  be  beneficial  [228].    Some  doubt  must  sit  over  the  results,  however,  given  the  
off-­target  effects  of  Dummy  DAB  observed  in  the  experiments  with  neutrophils.    The  
next   stage   of   work   to   analyse   this   further   would   require   agonist   and   antagonist  
panels  to  delineate  the  importance  of  TNF  in  controlling  macrophage  phagocytosis,  
but  there  were  insufficient  clinical  samples  or  time  to  complete  this.      
Investigating   macrophages,   especially   from   current   or   ex-­smokers,   using   flow  
cytometry   was   challenging   due   to   their   high   autofluorescence.      Given   the  
importance   of   smoking   in   ARDS   risk   [25,   229],   smokers’   macrophages  may   be  
phenotypically   different   from   non-­smokers,   but   the   frequency   of   non-­smokers  
presenting  for  thoracic  surgery  is  low  and  collecting  adequate  numbers  of  samples  
was  not  feasible.      
Additionally,   supplies   of   sample   tissue   via   the  MLTC   were   dependent   on   other  
clinical  factors,  including  frequency  and  type  of  surgery  performed,  sufficient  tissue  
not  needed  for  histology  being  available  and  rate  of  procedures  being  performed.    
This   limited   the  supplies  of  alveolar  macrophages  available   for  experiments  and  
necessitated  switching  to  THP-­1  cells  to  allow  completion  of  planned  experiments.    
Clearly,   these   data   are   not   directly   comparable,   and   further   work,   repeating   the  
experiments  with  alveolar  macrophages  to  elucidate  the  effects  of  DAB  on  survival  
and  ROS  production  is  required.  
THP-­1  cells  did  not  respond  to  DAB,  however  there  were  no  significant  effects  in  
the  positive  controls  of  the  ROS  assays.    It  may  be  that  these  particular  cells  (or  this  
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subset   at   high   passage   levels)   were   not   sufficiently   representative   of   alveolar  
macrophages  to  permit  accurate  modelling  of  the  effects  of  DAB.  
It  was  not   possible   to   cross   validate   the   cytokine  analyses   for   the   two   trials   are  
equivalent  as  they  were  run  several  years  apart,  although  they  are  calibrated  to  the  
same  concentrations.    As  discussed  above,  plasma  levels  may  not  accurately  reflect  
cellular   effects,   down-­stream   signalling   is   important   for   regulation   and   clinical  
limitations  on  blood  sampling  limit  the  number  of  time  points  that  can  be  analysed.    
Furthermore,   there   may   be   confounding   by   individual   surgical   and   anaesthetic  
factors  not  captured  in  these  data.    A  limitation  of  the  perioperative  model  for  tissue  
damage   is   the   immune  modulating  effects  of  anaesthesia,  which   is  complex  and  
difficult   to   standardise   for   trials,   [226]   and  a   better   understanding   of   these   is   of  
immense  importance  [230].    Similarly,  surgical  technique  and  duration  will  result  in  
variable  levels  of  tissue  damage  that  again  cannot  be  standardised  [13].  
The   limitations   of   the   TFR116341   trial   recruitment   and   its   implications   for   the  
originally  planned  work  have  been  outlined  in  the  introduction  to  this  chapter.    Given  
the  signal   for  DAB  modulating  macrophage  phagocytosis,  and   the  macrophage’s  
canonical  role  in  ARDS  [65,  213],  it  is  clearly  of  importance  to  analyse  the  effect  of  
DAB  on  this  cell  type  in  more  detail.    Further  experiments  need  to  confirm  the  effect  
of   DAB,   study   other   macrophage   functions,   including   ROS   production,   and  
macrophage  survival,  and   the  effects  on  signalling   to  downstream   immune  cells.    
Characterisation   of   effects   in   both   the   initial   pro-­inflammatory   response  and   the  




Understanding   the   kinetics   of   the   inflammatory   response   is   important.      The  
availability  of  cytokine  samples  from  TFR116341  was  provide  a  useful  comparison  
with   these   trials.     Clearly,  more   frequent   sampling,   including   intra-­operatively,   is  
required  and  potentially  this  may  provide  a  range  of  useful  insights  into  the  nature  
of  the  inflammatory  response  to  surgery.    It  remains  the  case  that  plasma  cytokine  
levels  may  not   correlate  well  with   paracrine/autocrine   effects,   as  may  be   true   in  
sepsis   [207],   therefore   tissue   sampling,   perhaps   from   animal   models,   may   be  
helpful  in  investigating  this.  
In  conclusion,  macrophage  phagocytosis   is   increased  by  DAB  GSK2862277,  but  
modulation   of   ROS   or   cell   survival   was   not   observed   in   THP-­1   derived  
macrophages.      There   have   been   changes   in   in   an   array   of   pro-­   and   anti-­
inflammatory  cytokines  but  not  IL-­6,  suggesting  the  clinical  changes  seen  may  be  
reflected  in  immunomodulation.    GSK2862277  appears  to  modulate  the  activity  of  a  
critical  cell   in  ARDS,  and  further  mechanistic  understanding  of   the  agent’s  action  
may  better-­elucidate  the  drug’s  effect  in  vivo.  









Given  the  number  of  patients  undergoing  surgery  and  the  disproportionate  burden  
of   complications   that   fall   on   the   high   risk   patient,   reducing   complications   in   this  
cohort  is  a  global  public  health  priority  [2].    The  predictability  of  complications,  critical  
illness  and  ARDS  following  oesophagectomy  [8,  9,  231]  has  made  it  a  potentially  
useful  resource  for  studying  critical  illness  for  previous  trials  [148].  
Using   samples   from   patients   undergoing   these   procedures   allows   the   study   of  
perioperative  immunological  changes  in  vitro  which  may  be  important  factors  in  the  
development  of  complications.    Immune  modulation  in  the  perioperative  period  may  
have  major  consequences  [71]  via  a  variety  of  potential  mechanisms  [67],  driving  
adverse  outcomes.  
In  this  thesis,  oesophagectomy  as  a  model  of  critical  illness  has  been  evaluated  and  
perioperative  immune  modulation  was  investigated.      
8.2  The  impact  of  the  acute  respiratory  distress  syndrome  on  outcome  after  
oesophagectomy  
ARDS  is  associated  with  a  number  of  adverse  outcomes,  including  non-­respiratory  
organ  failure,  longer  ICU  and  hospital  stay.    Late  ARDS,  which  was  suspected  to  
be   more   likely   to   be   related   to   secondary   complications   such   as   sepsis   and  
anastomotic   leak,  had  worse  outcomes  than  early  ARDS.     This   is  similar   to   late-­
onset   ARDS   in   a   general   critical   care   cohort   (which   used   over   48   hours   from  
admission  as  a  definition)  [232].     Oesophagectomy  was  a  useful  ARDS  model   in  
this   trial,   with   the   risk   around   25%,   which   permitted   the   effective   evaluation   of  
salmeterol  in  the  perioperative  period  [138].  
151  
  
8.3  ARDS  Following  Oesophagectomy:  A  Comparison  of  Two  Trials.  
This  study  showed  a  fall  in  the  rate  of  ARDS  between  the  BALTI-­P  and  VINDALOO  
trials,  associated  with  a  number  of  changes  in  clinical  practice.    They  remain  high  
compared  to  other  surgical  cohorts  [2]  and,  indeed,  populations  identified  as  high  
risk  [154,  158,  213].    This  study  also  reiterated  the  importance  of  smoking  as  a  risk  
factor   for  ARDS  and  post-­operative  complications   [22,  25,  229]  but  also   found  a  
signal  that  dihydropyridine  use  pre-­operatively  was  a  risk  factor.      
This  is  a  novel  finding  that  requires  confirmation  in  other,  larger  cohorts,  cellular  and  
animal   studies,   mechanistic   assessment   and,   perhaps   eventually   interventional  
trials.      It   indicates   there  may  be  an  array  of   factors   that   influence  post-­operative  
outcome  that  have  yet  to  be  investigated.    Clinical  trials,  such  as  SPACE  (EudraCT  
number   2016-­004141-­90)   and   PREVENTION   HARP-­2   (ISRCTN48095567),   are  
now  taking  place,  to  study  concurrent  medical  therapy  in  the  perioperative  period.      
Although  ARDS  was  less  frequent  in  the  VINDALOO  trial,  the  rates  of  severe  post-­
operative  complications  are  substantial  and  have  not   fallen  between   these   trials.    
Other   surgical   cohorts   have   demonstrated   that   post-­operative   pulmonary  
complications  are  associated  with  late  deaths  and  increased  hospital  resource  use  
[22].      
The  lower  ARDS  rate  in  VINDALOO  is  still  comparable  to  other  methods  derived  to  
date  to  identify  high-­risk  cohorts  for  studies  [154,  158].    A  better  understanding  of  
specific  risk  factors  for  ARDS  in  oesophagectomy,  such  as  smoking,  would  improve  
the  event  rate  in  the  control  group  of  trials,  which  would  enhance  trial  power  [233].    
Reducing   severe   post-­operative   complications   (be   that   specifically   pulmonary   or  
more  general)  may  well   be   a   pragmatic   target   for   future   trials   using   this  model,  
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which,  although  less  specific  than  ARDS,  is  of  practical  concern  to  clinicians  and  
more  patient-­centred  [9,  12].  
8.4  Evaluation  of  the  TFR116341  Trial  
TFR116341  was  a   recent   trial  attempting   to  use  oesophagectomy  as  a  phase   II  
efficacy  study   to  evaluate  GSK2862277,  and  provide  a  mechanistic   translational  
sub-­study.      It   was   designed   prior   to   the   completion   of   VINDALOO   [140].      Poor  
patient  accrual  was  a  major  problem,  due  to  exclusion  criteria  and  the  reluctance  of  
patients   to   participate,  which   had   changed   from  previous   trials   [138,  143].      This  
prevented  the  envisaged  translational  sub-­study  being  possible.  
All  trials  have  recruitment  hurdles,  but  the  aggregation  of  several  has  the  potential  
to  make  a  trial  undeliverable  in  a  realistic  time-­frame  [192].    Careful  trial  design,  to  
optimise   recruitment   and   obtain   the   best   possible   data,   is   important,   for   both  
scientific  and  ethical  reasons  [234].    Research  participation  can  deliver  individual  
patient  benefit  and  patient  empowerment,  which  could  be  used  to  aid  recruitment  
and  better  engage  clinical  staff  in  future  studies  [180,  182,  183,  191].  
8.5  TFR116341  Translational  Sub-­Study  
This   study   demonstrated   important   differences   in   NETosis   between   established  
critical   illness  and   the  perioperative  period.     Furthermore,   there  are  much  higher  
levels  of  cfDNA  in  the  established  critical  illness  cohort.    Clearly  immune  function  is  
different  in  these  two  groups,  which  correlates  with  the  known  temporal  patterns  of  
inflammation  in  critical  illness  [207,  210].    How  the  surgical  insult  interacts  with  the  
various  other   factors   in   the  perioperative  period   to   lead   to  complications  remains  
incompletely  understood,  but  NETosis  is  at  least  one  mechanism  by  which  this  may  
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occur   [67,  87,  98,  206].     Baseline  NETosis  was  not  elevated,  but  a  much   larger  
response  was  elicited  when  stimulated.    NETosis  has  been  associated  with  tissue  
damage   [92]  and  hypercoagulability   [85],   so   it  may  be   the  effect  of  surgery   is   to  
prime  neutrophils  which   then   response   in  an  exaggerated  way   to   further   insults,  
increasing  vulnerability  to  and/or  worsening  post-­operative  complications.  
Modulation  of  macrophage  phagocytosis,  but  not  phagocytosis  by  neutrophils  nor  
NETosis,   by  GSK2862277  was   demonstrated.      This   builds   on   Proudfoot’s   work  
showing  downregulation   of   reactive   oxygen  species   in   neutrophils   production   by  
GSK2862277’s   predecessor   molecule   [148].      ARDS   is   driven   by   multiple  
interdependent   signalling   molecules,   with   both   second  messenger   pathway   and  
temporal  sequencing  having  immunomodulatory  effects  [65,  178,  213,  227].    In  vitro  
conditions   and   isolating   individual   cell   experiments   may   not   adequately   model  
conditions  in  vivo,  which  may  explain  negative  results  despite  efficacy  in  animal  and  
pre-­clinical  models.  
8.6  Limitations  
The   limitations   have   been   discussed   in   each   chapter.      Chapters   3   and   4   are  
retrospective  studies,  limited  by  their  size,  the  use  of  databases  for  analyses  (with  
respect   to  chapter  4)  not  planned  a  priori  and   inconsistencies   in  data   recording.    
Nevertheless,  without  prospective  cohort  studies,  these  data  would  not  otherwise  
be  available.    This  is  turn  would  limit  the  understanding  of  the  changes  in  ARDS  and  
its  implications  for  patients  that  have  occurred  [8,  235],  which  has  implications  for  
the  use  of  oesophagectomy  as  an  ARDS  model.  
8.7  Future  investigations  
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Future  work  studying  clinical  outcomes  following  oesophagectomy  needs  to  include  
prospective   cohort   studies   looking   the   incidence   of   ARDS   in   the   current   era,  
especially  utilising  the  Berlin  Definition  [45],  modern  anaesthetic  techniques  [12,  13]  
and  therapeutic  interventions  [213,  236].    Concurrent  systematic  screening  for  other  
complications,  including  post-­operative  pulmonary  complications  [237]  and  sepsis  
[238]  would   provide  more  detailed   insight   into   post-­operative   critical   illness,   and  
endpoints   should   be   primarily   patient-­centred   [239].      Ensuring   adequate   trial  
recruitment  rates  will  also  be  critical  for  success,  as  discussed  in  Chapter  5.    The  
identification   of   dihydropyridines   as   a   potential   modifiable   risk   factor   for   ARDS  
requires  replication  in  other  databases  and  mechanistic  work  (perhaps  utilising  an  
animal   model   of   ARDS),   prior   to   a   randomised   trial   of   withdraw/exchange   of  
dihydropyridines  prior  to  surgery  versus  standard  care.  
Animal  models  probably  offer  the  most  efficient  mode  of  better-­understanding  the  
effects  of  DAB,  which  could   then  be  sought   in  confirmatory  human  studies.     The  
temporal  effects  on  different  cell  groups,  especially  macrophages,  as  important,  as  
they  have  different  effects  during  the  course  of  ARDS  [65,  213].    Determining  the  
mechanism  of  the  off-­target  effects  of  Dummy  DAB  is  also  important,  firstly  so  a  true  
dummy  negative  control   is  available  and  secondly  as   this  might   reveal   important  
mechanisms  by  which  domain  antibodies  function  [133].      
Future  trials  of  GSK2862277  will  need  to  consider  optimum  disease  targeting  and  
careful  trial  design  to  determine  clinical  effectiveness.    Such  trials  will  be  informed  




Multiple  mechanisms  contribute  to  ARDS,  rather  than  a  defined  canonical  pathway  
[213,  227,  240].     Furthermore,   the  definition  of  ARDS  [45]  has   limited  correlation  
with   pathological   definitions   [241],   which   may   pollute   trial   cohorts.      More  
sophisticated  patient  characterisation,  disease  phenotyping  and  factorial  trial  design  
offer  the  chance  to  elicit  effective  therapeutic  strategies  [56,  148,  227].    Managing  
variability   in   participants’   clinical   care   in   pragmatically-­designed   randomised  
remains  a  major  problems  for  perioperative  and  critical  care  trials  [242].  
A  deeper  mechanistic  understanding  of  the  disease  alongside  more  sophisticated  
models  will  be  required  to  develop  individualised  therapeutic  strategies  [227].    For  
example,  if  further  studies  confirm  priming  neutrophils  for  NETosis  is  an  important  
driver  of  perioperative  complications,  phenotyping  potential  NETosis  would   firstly  
identify  individuals  as  high-­risk  and  secondly  provide  an  enriched  cohort  for  testing  
therapeutic  interventions.    Further  mechanistic  work,  especially  using  studies  of  the  
metabolome  and  complex  multicellular  and  animal  models  will  be  needed  to  provide  
insights  to  develop  such  treatments  [148,  223,  243].  
Oesophagectomy   remains   a   surgical   procedure   with   a   high-­risk   of   ARDS   and  
perioperative  complications.    Smoking  appears  to  be  a  key  contributing  factor  to  this  
risk.      Falling   incidence   renders   oesophagectomy  a   less   useful  model   for  ARDS.    
Dihydropyridine  drugs  may  also  be  important  aetiological  agents  for  perioperative  
ARDS.      This   requires   repetition   in   other,   larger   cohorts   and   mechanistic  
investigation.      
GSK2862277   enhances   macrophage   phagocytosis   and   better   understanding   of  
these   cells   in   ARDS   and   in   the   perioperative   period   may   further   elucidate   the  
beneficial   effects   of   GSK2862277   observed   in   pre-­clinical   models.      Patterns   of  
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NETosis   are   different   in   perioperative   and   ongoing   critical   illness.      NETosis   is  
potentially  an  under-­investigated  mechanism  contributing  to  the  pathophysiology  of  
clinical  complications  in  these  groups.  
High-­risk  surgery  is  a  common  occurrence  globally  and  preventing,  mitigating  and  
treating  post-­operative  complications  is  an  important  public  health  challenge  [2].    A  
better  understanding  of  immunological  function  in  the  perioperative  period  is  vital  




Supplementary  data  published  as  part  of  Chapter  3  
Prepared  by  the  trial  statistician  (Mr  C  Knox).  
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Linear  regression  of  the  secondary  outcomes  comparing  ARDS  status  to  no  ARDS  
was  carried  out  with  and  without  adjustment  for  randomised  treatment  (table  A1).  
Significant  differences  were  found  for  all  outcomes  at  all  stages  with  the  exception  
of:  late  ARDS  and  duration  of  level  0/1  care,  early  ARDS  and  EQ-­5D  score  at  day  
28,  EQ-­5D  VAS  score  at  day  28  and  each  ARDS  status,  EQ-­5D  score  at  day  90  and  
each  ARDS  status  and  EQ-­5D  VAS  score  at  day  90  and  each  ARDS  status..     
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Table  A1:  Linear  regression  of  secondary  outcomes  by  ARDS  status  
  
Outcome  Measure   Early  ARDS  (day  0-­3)   Late  ARDS  (day  4-­28)  
   Difference  (95%  CI)   p   No.   Difference  (95%  CI)   p   No.  
Organ  failure  free  days   *-­2.40  (-­3.60,  -­1.19)   <0.001   329   *-­5.77  (-­7.55,  -­3.99)   <0.001   329  
†-­2.40  (-­3.61,  -­1.19)   <0.001      †-­5.72  (-­7.50,  -­3.94)   <0.001     
Ventilator  free  days   *-­5.28  (-­6.81,  -­3.76)   <0.001   330   *-­10.14  (-­12.38,  -­7.89)   <0.001   330  
†-­5.27  (-­6.80,  -­3.75)   <0.001      †-­10.21  (-­12.46,  -­7.96)   <0.001     
Hospital  length  of  stay   *3.93  (2.09,  5.77)   <0.001   328   *10.34  (7.63,  13.06)   <0.001   328  
†3.91  (2.07,  5.74)   <0.001      †10.54  (7.83,  13.25)   <0.001     
Duration  of  ICU  stay     *4.82  (3.00,  6.65)   <0.001   331   *12.89  (10.20,  15.58)   <0.001   331  
†4.81  (2.99,  6.64)   <0.001      †12.97  (10.27,  15.67)   <0.001     
Duration   of   ICU   stay  
excluding  deaths  
*4.78  (2.91,  6.64)   <0.001   326   *12.89  (10.20,  15.58)   <0.001   326  
†4.76  (2.89,  6.63)   <0.001      †12.97  (10.27,  15.67)   <0.001     
Duration  of  Level  0/1  care   *-­1.76  (-­3.43,  -­0.10)   0.038   330   *-­2.40  (-­4.86,  0.06)   0.055   330  
†-­1.78  (-­3.44,  -­0.12)   0.036      †-­2.27  (-­4.73,  0.19)   0.070     
Duration  of  Level  2  care   *0.98  (0.08,  1.88)   0.033   330   *4.06  (2.73,  5.39)   <0.001   330  
†0.98  (0.08,  1.86)   0.033      †4.04  (2.71,  5.38)   <0.001     
Duration  of  Level  3  care   *4.48  (3.21,  5.74)   <0.001   330   *8.76  (6.90,  10.63)   <0.001   330  
†4.47  (3.20,  5.73)   <0.001      †8.85  (6.98,  10.72)   <0.001     
EQ-­5D  Day  28   *-­0.08  (-­0.18,  0.02)   0.119   263   *-­0.24  (-­0.39,  -­0.09)   0.002   263  
†-­0.08  (-­0.18,  0.02)   0.119      †-­0.24  (-­0.39,  -­0.09)   0.002     
EQ-­5D  VAS  Day  28   *-­2.76  (-­8.60,  3.08)   0.353   262   *-­6.56  (-­15.70,  2.57)   0.158   262  
†-­2.75  (-­8.60,  3.11)   0.356      †-­6.62  (-­15.78,  2.54)   0.156     
EQ-­5D  Day  90   *-­0.02  (-­0.11,  0.06)   0.630   260   *-­0.12  (-­0.26,  0.01)   0.073   260  
†-­0.02  (-­0.11,  0.06)   0.616      †-­0.12  (-­0.26,  0.01)   0.077     
EQ-­5D  VAS  Day    90   *-­2.75  (-­8.81,  3.30)   0.372   261   *-­7.88  (-­17.42,  1.65)   0.105   261  
†-­2.75  (-­8.82,  3.31)   0.372      †-­7.89  (-­17.43,  1.68)   0.106     
*Unadjusted  difference  between  patients  with  ARDS  and  those  without  
†Estimated  difference  between  patients  with  ARDS  and   those  without  adjusted   for  
treatment  allocation  
CI  95%  confidence  interval  
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Logistic   models   were   fitted   for   each   stage   of   ARDS   with   an   interaction   term   to  
examine  whether   the   response   to   different   treatments   depends  on   the   specified  
baseline  characteristics.  An  unadjusted  model  was   fitted   including  a   term   for   the  
treatment  allocation,  baseline  moderator  and  a  term  for  the  treatment  by  moderator  
interaction.   An   adjusted   model   was   also   fitted   containing   a   term   for   treatment,  
moderator  and  an  interaction  term  adjusted  for  age  and  hospital.  The  table  below  
shows  the  mean  effect  size  for  the  treatment  by  moderator  interaction  effect  as  well  
as   the   p-­value   for   the   test   of   the   interaction   term.   Statistical   significance   was  
approached  in  modelling  of  early  ARDS  for  the  interaction  of  treatment  allocation  
with  age,  mid-­oesophagus   tumour   type  and  oesophageal-­gastric   junction   tumour  
type.  The  adjusted  and  unadjusted  model  for  age  and  treatment  suggests  that  for  
participants  allocated  to  salmeterol  that  for  an  increase  in  age  there  is  an  additional  
increase   in   risk   of   early   ARDS.      The   adjusted   and   unadjusted   model   for   mid-­
oesophageal   tumour   and   treatment   suggests   that   for   participants   allocated   to  
salmeterol  who  have  a  mid-­oesophageal  tumour  there  is  an  additional  increase  in  
risk  of  early  ARDS  compared  to  patients  with  other  tumour  types.  The  adjusted  and  
unadjusted  model  for  oesophageal/gastric  junction  tumour  and  treatment  suggests  
that   for   participants   allocated   to   salmeterol   who   have   an   oesophageal-­gastric  
junction  tumour  there  is  an  additional  decrease  in  risk  of  early  ARDS  compared  to  
patients  with  other  tumour  types  (table  A2).     
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Table  A2:  Multivariate  analyses  of  ARDS  –  Interaction  between  treatment  allocation  
and  baseline  variables  
Baseline  Variable  




OR  (95%  CI)   p   No.  
OR  (95%  
CI)  
p   No.   OR  (95%  CI)   p   No.  
Age  (years)   *1.06  (1.00,  
1.13)  
0.045   332  
*0.98  (0.90,  
1.06)  
0.568   331   *1.04  (0.99,  1.10)   0.130   331  
†1.07  (1.01,  
1.14)  
0.023   332  
†0.97  (0.89,  
1.06)  
0.475   331   †1.05  (0.99,  1.10)   0.091   331  
Gender   *1.66  (0.41,  
6.66)  
0.475   332  
*0.71  (0.09,  
5.35)  
0.737   331   *1.25  (0.37,  4.14)   0.720   331  
†1.35  (0.32,  
5.82)  
0.656   332  
†0.58  (0.07,  
4.66)  





0.683   332  
*7.76  (0.70,  
86.42)  
0.096   331   *1.74  (0.51,  5.93)   0.378   331  
†0.71  (0.16,  
3.14)  
0.647   332  
†8.42  (0.70,  
101.56)  
0.093   331   †1.66  (0.47,  5.84)   0.430   331  
American  Society  of  
Anesthesiologists’  
grade  2  or  more  
-­   -­   -­   -­   -­   -­   *0.34  (0.02,  4.93)   0.429   314  
-­   -­   -­   -­   -­   -­   †0.27  (0.02,  4.22)   0.354   314  
American  Society  of  
Anesthesiologists’  
grade  3  or  more  
*1.07  (0.29,  
3.95)  
0.917   314   -­   -­   -­   *2.15  (0.64,  7.27)   0.216   314  
†1.16  (0.30,  
4.52)  
0.831   314   -­   -­   -­   †2.50  (0.71,  8.76)   0.152   314  




0.254   297  
*1.00  (0.98,  
1.01)  
0.610   297   *1.00  (0.99,  1.01)   0.482   297  
†1.01  (0.99,  
1.02)  
0.374   297  
†1.00  (0.98,  
1.01)  
0.561   297   †1.00  (0.99,  1.01)   0.612   297  
Cumulative   fluid  




0.447   316  
*1.20  (0.61,  
2.35)  
0.604   315   *1.24  (0.88,  1.75)   0.229   315  
†1.19  (0.79,  
1.78)  
0.406   316  
†1.22  (0.60,  
2.47)  
0.660   315   †1.27  (0.88,  1.83)   0.263   315  
Surgical  approach   *0.69  (0.19,  
2.49)  
0.569   329  
*0.21  (0.02,  
2.85)  
0.240   329   *0.45  (0.14,  1.49)   0.191   329  
†0.85  (0.22,  
3.25)  
0.756   329  
†0.20  (0.01,  
2.92)  
0.240   329   †0.51  (0.15,  1.76)   0.289   329  




0.010   325   -­   -­   -­   *1.74  (0.54,  5.62)   0.356   325  
†7.50  (1.53,  
36.68)  








0.029   325   -­   -­   -­   *0.85  (0.27,  2.65)   0.773   325  
†0.22  (0.05,  
0.94)  
0.041   325   -­   -­   -­   †0.88  (0.26,  2.89)   0.827   325  
OR  mean  estimated  odds  ratio  of  the  interaction  term    
*Unadjusted  treatment  effect  
†Treatment  effect  adjusted  for  hospital    and  age  at  randomisation    
Missing  Late  ARDS  estimates  are  due  to  insufficient  numbers  of  cases  in  these  groups  
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